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CHAPTER 1: INTRODUCTION 
1.1 BACKGROUND AND SIGNIFICANCE 
Antibiotic use in modern medicine began in 1941 when penicillin, discovered by 
Alexander Fleming,1 was first administered to a patient infected with both staphylococci and 
streptococci bacteria.2 Treatment of the first patient was an amazing success, however, even 
before the first human trials bacteria were already known to have developed a resistance to 
penicillin.3 Since then infectious bacteria have managed to keep pace with our ability to fight 
them and have developed resistance mechanisms to nearly all of our current weapons. In 
particular, the NDM-1 enzyme presents a major threat as it confers resistance to nearly all 
antibiotics in clinical use.4-5 It is estimated that over 2 million people in the United States alone 
suffer from antibiotic-resistant infections each year leading to the death of around 23,000 people 
per year.3 Despite the rapid ability of bacteria to develop resistance to antibiotics, approvals for 
new antibiotics have rapidly decreased from 28 in the 1980s to just 7 in the 2000s. The main 
reasons for this decrease in development stem from the low profitability for antibiotics when 
compared to other drugs and from the smaller number of groups working on antibiotic projects 
in industry. The low profit margins are because antibiotics are generally given for 1 to 2 weeks to 
cure a patient from an infection, as opposed to drugs for chronic conditions which bring in 
revenue for the remainder of the patient’s life.6-7 Due to the low profitability and the merging of 
drug companies, antibiotic groups are frequently shut down or merged which reduces the 






research in the past decade resulting in the approval of several new drugs, there remains a need 
to increase the momentum in order to keep antibiotic resistant pathogens at bay.6, 9  
Antibiotics are divided into four categories based on their mechanism of action. Inhibition 
of folic acid synthesis, as with sulfonamides, indirectly prevents DNA synthesis because folic acid 
derivatives are used in the synthesis of purine and pyrimidine bases needed to build DNA. 
Inhibition of enzymes involved in DNA replication as seen with quinolones and others. Cell wall 
synthesis inhibitors, such as penicillin, inhibit enzymes involved in the synthesis of the 
peptidoglycan which is used to make the bacterial cell wall. Finally, inhibitors of protein synthesis 
such as aminoglycosides interfere with ribosomal translation processes to slow the synthesis of 
proteins or reduce the fidelity of their synthesis.2 
The first aminoglycoside, streptomycin 4, was discovered by Selman Waksman in 1943 
through isolation from the soil bacteria Streptomyces griseus.10 This was the first antibiotic 
effective against Mycobacterium tuberculosis (TB), which had previously been a death sentence.2, 
11 Since the introduction of streptomycin many other aminoglycosides have been discovered and 
used as effective antibacterial agents for both Gram-positive and Gram-negative bacteria as well 
as mycobacteria.11 Although aminoglycoside antibiotics (AGAs) are highly active against a broad 
spectrum of bacteria, the issues associated with their use including nephrotoxicity, ototoxicity, 
and resistance, have caused them to lose favor in the clinic. Recently, however, there has been a 
resurgence in the study of AGAs with a focus on chemical modification to circumvent resistance 







1.2 STRUCTURE OF AMINOGLYCOSIDE ANTIBIOTICS 
Aminoglycosides are based on an aminocyclitol ring, usually a 2-deoxystreptamine 1 or 
streptidine 2 ring, substituted at various positions with amino sugars (Figure 1). The suffix of the 
aminoglycoside name indicates which genus of bacteria the drug was isolated from: AGAs 
isolated from Streptomyces end in mycin, and AGAs isolated from Micromonospora end in micin. 
Due to the relatively high number of amines and hydroxy groups AGAs are very polar and highly 
water soluble, which causes the oral bioavailability of the drug to be low making IV injection the 
preferred route of administration.2, 16 
 






 The 2-deoxystreptamine (2-DOS) AGAs are subdivided into 4,5-substituted and 4,6-
substituted classes, although there are rare exceptions such as apramycin 5, which is 
monosubstituted at the 4-position. The major examples of AGAs in the clinic, tobramycin 6 and 
gentamicin 7, are members of the 4,6-series, however, there is growing interest in the 4,5-series 
as clinical candidates.11-12, 17 
 
Figure 2: Structures of Apramycin, Tobramycin, and Gentamicin 
1.3 AGA MECHANISM OF ACTION 
The mechanism of action for aminoglycoside inhibition of protein synthesis is well 
studied.18-20 Aminoglycosides inhibit protein synthesis in a concentration dependent manner as 






concentration (MIC) for a short period of time are more effective than long term concentrations 
at the MIC.2 In addition, aminoglycosides are able to kill bacterial cells as opposed to simply 
stopping their growth as with some antibiotics, making AGAs a better choice for 
immunocompromised patients. Although AGAs are effective against Gram-positive, Gram-
negative, and mycobacteria, they remain ineffective against anerobic bacteria due to their 
uptake mechanism. 
1.3.1 UPTAKE 
There is some controversy as to whether AGAs diffuse through the cell membrane or pass 
through porin channels to enter bacterial cells.21-22 Nevertheless it is known that the uptake of 
AGAs proceeds in three steps. First, due to the cationic nature of AGAs and the negative charge 
of the lipopolysaccharide outer membrane, the drug is held at the membrane electrostatically. 
Following this is an energy dependent phase I (EDPI) where the AGA passes through the cell 
membrane. This is tied to cellular respiration, which explains why AGAs are ineffective against 
anerobic bacteria. Finally, due to the buildup of faulty proteins essential for cell wall growth, 
energy dependent phase II begins (EDPII), where excess AGA may enter the cell.2 
1.3.2 INHIBITION OF PROTEIN SYNTHESIS 
Proteins are synthesized in the cell through translation of messenger RNA (mRNA) by 
ribosomal RNA (rRNA), which selects amino acid building blocks by pairing the codons in the 
mRNA to a specific set of anticodons in transfer RNA (tRNA).23 Each tRNA has an amino acid which 
the rRNA stitches to the growing peptide chain in sequence to make the protein. AGAs inhibit 






synthesized in much the same way in both prokaryotic and eukaryotic cells, which means the 
AGAs must be selective for bacterial ribosomes although some activity against eukaryotic 
ribosomes is inevitable. 
Ribosomes consist of two subunits, large and small, as well as several proteins. 
Prokaryotic ribosomes, as well as those found in mitochondria and chloroplasts, contain a 50S 
and a 30S subunit, while eukaryotic ribosomes contain a 60S and a 40S subunit. AGAs bind to 
helix 44 of the smaller subunit where the decoding A-site is located.24-25 
There are three decoding sites in rRNA; the aminoacyl site (A-site), the peptidyl site (P-
site), and the exit site (E-site). The A-site is where the mRNA initially binds to the ribosome and 
waits to be paired with the tRNA containing the correct anticodon. Binding of the tRNA causes a 
conformational change in the ribosome where rRNA bases A1492 and A1493 are flipped out of 
the helix causing the mRNA-tRNA pair to move to the P-site. In the P-site the peptide attached to 
the tRNA is transferred to the peptide chain being synthesized before the RNA passes to the E-







Figure 3: Translation of mRNA 
AGAs bind to the A-site through two major interactions; their cationic nature causes an 
electrostatic interaction with the phosphate backbone of the rRNA as well as hydrogen bonding 
interactions with various bases in the A-site.2, 11 Some of these hydrogen bonding interactions 
vary between AGAs, however, there are certain key interactions that are much more common. 
These include the pseudo base pair between the amine or hydroxy group at the 6’-positon and 
the ring oxygen of ring I with A1408 (Figure 4), as well as the 2-DOS hydrogen bonding network 
to A1406, UG1494, and U1495. The binding of the AGA in this way stabilizes the flipped-out 
conformation of A1492 and A1493 (Figure 5) which lowers the energy required for tRNA with 
incorrect anticodons to bind and reduces the fidelity of translation. Proteins with the incorrect 
amino acid sequence will not function properly and lead to cell death due to the buildup of 







Figure 4: A Pseudo Base Pair Interaction 
 
Figure 5: A1492 and A1493 in the Flipped-out Conformation in the Complex of Thermus 







1.4 RESISTANCE AND TOXICITY 
Although AGAs have many desirable properties as antibacterial drugs, there are a few key 
issues which have caused them to lose favor in the clinic. Thus, due to the similarity between 
bacterial and human decoding A-sites, AGAs can be toxic to humans.30-31 Further, due to their 
initial widespread and improper use combined with the rapid evolution of bacteria, many species 
have developed AGA resistance. Although these problems may seem severe the source of these 
issues is well studied allowing medicinal chemists to overcome them via rational modification. 
1.4.1 RESISTANCE 
Bacterial resistance to AGAs stems mostly from three distinct mechanisms; target 
modification32-34, altered transport35-36, and substrate modification.37-39 Target modification 
involves bacteria making changes to the A-site in the ribosome in order to prevent the AGAs from 
binding. Altered transport can cause reduced uptake, where the process of AGAs entering the 
cell is inhibited, as well as increased efflux, where the cell is able to remove AGAs after they have 
passed through the membrane. Finally, the most prevalent resistance mechanism is substrate 
modification using aminoglycoside modifying enzymes (AMEs), which modify functional groups 
on the AGA in order to prevent it from fitting into the binding site. Due to the nature of bacteria 
these resistance mechanisms are subject to horizontal gene transfer under the correct conditions 
allowing them to spread quickly between species if infections are not treated properly. 
Bacteria which produce AGAs naturally must have resistance mechanisms to ensure that 






circumvent resistance, the most important measure for managing AGA resistance is proper use 
of antibiotics.9 
1.4.1.1 TARGET MODIFICATION 
Target modification refers to alteration of the decoding A-site which can be done either 
through methylation during a post translational modification or through a point mutation where 
one RNA base is changed. These modifications are the least clinically relevant because they 
mostly occur in bacteria which produce AGAs. Cases of nucleotide mutation such as A1408G give 
high levels of resistance to 2-DOS AGAs and have been found in rare cases in Mycobacterium 
tuberculosis.40-41 
Methylation of RNA bases is done by enzymes as a post translational modification in many 
AGA producing bacteria.42 The most clinically relevant methylases are in the arm family11 which 
have been found in S. marcescens,33 K. pneumoniae,43 and E. coli where they methylate G1405 
(Figure 6).44 These modifications greatly reduce the activity of 4,6-substituted 2-DOS 







Figure 6: Gentamycin C1A Shown Bound to G1405 and G1405 Drawn with Methylation. PDBID 
4LF9 
1.4.1.2 ALTERED TRANSPORT 
Altered transport refers to methods bacteria use to lower the concentration of AGA in the 
cell. Decreased uptake through the cell membrane can cause the internal concentration of AGAs 
to be much lower than expected relative to the extracellular concentration. Although there is 
controversy as to whether AGAs use porin channels to pass through the outer membrane, it is 
known that P. aeruginosa strains with inactive porin proteins are resistant to gentamicin.11, 45 The 
genes controlling the porin proteins are also known to affect the modification of 
lipopolysaccharides, which can explain the difference in uptake if the AGAs do not pass through 
porins. 
Bacterial cells can also have efflux systems, which lower the concentration of AGAs in the 






known to have efflux systems, of which the most common family is the resistance nodulation 
division (RND) which consists of an efflux pump paired with a periplasmic membrane fusion 
protein and an outer-membrane factor.46 The levels of resistance conferred by different efflux 
pumps varies greatly. The MexAB-OprM pump found in P. aeruginosa is not very effective at 
removing a therapeutic dose of AGA, however, MexXY in the same species grants a broad range 
of AGA resistance. These efflux systems are only found in Gram-negative bacteria and are not 
restricted to efflux of AGAs but also can remove other antibiotics and dyes.11  
1.4.1.3 AMINOGLYCOSIDE MODIFYING ENZYMES 
The most prominent mechanism of AGA resistance in pathogenic bacteria is the 
aminoglycoside modifying enzymes (AMEs). These enzymes covalently modify AGAs, which 
prevents them from properly binding to the A-site due to steric constraints or blocking of key 
hydrogen bonding interactions. Most AMEs are encoded on plasmids, which facilitates rapid 
spread of resistance through horizontal gene transfer. There are three classes of AMEs 
determined by the type of group added during modification. Aminoglycoside acetyl transferases 
(AAC) acetylate amine groups, aminoglycoside phosphotransferases (APH) phosphorylate 
hydroxy groups, and aminoglycoside nucleotidyltransferase (ANT) adenylate hydroxy groups on 
the AGA.47-48 AMEs are named based on the three-letter abbreviation of their class, the position 
they modify, their phenotype expressed as a Roman numeral, and finally a letter annotating the 
gene which encodes them.49 For example, AAC(3)-Ia will acetylate N-3 of gentamicin and 
sisomicin, however, AAC(3)-VII will only acetylate gentamicin. Figure 5 shows some common 







Figure 7: Aminoglycoside Modifying Enzyme Targets 
The most common type of AMEs are the AACs which can be found in both Gram-positive 
and Gram-negative bacteria and cause resistance to a broad range of AGAs. There are four 
subclasses of AACs which act on amines at the 1, 3, 2’, and 6’-positions common to most AGAs.11 
They are members of the GCN5-related N-acetyltransferase superfamily (GNAT), which notably 
share very little commonality in amino acid sequence but are characterized by the similarity in 
their folding pattern around their co-substrate, acetyl-CoA.50 GNAT enzymes are generally 
promiscuous, and AACs have been found to act on different substrates in the cell indicating that 






 The five members of the ANT enzyme family modify hydroxy groups at the 9, 3’, 4’, 6’, 
and 2’’-positions of various aminoglycosides using ATP as a co-substrate. The most clinically 
relevant member of this family is ANT(2’’)-Ia having been found in many strains of Gram-negative 
bacteria and which causes high levels of gentamicin and tobramicin resistance in North 
America.11 Nevertheless, ANT enzymes are the least prominent AMEs. 
 APHs use ATP as a co-substrate to phosphorylate hydroxy groups at the 4, 6, 9, 3’, 2’’, 3’’, 
and 7’’-positions of AGAs. The addition of a negatively charged phosphate group reduces binding 
due to both steric bulk and electrostatic repulsion with the negatively charged RNA backbone. 
The APH(3’)-IIIa enzyme has been found in numerous Gram-positive bacteria and grants 
resistance to a broad range of AGAs including kanamycin 9, paromomycin 3, and neomycin 8. 
 Resistance from AMEs can be overcome by either inhibiting the AMEs, or more 
commonly, synthetic modification of AGAs to block AME activity. Inspired by the natural AGA 
butirosin 10, a semisynthetic derivative of kanamycin known as amikacin 11 was developed with 
a 4-amino-2-hydroxybutyramide group on N-1, resulting in a recovery of activity against bacterial 
strains with AAC(1) and AAC(3) enzymes. It has also been shown that alkylation of the 2’-amine 







Figure 8: Amikacin, Inspired by Kanamycin A and Butirosin 
1.4.2 TOXICITY 
The major adverse effect of AGA treatment is toxicity to human cells, which mostly 
manifests as kidney damage through nephrotoxicity and hearing damage through ototoxicity. 
These side effects are expressed to different degrees based on the antibiotic and the individual 
being treated. In addition there seems to be no correlation between ototoxic potential and 
nephrotoxic potential for a given AGA.11 The reason for this toxicity is due to the similar structure 
of human and bacterial ribosomes shown in Figure 7 with numbering to match the bacterial A-






including G1405, A1408, C1490, G1491 A1493, G1494, and U1495. Of these 7 residues 5 are 
conserved between bacterial ribosomes and human mitochondrial ribosomes and 4 are 
conserved in human cytosolic ribosomes. Due to this similarity aminoglycosides can inhibit 
protein synthesis in human cells, albeit to a lesser extent. The mitochondrial ribosome with the 
A1555G mutation, (corresponding to 1490 in bacterial numbering), changes the interaction with 
C1410 from a non-canonical base pair to a Watson-Crick base pair, thus tightening up the binding 
site and increasing susceptibility to AGAs.52-54 This mutation significantly increases the risk of 
hearing damage in patients treated with AGAs.  
 








Despite extensive study the mechanism of aminoglycoside nephrotoxicity is not 
completely understood.2 The cationic nature of AGAs combined with IV administration results in 
about 90% of the dose being excreted through the kidneys within 24 hours.55 Over the course of 
collection in the kidneys the proximal tubule can reabsorb a significant amount of the drug, 
causing kidney cells to maintain higher concentrations of the drug for longer than most other 
tissues. Once absorbed into the kidney cells AGAs, due to their polycationic nature, can bind to 
phospholipid membranes and inhibit lysosomal phospholipase activity.56 There are two proposed 
mechanisms for the resulting kidney cell necrosis. Either the localization of the aminoglycosides 
by the lysosomes results in a concentration dependent toxicity, or the toxicity occurs after the 
AGAs are released from the lysosomes. In either case, aminoglycosides chelate with iron in the 
mitochondria to form reactive oxygen species (ROS).57 
Clinically nephrotoxicity is the lesser of the two toxicity issues because it is reversible in 
most cases and more easily managed. Studies have shown that the best method of AGA 
administration to reduce nephrotoxicity is to use a once daily dose instead of a continuous dose 
because the kidney cells become saturated at a low concentration, preventing more of the drug 
from being absorbed as it is excreted.58 Acylation of N-1 of the 2-DOS have also shown an increase 
in selectivity for bacteria over kidney cells by reducing the binding to phospholipids.21 









Ototoxicity from aminoglycosides, which affects up to 20% of patients, is a more serious 
issue because it is difficult to monitor and results in permanent hearing damage. AGA ototoxicity 
affects both the vestibular system, which results in a loss of balance, and the cochlea, which 
results in a loss of hearing. Toxicity to the vestibular system and the cochlea vary randomly 
between AGAs. Neomycin, amikacin, and dihydrostreptomycin are more cochleatoxic, whereas 
streptomycin and gentamicin are more vestibulotoxic.2, 11  
Uptake of AGAs in the ear occurs rapidly with toxicity setting in within four hours of the 
first dose in some patients.59 It was previously thought that there was accumulation of AGAs in 
the inner ear although more recent studies show that concentrations do not even reach serum 
levels.60 In some patients hearing loss does not occur until after treatment has finished because, 
although the half-life of AGAs is usually 3-5 hours, the inner ear retains AGAs much longer with a 
half-life of up to 30 days.11 
The mechanism of ototoxicity is also not completely understood; however, it is known 
that the deafness occurs when cochlear hair cells die. The cochlear hair cells translate vibrations 
from sound into electrical impulses in the nerves. When these hair cells die, they do not regrow, 
which is why ototoxicity is permanent. The first hair cells to die are the basal cochlear cells which 
translate high frequency sound as the drug works its way to the apical cells which translate low 
frequency sounds.61  
Cochlear cell death has been linked to the buildup of reactive oxygen species although 






complexes with iron and arachidonic acid to produce ROS.63 Another theory suggests that AGAs 
activate Rho-GTPase, which then activates the NADPH oxidase complex, in turn forming 
superoxide radicals.64 Recently, however, it is thought that inhibition of protein synthesis in the 
mitochondrial ribosomes, which have a more similar A-site to bacteria, causes this buildup of 
reactive oxygen species.65-67 This evidence is further supported by the fact that genetically 
susceptible individuals with an A1555G mutation in their mitochondrial RNA suffer a much 
greater risk of hearing damage when given aminoglycosides.68 It has been shown that 
administration of Aspirin as a radical scavenger to neutralize ROS is effective at reducing 
ototoxicity.69-70 
1.5 RECENT ADVANCES 
One of the most important contributions to the search for better AGA derivatives is the 
suite of chemical biology tools developed by the Böttger group. Strains of M. smegmatis were 
developed with the A-sites of human cytosolic ribosomes, human mitochondrial ribosomes, and 
human mitochondrial ribosomes with the A1555G mutation.71 This work has shown that helix 44 
of the ribosome functions independently, and that by swapping the eukaryotic A-sites into strains 
of bacteria rapid preliminary screening of compounds for selectivity can be achieved. 
The most recently approved AGA is plazomicin 13, a sisomicin 12 derivative developed by 
Achaogen.34, 72 Plazomicin was approved in 2018 for the treatment of drug resistant urinary tract 
infections. This AGA was designed with a 4-amino-2(S)-hydroxybutyryl (L-HABA) group on N-1 
which protects from modification by AAC(1), AAC(3), APH(2’’), and ANT(2’’) enzymes in addition 






AAC(6’). This antibiotic is a step in the right direction, however, it still displays ototoxicity,73 and 
as a member of the 4,6-substituted 2-DOS series, it loses activity in the presence of armA 
modification. 
 
Figure 10: Structures of Sisomicin and Plazomicin 
 Propylamycin 14, 4’-deoxy-4’-C-propyl paromomycin, is a recently developed 
paromomycin derivative, which has been shown to have good activity against a wide range of 
Gram-positive and Gram-negative bacteria.12 It is considered that replacement of O-4’ with a 
methylene group causes O-5 to be more basic due to the increase in electron density, which in 
turn allows it to make a stronger hydrogen bond to A1408. It is also thought that there is a 
hydrophobic interaction with the propyl group further enhancing binding to the ribosome. The 
addition of the propyl group also protects from modifications by the ANT(4’) and APH(3’) 







Figure 11: Structure of Propylamycin 
Apramycin 5 is a unique aminoglycoside due to its bicyclic ring I and monosubstituted 2-
DOS that has recently gained interest for clinical use. Although it is slightly less active than most 
AGAs that have been approved for clinical use, it has the best selectivity profile in recent 
studies.74 The only known AME which affects apramycin is AAC(3)IV75 making it an excellent 
candidate for multidrug resistant infectious diseases.76-77 Phase 1 clinical trials for apramycin will 
begin in Germany in 2019.78 
1.6 OVERALL GOALS 
The goal of this project is to develop new AGAs, which are more selective for inhibition of 
protein synthesis in bacteria than in human cells. The interaction between the aminoglycoside 
ring 1 and A1408 is crucial for drug binding and selectivity suggesting that ring I is the area of 
interest for modification. Paromomycin is an interesting substrate for modification because it has 






armA resistance mutation. X-ray structures show that the side chain of paromomycin is in a 
particular conformation when bound (Figure 10),29 which suggests that modifications to the 6’-
position which would encourage preorganization into this conformation would be ideal for 
increasing activity. 
 
Figure 12: Pseudo Base Pair Interaction of Paromomycin Ring I with A140829 
In addition to the other benefits of the 4’-C-propyl group on propylamycin it is possible 
that the added steric bulk at the 4’-position causes the side chain to preorganize into the bound 
conformation. NMR studies of the side chain of propylamycin would shed new light on the 
function of this AGA, however, due to the complex NMR spectrum of this molecule a simpler 
substrate should be used. Synthesis of a model monosaccharide will be carried out in order to 







CHAPTER 2: MODIFICATIONS TO THE 6’-POSITION OF PAROMOMYCIN AND 
NEOMYCIN 
2.1 RIBOSOMAL INTERACTIONS WITH PAROMOMYCIN AND NEOMYCIN 
Paromomycin and neomycin are members of the 4,5-series of 2-DOS aminoglycosides and 
differ only in the functional group at the 6’-position, a hydroxy group in paromomycin and an 
amine in neomycin. Despite the similarity these AGAs have very different selectivity profiles with 
neomycin being slightly more active in bacteria and significantly more active in human 
mitochondria.  
The interactions between paromomycin and the bacterial ribosomal A-site are shown in 
Figure 11. The ring oxygen of ring I and the 6’-hydroxy group form a pseudo base pair interaction 
with A1408, while H-4’ takes part in a CH-π interaction with G1491, and the 4’-hydroxy group 
forms a hydrogen bond to the phosphate of A1493.29 On ring II the amine at the 1-position forms 
a hydrogen bond to U1495, and N-3 interacts with G1494 through hydrogen bonding. Only the 
5’’-hydroxy group of ring III interacts with the ribosome where a hydrogen bond to G1491 is 
stabilized by another hydrogen bond to N-2’. The 6’’’-amine of ring IV forms a hydrogen bond to 
the backbone of C1490 and the 3’’’-hydroxy group acts as a hydrogen bond donor to the 







Figure 13: Interactions Between Paromomycin and the Bacterial Ribosome 
 Pyranose sugars have the three staggered conformations for the side chain shown in 
Figure 14.79 In the gg conformation the C6-X6 bond is gauche to both the C5-O5 and the C4-C5 
bonds, this conformation is the lowest in energy in a glucose system. The next most favorable 
conformation in glucose is gt, where the C6-X6 bond is gauche to the C5-O5 and trans to the C4-C5 
bonds. The third conformation, known as tg, has the C6-X6 bond trans to the C5-O5 and gauche to 
the C4-C5 bonds.80 The conformation adopted by paromomycin bound to the A-site is gt.29, 81 
 








The interaction between the 6’-hydroxy group and A1408 is particularly interesting 
because crystal structures show that the side chain is in a particular conformation29 (Figure 12) 
which is generally not the dominant conformation in a glucosamine system in free solution.82 Due 
to the entropic penalty incurred by organizing the side chain into this conformation for binding, 
a hypothesis was formulated whereby activity may increase when the 6’-position is substituted 
in such a way that the bound conformation is more favorable. This prediction is backed up further 
by the structure of the naturally occurring aminoglycoside geneticin (G418) 15 which has a methyl 
group in the side chain with the 6’-(R) configuration, which should be preferred for this 
preorganization. 
 








Figure 16: Structure of Geneticin 
2.3 SYNTHESIS OF 6’-METHYL PAROMOMYCIN AND NEOMYCIN DERIVATIVES 
 Compounds 21(R) and 21(S) were made starting with diol 16 initially reported by the 
Vasella group.83 Initial attempts to selectively oxidize the primary alcohol of 16 to the aldehyde 
followed by alkylation with Grignard reagents were met with low yields and difficult purification 
prompting a switch from the aldehyde to a Weinreb amide.84 Selective oxidation of the 6’-
hydroxy group with BAIB and TEMPO gave the carboxylic acid 17 in 99% yield.85 Acid 17 was then 
coupled to Weinreb’s amine using DCC and DMAP to give Weinreb amide 18 in 67% yield. The 4’-
hydroxy group of 18 was then protected as a trimethylsilyl ether using hexamethyldisilazane in 
acetonitrile86 followed by alkylation with the methyl Grignard reagent in THF to give ketone 19 
in 39% yield. Reduction of ketone 19 with sodium borohydride resulted in a 1:1 mixture of 







Scheme 1: Synthesis of Intermediates 20(R) and 20(S) 
 Determination of the configuration at the 6’-positions of alcohols 20(R) and 20(S) was 
done by deprotection of the trimethylsilyl ether of the less polar alcohol using 
tetrabutylammonium fluoride (TBAF), followed by formation of a benzylidene acetal to give 
compound 21 in 60% yield. The configuration of the 6’-position in this compound was determined 
through proton and ROESY NMR experiments. ROESY correlations between the methyl group, H-
4’, and the benzylidene proton, together with the coupling constant of 5.9 Hz between H-5’ and 







Scheme 2: Determination of Configuration at the 6'-Position 
 Compounds 20(R) and 20(S) were subjected to silyl ether deprotection using TBAF 
followed by global deprotection using palladium on carbon and acetic acid under 50 psi of 
hydrogen gas to give 22(R) and 22(S). Purification over CM-Sephadex® 25 cation exchange resin 
followed by lyophilization with excess acetic acid afforded both 6’-methyl paromomycin 








Scheme 3: Deprotection of 6’-Methyl paromomycin Derivatives 
 The 6’,6’-dimethyl paromomycin 24 was accessed from methyl ketone 19, which was 
further alkylated with methylmagnesium chloride to give the 6’,6’-dimethyl alcohol 23 in 78% 
yield. Compound 23 was then subjected to TBAF for removal of the trimethylsilyl ether, followed 
by hydrogenolysis with palladium on carbon and acetic acid under 50 psi of hydrogen to give the 







Scheme 4: Synthesis of 6’,6'-Dimethyl paromomycin 
2.4 SYNTHESIS OF 6’-ETHYL PAROMOMYCIN DERIVATIVES 
Due to the modest yields in the formation of the 6’-methyl paromomycin derivatives, the 
6’-ethyl paromomycin derivatives were made using an alternate route starting from diol 16. The 
6’-hydroxy group of 16 was protected as the triisopropylsilyl ether using TIPSOTf and 2,6-lutidine 
to give 25 in 82% yield. The 4’-hydroxy group of 25 was then converted to the 4-methoxybenzyl 
ether using 4-methoxybenzyl chloride and sodium hydride to give 26 in 89% yield. The silyl ether 






oxidizing 27 to the aldehyde using Swern conditions87 and alkylation with the ethyl Grignard 
reagent, an inseparable 3:1 mixture of diastereomers favoring the (S) isomer was obtained. This 
mixture was subjected to acid hydrolysis of the OPMB ether using trifluoroacetic acid which 
afforded 28(R) and 28(S) in 79% yield. Further purification using preparative HPLC gave 28(R) and 
28(S) in 9% and 35% isolated yield respectively. The selectivity seen in this Grignard reaction 
agrees with the Cram chelation model88 (Figure 17) where the nucleophile attacks from the less 
hindered side. Compounds 28(R) and 28(S) were deprotected using the standard hydrogenolysis 
conditions to give 29(R) in 34% yield and 29(S) in 35% yield. 
 







Scheme 5: Synthesis of 6'-Ethyl paromomycin Derivatives 
 The configurations of compounds 28(R) and 29(S) were determined in the same manner 
as the corresponding 6’-methyl compounds. Thus, the less polar isomer was converted to the 
benzylidene acetal using benzaldehyde dimethyl acetal and camphorsulfonic acid to give 
compound 30 in 47% yield. In the case of 30 the coupling constant of 9.3 Hz between H-5’ and H-






This switch in the configuration/polarity relationship as compared to the 6’-methyl series is due 
to the absence of the 4’-OTMS group in the ethyl series. 
 
Scheme 6: Assignment of Configuration of 32(R) 
2.5 SYNTHESIS OF 6’-PROPYL PAROMOMYCIN DERIVATIVES 
 The 6’-propyl paromomycin derivatives were synthesized starting from compounds 31(R) 
and 31(S) as previously reported by the Crich group.89 The configuration of these compounds was 
proven in the same manner as in the methyl and ethyl series where the less polar isomer was 
determined to have the (R) configuration.89 These compounds were simply deprotected using 
the standard hydrogenolysis conditions which also reduced the double bond to give 32(R) in 42% 







Scheme 7: Synthesis of 6'-Propyl paromomycin Derivatives 
2.6 SYNTHESIS OF 6’-METHYL NEOMYCIN DERIVATIVES 
The 6’-methyl methyl neomycin 34(S) was first made from compound 20(R) which was 
subjected to triflation using triflic anhydride and pyridine followed by displacement with lithium 
azide to give the 6’-azido derivative 33 in 40% yield as a single diastereomer. Due to the cleavage 
of the silyl ether in the triflation step, global deprotection was done under the hydrogenolysis 






much less stable and decomposed before the triflate could be displaced by azide forcing the 
development of a different route. 
 
Scheme 8: Synthesis of 6'-(S)-Methyl neomycin 
Accordingly, compound 19 was stirred with hydroxylamine hydrochloride to form an 
oxime followed by reduced using sodium cyanoborohydride in acidic methanol to give a mixture 
of hydroxylamines 35(R) and 35(S) in a 2:1 ratio of diastereomers favoring the (R) configuration 
as is predicted by the Cram chelation model. Compound 35(R) was isolated in 39% yield and 






hydrogenolysis conditions to give 34(R) in 36% yield and 34(S) in 34% yield. The NMR spectra of 
34(S) matched those of the product from the previous route. 
 
Scheme 9: Synthesis of 6'-Methyl neomycin Derivatives 
2.7 NMR SPECTROSCOPIC ANALYSIS OF SIDE CHAIN CONFORMATION 
 NMR spectroscopic studies were conducted on compounds 22(R) and 22(S) to determine 
the conformation of the ring I side chain in solution (Figure 18). The methyl group of 22(R) shows 
a strong ROE correlation to H-4’ and weaker correlation to H-5’. This along with the 3JH5’,H6’ value 
for 22(R) of 2.5 Hz indicates a large population of the gt conformation is present in solution.90 
The 6’-methyl group of 22(S) shows a near equally strong correlation to H-4’ and H-5’, and has a 






NMR data strongly supports the theory that the methyl group causes preorganization into the gt 
conformation in the case of 22(R). The 6’-ethyl and propyl derivatives are considered to adopt 
comparable conformations of the side chain as the comparably configured 6’-methyl derivatives 
on the basis of their homologous structures and the similarity of the diagnostic coupling 
constants. 
  
Figure 18: Coupling Constants and NOE Interactions Defining the Side Chain Conformations of 
the 6’-Methyl paromomycin Derivatives 
 The coupling constants between H-5’ and H-6’ in the case of the neomycin series were 
2.9 Hz for 34(R) and 3.0 Hz for 34(S). The (R) isomer is likely predominantly in the gt conformation 
as is the case with neomycin in solution. Based on the coupling constants it appears that the 34(S) 
isomer is in the tg conformation which may be stabilized by a hydrogen bond from the 







Figure 19: Coupling Constants Defining Side Chain Conformation in 6'-Methyl neomycin 
Derivatives 
2.8 BIOLOGICAL DATA 
All deprotected compounds were subjected to cell free ribosomal assays using the 
engineered M. smegmatis ribosomes developed by the Böttger group (Figure 9).71 These 
ribosomal assays provide information about the activity and selectivity of each compound, and 
in combination with anti-bacterial data, determine which compounds are candidates for further 
screening. Bacterial strains tested include the Gram-positive MRSA as well as the Gram-negative 
E. coli, P. aeruginosa, A. baumannii, K. pneumoniae, and E. cloacae. 
Table 1: Cell Free Ribosomal Assays for 6’-Alkylated Derivatives 
  in vitro M. smegmatis IC50 μg/mL Selectivity 
Line Compound Bacterial Mit13 1490G* Cyt14 Mit13 1490G* Cyt14 
1 Paromomycin 0.02 60 6 15 3000 300 750 
2 22(R) 0.01 91 5.3 1.3 9100 530 130 
3 22(S) 0.04 119 56 44 2975 1400 1100 
4 24 0.04 211 56 30 5275 1400 750 
5 29(R) 0.07 231 109 152 3300 1557 2171 
6 29(S) 0.12 541 142 310 4508 1183 2583 
7 32(R) 0.04 107 20 34 2675 500 850 
8 32(S) 0.16 328 93 259 2050 581 1619 
9 Neomycin 0.02 1.87 0.31 14 94 16 700 
10 34(R) 0.01 7.9 0.72 64 790 72 6400 
11 34(S) 0.01 4.2 0.62 12 420 62 1200 
 
 Cell free ribosomal assays were performed with four types of ribosomes; Bacterial, Mit13, 






and Cyt14 have the human mitochondrial and human cytosolic A-sites, respectively. The 1490G 
ribosomes contain a human mitochondrial A-site with the A1555G deafness mutation known to 
cause higher susceptibility to ototoxicity (Figure 9). Selectivity factors, shown on the right of Table 
1, are calculated by dividing the listed ribosome’s IC50 by the IC50 of the bacterial ribosome and 
show the preference of the drug for bacterial over humanized ribosomes. 
 The cell free ribosomal data indicate that in paromomycin methylated at the 6’-position 
the (R) configuration results in four times the activity of the (S) isomer and twice the activity of 
the parent. Additionally, for the ethyl and propyl the (R) isomer is similarly 2-4 times more active 
than its (S) counterpart. The dimethyl compound 24 shows a decrease in activity over the parent. 
In the neomycin series both diastereomers of 34 showed an increase in activity over the parent 
as well as increases in selectivity, however, the (R) isomer had the greater improvement in 
selectivity. The general trend for selectivity is that alkylation at the 6’-position causes only minor 
changes in either the positive or negative direction, however, compound 22(R) seems to be an 
outlier as the selectivity factor for Cyt14 decreased greatly. Although 22(R) has great selectivity 
for bacteria over both mitoribosomes, the Cyt14 data is of concern for a drug candidate because 







Table 2: MRSA MIC Assays for 6’-Alkylated Derivatives 
 Bacteria MRSA MIC (mg/L) 












1 Paromomycin 4 >256 >256 4-8 
2 22(R) 4-8 >128 >128 2-4 
3 22(S) 8 >64 >64 4 
4 24 8-16 >128 >128 4-8 
5 29(R) 4-8 >64 >64 - 
6 29(S) 4-8 >32 >32 - 
7 32(R) 4 >128 >128 2 
8 32(S) 32-64 >64 >64 16 
9 Neomycin 0.5-1 128 128 0.5-1 
10 34(R) - 128 128 2 
11 34(S) 2 >128 >128 1 
 
Table 3: E. coli MIC Assays for 6’-alkylated Derivatives: Wild Type 
 Bacteria E. coli Wild Type MIC (mg/L) 
  AG001 AG055 AG006 
Line Resistance Mechanism Compound - - - 
1 Paromomycin 2-4 2 1-2 
2 22(R) 2-4 4 1 
3 22(S) 8-16 8-16 2 
4 24 8 8 2-4 
5 29(R) 4-8 8 2-4 
6 29(S) 4-8 8-16 2-4 
7 32(R) 2 2 1 
8 32(S) 32 32 4-8 
9 Neomycin 1 1 0.25-0.5 
10 34(R) 2 2 1-2 








Table 4: E. coli MIC Assays for 6'-alkylated Derivatives: Strains with Engineered Resistance 
 Bacteria E. coli with Engineered Resistance MIC (mg/L) 









1 Paromomycin 4 2-4 1-2 2-4 64 >128 2 
2 22(R) 4 2-4 2 2 32-64 >32 1 
3 22(S) 8-16 4-8 4 4 >32 >32 8 
4 24 8 4-8 2-4 4 16-32 >64 4-8 
5 29(R) 4 4-8 4 8 - - - 
6 29(S) 8 8-16 4-8 8 - >32 8 
7 32(R) 8 2-4 2 4 32-64 >32 1 
8 32(S) 32 - 8 16 64 >128 16-32 
9 Neomycin 1 1-2 0.5-1 4 4-8 >64 0.25-0.5 
10 34(R) 2 2 1-2 2 16 >128 0.5 
11 34(S) 2 - - 0.5 16 >64 1 
 
Table 5: Gram-negative ESKAPE Pathogen MIC Assays for 6'-alkylated Derivatives 















APH(3')-II - - - 
1 Paromomycin >128 >128 >128 >128 2-4 1 2 
2 22(R) >32 >32 >32 - 2 1 1 
3 22(S) >32 >32 >32 - 4 2 2-4 
4 24 >128 >128 >128 >128 4 2-4 2 
5 29(R) >32 >32 >32 - 8 2 2-4 
6 29(S) >64 >64 >64 - 4-8 2 2-4 
7 32(R) >128 >128 >128 >128 2 1 1 
8 32(S) >64 >64 >64 >64 8-16 4 4-8 
9 Neomycin 32 32-64 >128 >128 1-2 0.25-0.5 1 
10 34(R) 128 128 >128 - 2 1 1 
11 34(S) >128 128 >128 16 1 0.25-0.5 0.5 
 Minimum inhibitory concentration assays (MIC) with live clinical isolates of E. coli and 
ESKAPE pathogens are used to verify the results of the cell free ribosomal assays, as well as test 
compounds against known resistance determinants. ESKAPE pathogens include E. faecium, S. 






tested here because it is commonly found in the GI tract which AGAs are not typically used to 
treat. MIC data for the 6’-alkyl paromomycin derivatives with the (R) configuration agree with 
the cell free data where the methyl derivative is more active than the propyl one, which is more 
active than the ethyl one in cases where no resistance mechanisms are present. The MIC data for 
the 6’-alkyl series with the (S) configuration also agrees with the cell free translational assay 
trends where increasing the length of the chain decreases activity. In the neomycin series there 
is little difference in activity between the parent and either configuration of the methylated 
compounds. 
 For the MRSA strains AG039 and AG042, as well as E. coli strain AG036 where the ANT(4’) 
resistance enzyme is present all compounds are inactive indicating that alkylation at the 6’-
position does not block the ANT(4’) AME that is present. Activity is also absent in the presence of 
the APH(3’) AME found in all strains of P. aeruginosa. Lastly, the APH(3’-5’’) AME found in E. coli 
strain AG037 also renders all of these compounds inactive. 
2.9 CONCLUSIONS 
 Derivatives of paromomycin alkylated at the 6’-position cause a predictable change in the 
activity of the drug. Paromomycin derivatives with the (R) configuration at the 6’-position show 
activity 2-4 times greater than their (S) counterparts with overall activity decreasing as the length 
of the alkyl chain increases. The NMR analysis of the methyl derivatives shows the (R) 
configuration increases the population of the gt conformation in solution while the (S) 
configuration causes a lower population of the gt conformation. Based on the biological and NMR 






paromomycin. The 6’-(R)-methyl paromomycin shows increased activity and selectivity for 
bacteria over mitoribosomes compared to the parent, however, the decrease in cytosolic 
ribosomal selectivity disqualifies it from being a drug candidate. The overall activity of the 6’-
methyl neomycin derivatives is slightly lower than the parent in both cases, however, both 
diastereomers show a significant increase in selectivity with the (R) configuration being much 







CHAPTER 3: BICYCLIC RING I DERIVATIVES OF PAROMOMYCIN 
3.1 RATIONALE 
 Based on the data from the 6’-alkyl derivatives an increase in the population of the gt 
conformation of the ring I side chain causes an increase in activity in the paromomycin series. 
Therefore, complete organization of the side chain into the gt conformation should maximize this 
increase. By forming a bicyclic ring I, the conformation of the side chain can be locked such that 
there is no energy penalty for organizing into the bound conformation. Additionally, by varying 
the size of the conformation-locking appended ring, subtle changes in the angle of the side chain 
can be investigated to determine if a perfect gt conformation is ideal.  
3.2 PREVIOUS WORK 
 Bicyclic ring I derivatives of paromomycin and neomycin have previously been 
synthesized in the Crich group where the 4’-hydroxyl group and the 6’-carbon were connected to 
form a 6 membered ring with an equatorial methyl group at the 8’-position as shown in Figure 
20.89 Compounds 36 and 38 where the hydrogen bond donating groups (OH or NH2) are 
equatorial, mimicking the gt conformation of the 5’,6’-bond, showed significantly higher activity 
than their axial counterparts 37 and 39, which mimic the gg conformation. These compounds 
also regained some activity in the presence of ANT(4’) and APH(3’) AMEs due to the absence of 







Figure 20: Previous Bicyclic Ring I Derivatives 
3.3 SYNTHESIS OF 5-MEMBERED BICYCLIC DERIVATIVES 
 In order to further investigate the effect of locking the conformation of the ring I side 
chain, paromomycin derivatives with a five membered ring connecting O-4’ and C-6’ were 
synthesized starting with compound 27, which was oxidized to the aldehyde using Swern 
conditions.87 This was followed by alkylation with the vinyl Grignard reagent to give an 
inseparable 1:1 mixture of diastereomers. The mixture was then subjected to benzylation 
conditions using benzyl bromide and sodium hydride with TBAI gave an inseparable mixture of 
compounds 40 in 60% yield. Compounds 40 were then subjected to ozonolysis, followed by 
tosylation of the resulting 7’-hydroxyl group before removal of the PMB ether at the 4’-position 
using TFA to give diastereomers 41(R) and 41(S) each isolated in 14% yield after normal phase 






compounds 42(ax) and 42(eq) in 52% and 69% yields, respectively. The configuration at C-6’ was 
assigned based on the 3JH5’,H6’ values of 4.3 Hz in 42(ax) and 7.4 Hz in 42(eq). Finally, both 42(ax) 
and 42(eq) were subjected to the standard hydrogenolysis conditions to give 43(ax) and 43(eq) 
in 46% and 18% yield, respectively (Scheme 10). The assignment of configuration at C-6’ in these 








Scheme 10: Synthesis of Bicyclic Paromomycin Derivatives 43(ax) and 43(eq) 
3.4 SYNTHESIS OF 6-MEMBERED BICYCLIC DERIVATIVES 
In order to make a more direct comparison between ring sizes, 6-membered bicyclic 
derivatives related to the previous alcohols 36 and 37 were synthesized that lack the 8’-methyl 
group. To this end mixture 40 was subjected to hydroboration conditions using BH3∙THF followed 






mixture of diastereomers in 43% yield. Tosylation of the mixture of 44 with tosyl chloride and 
Hunig’s base followed by OPMB removal using TFA, and ring closing displacement of the tosylates 
gave 45(eq) and 45(ax) in 10% and 9% yield, respectively. The configuration at C-6’ of compounds 
45(eq) and 45(ax) was assigned based on the 3JH5’,H6’ values of 9.4 Hz and 2.5 Hz, respectively. 
These assignments were further verified during the conformational analysis of the deprotected 
compounds below. Both isomers of 45 were subjected to hydrogenolysis conditions to give 







Scheme 11: Synthesis of Bicyclic 6-Membered Paromomycin Derivatives 
3.5 SYNTHESIS OF 7-MEMBERED BICYCLIC DERIVATIVES 
The bicyclic paromomycin derivatives with a 7-membered ring containing O-4’ and C-6’ 
were made starting with allylation of the 4’-hydroxyl group of 25 using allyl bromide, TBAI, and 






THF for removal of the 6’-OTIPS group to give 48 in 89% yield. Alcohol 48 was then oxidized using 
Swern conditions, followed by alkylation using the vinyl Grignard reagent to give compounds 49 
as an inseparable mixture of diastereomers in 47% yield. Mixture 49 was subjected to ring closing 
metathesis using Hoveyda-Grubbs second generation catalyst,91 which resulted in a mixture of 
diastereomers 50 in 49% yield, from which 50(ax) and 50(eq) were isolated in 18% and 16% yield, 
respectively. The configuration at C-6’ in these compounds was assigned based on the 3J5’,6’ values 
of 2.4 Hz for 50(ax) and 9.1 Hz for 50(eq). Compounds 50(ax) and 50(eq) were deprotected using 
standard hydrogenolysis conditions to give 51(ax) and 51(eq) in 31% and 18% yield, respectively 
(Scheme 12). The configuration at C-6’ was further verified during conformational analysis of the 














3.6 CONFORMATIONAL ANALYSIS OF BICYCLIC PAROMOMYCIN DERIVATIVES 
 Conformational analysis of the reported bicyclic paromomycin derivatives based on 
proton NMR coupling constants (Table 6) sheds light on the orientation of the bond between C-
6’ and O-6’. Both five and seven-membered rings are more conformationally labile than six-
membered rings,92 allowing the C5’-C6’ bond access to a greater range of conformations and the 
6’-C-O bond access to a correspondingly greater volume of chemical space. Based on deviations 
from limiting coupling constants obtained from the model compounds shown in Figure 2190 
variations in the conformation about the 5’,6’-bond can be determined. 
 
Figure 21: Model Compounds and Limiting Coupling Constants for the gg and gt 
Conformations90 
 The compounds with appended 6-membered rings in a trans-decalin system will have 
ideal chair conformations. The 3JH5’,H6’ values of 9.4 Hz for compounds 3689 and 46(eq) indicate 
that the heteroatom attached to C-6’ is equatorial and the side chain is in the gt conformation. 
Compounds 37 and 46(ax) have 3JH5’,H6’ values of 2.8 Hz and 2.0 Hz, respectively, indicating they 







Table 6: Essential Ring I Coupling Constants 




3JH1,H2 3JH2,H3 3JH3,H4 3JH4,H5 3JH5,H6 
36 6 4.1 9.9 9.5 9.5 9.4 
37 6 4.1 - - 10.0 2.8 
43(eq) 5 4.3 9.8 9.8 10.0 7.9 
43(ax) 5 4.2 9.9 9.9 9.9 4.5 
46(eq) 6 4.1 10.0 10.0 9.5 9.4 
46(ax) 6 4.1 10.2 10.2 9.4 2.0 
51(eq) 7 3.8 10.8 9.1 9.4 10.0 
51(ax) 7 3.9 10.5 9.5 9.5 3.5 
 
 Unlike 6-membered rings, saturated 5-membered rings prefer to adopt an envelope 
conformation, where four of the atoms are planar and the fifth, with the bulkiest substituent, 
extends out of the plane allowing the substituent to adopt a pseudo-equatorial orientation 
(Figure 22).92 Additionally, in a trans-fused bicyclo[4.3.0]nonane system, the 6-membered ring 
can only adopt a proper chair conformation if one of the bridgehead atoms is out of the plane of 
the five membered ring, limiting the conformational space of the 5-membered ring as shown in 
Figure 21 with dashed lines along the fold of the envelope. 
 
Figure 22: Conformations of Substituted 5-Membered Rings 
 In compound 43(ax) the 3JH2’,H3’, 3JH3’,H4’, and 3JH4’,H5’ values of 9.9 Hz indicate that the six 
membered ring is in a chair conformation. In combination with the 3JH5’,H6’ value of 4.5 Hz 






C-5’ is the out of plane atom in the 5-membered ring (Figure 23). Based on this analysis the 
conformation of the 5’,6’-bond approaches gg but is shifted minimally towards gt. Compound 
43(eq) has 3JH2’,H3’, 3JH3’,H4’, and 3JH4’,H5’ values of 9.8 Hz, 9.8 Hz, and 10 Hz, respectively, confirming 
that it also adopts a chair conformation of the 6-membered ring. The 3JH5’,H6’ value of 7.9 Hz shows 
these protons are not co-planar and that C-5’ is at the fold of the envelope in this case as well. In 
the case of 43(eq) the conformation of the 5’,6’-bond is approximately gt with a slight distortion 
towards the tg conformation (Figure 23). 
 
Figure 23: Conformational Analysis of 5-Membered Bicyclic Ring I Derivatives 
 Cycloheptane rings prefer to adopt a twist-chair conformation (Figure 24) where five 
atoms are in one plane with the remaining two atoms extending out of the plane in opposite 
directions.92 Unlike cyclohexanes with their relatively high energy barriers between 
conformations, cycloheptanes93 and oxepanes94 have low energy barriers to inversion making 
them more conformationally labile.  
 






 The bicyclic compound 51(ax) has 3J values between 9.5 and 11 Hz for protons at the 3’, 
4’, and 5’-positions indicative of a chair conformation in the 6-membered ring. The 3JH5’,H6’ value 
is 3.5 Hz, suggesting that the 5’,6’-bond is near the gg conformation, leaning slightly towards the 
gt conformation, but not quite as much as 43(ax) (Figure 25).  Bicyclic compound 51(eq) also 
appears to adopt an ideal chair conformation in the 6-membered ring of the bicyclic system based 
on the 3JH,H values. With a 3JH5’,H6’ value of 10 Hz the side chain is locked into an almost perfect 
staggered gt conformation. 
 
Figure 25: Conformational Analysis of 7-Membered Bicyclic Ring I Derivatives 
 Conformational analysis of these compounds suggests that the progression from the least 
gt-like conformation to most gt-like would be 46(ax) = 37 < 51(ax) < 43(ax) < 43(eq) < 51(eq) = 
46(eq) = 36. 
3.7 BIOLOGICAL DATA 
The work described in this chapter is based on the hypothesis that as the side chain 
approaches the ideal gt conformation, the activity should approach a maximum. Conversely, if 
the ideal bound conformation lies between the ideal gg and gt conformers the activity should not 






translation assay data for each of the bicyclic aminoglycoside derivatives discussed with 
compounds listed in order of increasing gt character. Consistent with the hypothesis, the data for 
the bacterial ribosome shows a trend of activity increasing as the conformation of the 5’,6’-bond 
progresses towards the gt conformation. In the paromomycin series, ignoring the 8’-methyl 
compounds 36 and 37, the bacterial IC50 trend shows that progression from least to most active 
is 46(ax) < 51(ax) < 43(ax) < 43(eq) < 51(eq) < 46(eq), in near perfect agreement with the 
progression from the gg to the gt conformation. The exception to the trend is that based on 
conformational analysis 46(eq) and 51(eq) would be equal in activity, however, the difference in 
activity could simply be due to the added flexibility of the seven-membered ring or its greater 
steric bulk. Compounds 36 and 37 are more active than their counterparts 46(eq) and 46(ax), 








Figure 26: Bicyclic Paromomycin Derivatives 
Analyzing the selectivity of these compounds (Figure 26) for the inhibition of bacterial 
over Mit13 mutant ribosomes shows there is also a trend of increasing selectivity as the 
conformation of the 5’,6’-bond approaches the ideal gt conformation. The exception to this trend 
concerns 43(eq) to 51(eq) where the selectivity drops from 1889 to 1456 only to increase to 8825 
in 46(eq). The selectivity for inhibition of bacterial over the A1490G mutant ribosome shows a 
similar pattern in which there is a dip in selectivity just before reaching an ideal gt conformation. 
Selectivity for bacterial inhibition over Cyt14 mutant ribosomes correlates the least with 







Table 7: Cell Free Ribosomal Assays for Bicyclic Derivatives 





(Hz) Conformation Bacterial Mit13 1490G* Cyt14 Mit13 1490G* Cyt14 
Paromomycin - - - 0.02 60 6 15 3000 300 750 
37 6 2.8 gg 0.47 193 213 169 411 453 360 
46(ax) 6 2.0 gg 1.24 51 121 58 41 98 47 
51(ax) 7 3.5 gg > gt 1.3 363 395 365 279 304 281 
43(ax) 5 4.5 gg > gt 0.2 130 117 276 650 585 1380 
43(eq) 5 7.9 gg < gt 0.09 170 5.9 38 1889 66 422 
51(eq) 7 10.0 gt 0.09 131 63 58 1456 700 644 
46(eq) 6 9.4 gt 0.04 329 44 50 8225 1100 1250 
36 6 9.4 gt 0.02 232 12 15 11600 600 750 
 
The general trend from the bacterial MIC assays stand with the cell-free ribosomal 
translation data however the difference between compounds is less pronounced. Corresponding 
6 and 7-membered compounds show little difference in activity when tested against E. coli and 
ESKAPE strains which are not resistant to paromomycin. The 8’-methyl group on compounds 36 
and 37 causes no significant improvement in activity over 46(eq) and 46(ax). 
All bicyclic paromomycin derivatives retained activity in strains of MRSA containing the 
ANT(4’)-I AME, as well as in E. coli strain AG036 containing the ANT(4’) AME, because the 4’-
hydroxyl group has been converted to an ether. Compounds 46(eq) and 36 also regained some 
activity in P. aeruginosa strains AG031 and AG032 known to have the APH(3’)-II AME likely due 
to the added bulk on O-4’ hindering the approach of the enzyme to the adjacent 3’-hydroxy 








Table 8: MRSA MIC Assays for Bicyclic Compounds 
   Bacteria MRSA MIC (mg/L) 
















Paromomycin - - - 4 >256 >256 4-8 
37 6 2.8 gg 32 32-64 16-32 32 
46(ax) 6 2.0 gg 32 32 32 32 
51(ax) 7 3.5 gg > gt 32 64 64-128 128 
43(ax) 5 4.5 gg > gt 8 4-8 4-8 8 
43(eq) 5 7.9 gg < gt 16-32 16 8-16 16-32 
51(eq) 7 10.0 gt 2 2-4 4 4 
46(eq) 6 9.4 gt 4 2 2-4 4 
36 6 9.4 gt 8-16 8 8 4 
 
Table 9: E. coli MIC Assays for Bicyclic Compounds: Wild Type 
   Bacteria E. coli Wild Type MIC (mg/L) 






- - - 
Paromomycin - - - 2-4 2 1-2 
37 6 2.8 gg 32 64-128 16-32 
46(ax) 6 2.0 gg 32-64 >32 32 
51(ax) 7 3.5 gg > gt 64 128 64 
43(ax) 5 4.5 gg > gt 16 16 8 
43(eq) 5 7.9 gg < gt 32 32 16 
51(eq) 7 10.0 gt 4-8 4-8 4 
46(eq) 6 9.4 gt 4-8 4-8 2 







Table 10: E. coli MIC Assays for Bicyclic Compounds: Strains with Engineered Resistance 
   Bacteria E. coli with Engineered Resistance MIC (mg/L) 













Paromomycin - - - 4 2-4 1-2 2-4 64 >128 2 
37 6 2.8 gg 64-128 - - - - - - 
46(ax) 6 2.0 gg >32 >32 32 >32 16 >32 >32 
51(ax) 7 3.5 gg > gt 128 128 64 128 32 >128 128 
43(ax) 5 4.5 gg > gt 16 8-16 8 16 2 >64 16 
43(eq) 5 7.9 gg < gt 32-64 32-64 16 64 8 >128 16 
51(eq) 7 10.0 gt 8 - 4 16 1 >128 - 
46(eq) 6 9.4 gt 8 4-8 4 8 1 >128 2-4 
36 6 9.4 gt 8 4-8 2-4 4 0.5 16 2 
 
Table 11: Gram-negative ESKAPE Pathogen MIC Assays for Bicyclic Compounds 






















APH(3')-II - - - 
Paromomycin - - - >128 >128 >128 >128 2-4 1 2 
37 6 2.8 gg >128 >128 >128 >128 - - - 
46(ax) 6 2.0 gg >64 >32 >32 - 32 >32 32 
51(ax) 7 3.5 gg > gt >128 >128 >128 - 64-128 64 32-64 
43(ax) 5 4.5 gg > gt >64 >64 >64 - 8-16 4 4-8 
43(eq) 5 7.9 gg < gt >128 >128 >128 - 32 32 16-32 
51(eq) 7 10.0 gt >128 >128 >128 - 4-8 2-4 2-4 
46(eq) 6 9.4 gt 64 64 128 - 4-8 4 2 
36 6 9.4 gt 32 16-32 >128 >128 2 2 2 
 
3.8 CONCLUSION 
Based on the results of the biological assays coupled with the conformational analysis of 
each bicyclic compound an ideal gt conformation is preferred when bound. There is an excellent 
correlation between the activity of these bicyclic compounds and the conformation of the 5’,6’-






increases. The selectivity for inhibition of bacterial over Mit13 mutant ribosomes also has a direct 
correlation to the conformation of the side chain and increases as the conformation becomes 
more gt-like. The selectivity for inhibition of bacterial over A1490G and Cyt14 mutant ribosomes 
does not appear to show any correlation with the transition from the gg to the gt conformation 
but is near its maximum in compound 46(eq), which is near perfectly in the gt conformation. 
Although the assays on inhibition of live bacteria agree with the cell free ribosomal assay, the 
magnitude of the difference between compounds is smaller. The methyl group of compound 36, 
which grants it higher activity than 46(eq) in the cell-free translation assays does not have much 
effect in the bacterial assays, although it grants a significant advantage for inhibition of bacterial 
over Mit13 mutant ribosomes.  
These bicyclic compounds also overcome resistance from ANT(4’)-I in MRSA, as well as 
recovering some activity in the presence of APH(3’)-II in P. aeruginosa. Conversion of the 4’-
hydroxyl group to an ether prevents AMEs from modifying it, which grants these compounds 
immunity. In the case of 46(eq) and 36 the protection from APH(3’)-II likely comes from the added 
bulk of the bicyclic ring preventing approach of the AME to the 3’-position, further increasing the 







CHAPTER 4: EFFECTS OF SUBSTITUENTS AT THE 4’-POSITION ON THE RELATIVE 
POPULATIONS OF THE SIDE CHAIN CONFORMATIONS 
4.1 RATIONALE 
 Propylamycin 14, one of the lead compounds from the aminoglycoside project, was 
synthesized as part of a series of modifications to the 4’-position. Of all the 4’-modifications 
made,12, 95-96 propylamycin showed the highest activity and the best selectivity profile, making it 
a good candidate for further study. There are several possible reasons for the increased activity 
of propylamycin including the increase in basicity of the ring oxygen (O-5’) due to the 
deoxygenation of the 4’-position, causing less electron density to be pulled away from O-5’ and 
therefore enhancing its ability to accept a hydrogen bond from A1408,97-98 as well as possible 
hydrophobic interactions with the propyl group. In yet another hypothesis, because 4’-deoxy 
paromomycin 52 (Figure 27) suffers a reduction in activity,12 a steric interaction between the 
propyl group and the side chain causes the latter to adopt a higher population of the gt 
conformation, and so increases affinity for the decoding A-site. Table 12 shows cell free ribosomal 







Figure 27: Structures of Paromomycin, 4'-Deoxyparomomycin, and Propylamycin 
Table 12: Cell Free Ribosomal Assay Data for Paromomycin, 4'-Deoxy Paromomycin, and 
Propylamycin 
  in vitro M. smegmatis IC50 μg/mL Selectivity 
Line Compound Bacterial Mit13 1490G* Cyt14 Mit13 1490G* Cyt14 
1 Paromomycin 0.02 60 6 15 3000 300 750 
2 4'-Deoxy Paromomycin 0.05 74 24 28 1480 480 560 
3 Propylamycin 0.03 167 52 64 5567 1733 2133 
 
In order to investigate the effects of 4’-substituents on the side chain conformation in 
solution, four model compounds (Figure 28) were synthesized for study by NMR spectroscopy. 
Because conformational analysis of  the side chain by NMR spectroscopy requires unambiguous 
assignment of the diastereotopic hydrogens at the 6’-position,80 methods were developed for 








Figure 28: Ring I Models Designed for Conformational Analysis of the Side Chain 
4.2 SYNTHESIS OF 4’-DEOXY RING I MODEL 
 Compound 53 was made simply by deprotecting compound 57, which was prepared by 
the method reported by Mayer (Scheme 13).99 Thus, compound 57 was subjected to 
hydrogenolysis conditions using palladium on carbon and acetic acid under 50 psi of H2. The 
resulting compound 53 was obtained as the acetate salt in 97% yield. 
 
Scheme 13: Hydrogenolysis of 57 
4.3 SYNTHESIS OF A 4’-DEOXY-4’-PROPYL RING I MODEL 
The propylamycin ring I model was synthesized starting from compound 58 previously 
reported by Wakamatsu100 and characterized by Shibasaki.101 After failed attempts to open the 
epoxide with sodium azide, 58 was opened by heating in benzylamine to give the trans-diaxial 
Fürst-Plattner102 product 59 in 77% yield (Scheme 14). Palladium catalyzed hydrogenolysis of the 
benzyl group and reduction of the allyl double bond under a hydrogen atmosphere gave the free 






derivative 61 in 91% yield. Ring opening of the anhydro sugar 61 using TFA and acetic anhydride 
followed by Fischer glycosylation in methanolic HCl resulted in an anomeric mixture of 62 in 69% 
yield with an α/β ratio of 1.5:1. Compounds 62α and 62β were isolated in 22% and 12%, 
respectively, after silica gel flash column chromatography. Hydrogenolysis of 62α gave the 
acetate salt 55 in 96% yield (Scheme 14). With ring I models 53 and 55 in hand a method to 
distinguish between 6-HR and 6-HS for the calculation of side chain populations was required. 
 







4.4 SYNTHESIS OF A 4’-DEOXY-6’-(S)-DEUTERIO RING I MODEL 
The method used to differentiate the protons at the 6-position was selective deuteration 
of the 6-HS using the method previously developed by Meguro104 and modified by Crich82 based 
on selective functionalization of the exo-face of 1,6-anhydroglucose (Scheme 15). 
Regioselectivity in the initial bromination reaction, which was conducted in α,α,α-
trifluorotoluene instead of the more common but environmentally unfriendly 
tetrachloromethane,105 arises because the least electron deficient hydrogen atom of 63 is 
abstracted. Stereoselectivity in the quenching of the ensuing radical occurs because bromine 
approaches from the more accessible exo-face to give bromide 64. Reduction of bromide 64 with 
Bu3SnD results in retention of configuration, again due to quenching of the intermediate radical 
from the less hindered exo-face, to give the deuterated compound 65 with the (S) configuration 
at the 6-position. The proton NMR spectrum of 63 shows a doublet of doublets at δ 4.10 ppm 
corresponding to the endo H6R with coupling constants of 7.7 and 1.1 Hz, as well as another 
doublet of doublets at δ 3.80 ppm corresponding to the exo H6S with coupling constants of 7.7 
and 5.7 Hz. After conversion to 64 the remaining H6 becomes a singlet at δ 6.41 ppm due to the 
loss of the 7.7 Hz geminal coupling. Following deuteration the proton NMR spectrum of 65 
matches that of 65 except for the absence of the peak at δ 3.8 ppm and a change in multiplicity 







Figure 29: Regioselective Deuteration of H6-exo 
Following regioselective deuteration, removal of the acetates from 65 with NaOMe 
followed by tosylation gave di-tosylate 66. Treatment of 66 with NaOMe results in selective 
displacement of the tosyl group at the 4-position to give the 3,4-epoxide 67, which was used as 
the common intermediate for both deuterated ring I models. 
 
Scheme 15: Synthesis of Labeled Intermediate 67 
 Epoxide 67 was opened using BF3∙OEt2 and NaBH4 in dimethoxyethane to give 68 in 99% 
yield (Scheme 16). Treatment of alcohol 68 with sodium methoxide formed the 2,3-epoxide 69 






benzoic acid, which resulted in the formation of 70(ax) as the minor isomer contrary to the Fürst-
Plattner rule, as discussed below. HPLC purification resulted in isolation of 5% of the desired 
70(ax) which was subjected to ring opening using TFA and acetic anhydride followed by Fischer 
glycosylation in methanolic HCl. The resulting inseparable mixture of anomers was subjected to 
hydrogenolysis conditions which gave the inseparable mixture 54 in 85% yield. The NMR spectra 
of mixture 54 were well resolved and facilitated determination of 6-HR and 6-HS for the pure 
isotopomer 53, due to the absence of a peak at δ 3.51 ppm, resulting from replacement of 6-HS 
with deuterium. 
 
Scheme 16: Synthesis of a 4’-Deoxy-6’-(S)-deuterio Ring I Model 
4.5 SYNTHESIS OF A 4’-DEOXY-4’-PROPYL-6’-(S)-DEUTERIO RING I MODEL 
The deuterated propylamycin ring I model was made analogously to the non-deuterated 
isotopomer. Epoxide 67 was alkylated with allylmagnesium chloride and copper iodide to give 71 






yield, followed by selective opening with benzylamine to 73 in 62% yield. Compound 73 was 
subjected to hydrogenolysis conditions to give the amine 74, with reduction of the allyl group at 
the 4-position, in 99% yield. Stick’s reaction converted the amino group of 74 to the azide of 75 
in 83% yield. Ring opening with TFA and acetic anhydride followed by Fischer glycosylation with 
methanolic HCl resulted in a 2:1 α/β mixture of 76 in 68% yield. Following silica gel flash column 
chromatography, 76α and 76β were isolated in 11% and 9% yield, respectively. The desired 
anomer, 76α, was subjected to hydrogenolysis conditions to give the ring I model 56 with the 
deuterium at the 6-position with the (S) configuration. The NMR spectra of this compound 
matched those of the non-deuterated isotopomer, except for the absence of the 6-Hs signal at δ 







Scheme 17: Synthesis of a 4’-Deoxy-4’-propyl-6’-(S)-deuterio Ring I Model 
 The change in regioselectivity in the ring openings of epoxides 69 and 72 with lithium 
azide and benzylamine respectively is noteworthy. The opening of 72 with benzylamine is 
consistent with the Fürst-Plattner rule and stereo-electronic control, despite suffering from a 
significant 1,3-diaxial interaction between the incoming nucleophile and the allyl group at the 
transition state. 
 In the opening of 69 with azide the minor regioisomer follows the Fürst-Plattner rule, 






isomer on the other hand is necessarily initially formed in a twist-boat conformation, which then 
relaxes to a chair with two equatorial substituents. Presumably this diversion from the usual 
Fürst-Plattner and Bartonian prediciton106 occurs because in the opening of the protonated 
epoxide there is considerable charge build up on carbon at the transition state. This partial 
positive charge on carbon is better accommodated on C-3 than on C-2 because of the absence of 
electron-withdrawing β-C-O bonds. Thus, the need to stabilize partial charge at the transition 
state overrides the stereo-electronic preferences of the Fürst-Plattner rule. 
 It can also be argued that ring opening of the protonated epoxide of 69 by azide proceeds 
with a loss of charge separation and so is highly exothermic, with a correspondingly early 
transition state that is not susceptible to stereo-electronic control. Opening of the neutral 
epoxide 72 by the neutral amine on the other hand proceeds with separation of charge and so is 
less exothermic, has a later transition state, and correspondingly obeys the dictates of stereo-
electronic control. Finally, the selectivity of the opening of epoxide 72 is likely further aided by 
the presence of the allyl group at the 4-position which shields C-3 from nucleophilic attack, 







Figure 30: Mechanism of Epoxide Opening 
4.6 ANALYSIS OF SIDE CHAIN POPULATIONS 
Since the advent of the Karplus equation,107 several methods have been devised to extract 
details about the conformation of bonds based on NMR coupling constants. The conformation of 
the side chain in carbohydrates has been a topic of study for many groups,79-80, 108-109 due to its 
importance for carbohydrate-enzyme binding29 and influence on selectivity of glycosylation 
reactions.110-117 Rotation of the side chain is rapid enough that on the NMR time scale the 
individual rotamers are not visible and the observed 3J values are a time weighted average based 
on the relative ratios of the populations of each side chain conformation and the limiting coupling 
constants for each rotamer as described by Equations 1 and 2 (Figure 31). Equation 3 simply 
states that the sum of the fractions of each population must total up to 1. With known limiting 























      (3)   1 = 𝑓𝑔𝑔 +  𝑓𝑔𝑡 +  𝑓𝑡𝑔 
Figure 31: Equations for Determination of Side Chain Populations in Solution 
Recently the Crich group described a study and evaluation of mimetics of each staggered 
side chain conformation, with both the gluco and galacto-configurations to determine better 
approximations of the limiting coupling constants for equations 1 and 2, allowing more accurate 
calculation of the population of side chain conformations in solution using experimental 3JH5,H6 
values.90 The relevant models for the gluco series are shown in Figure 32 with the coupling 
constants for H6R and H6S. The averages of these coupling constants were used as more accurate 
limiting coupling constants, shown in Table 13, for calculation of side chain populations in the 
model compounds synthesized above. The digital resolution of the spectra from which these 
coupling constants are taken is 0.4 Hz indicating that the uncertainty in calculations based upon 







Figure 32: Models for Determination of Limiting Coupling Constants; Values in Hz, Measured 








Table 13: Limiting Coupling Constants 
 gg gt tg 
3JH5,H6R Hz 1.0 11.0 4.8 
3JH5,H6S Hz 2.2 2.5 10.2 
 
The experimental coupling constants from the α-methyl glycoside of glucosamine 76 
(Figure 33) at pH 5 were determined previously as 3JH5,H6R = 4.9 Hz and 3JH5,H6S = 2.2 Hz,82 from 
which it is calculated using the equations in Figure 31 and the limiting coupling constants from 
Table 13 that its side chain adopts a 62:40:-2 gg:gt:tg mixture of conformations. As the α-methyl 
glycoside of glucosamine serves as a model for ring I of paromomycin, the side chain of 
paromomycin ring I is likewise considered to take up a 62:40:-2 mixture of gg:gt:tg conformers 
(Table 14). Self-evidently a population of -2% is impossible. This is an artifact of the method and 
its errors, and is considered to be indistinguishable from a 0% population. 
 
Figure 33: Ring I Models 
The 4’-deoxy ring I model 53 displayed coupling constants of 3JH5,H6R = 5.8 Hz and 3JH5,H6S 
= 2.5 Hz revealing its side chain and by extrapolation that of the 4’-deoxy paromomycin adopt a  
51:47:2 gg:gt:tg mixture of conformations. Finally, for the propylamycin ring I model 55 the 
coupling constants of 5.3 Hz for H5-H6R and 2.2 Hz for H5-H6S indicate that its side chain, and that 






Table 14: Side Chain Coupling Constants and Populations 
Ring I Model Aminoglycoside 3JH5,H6R 3JH5,H6S fgg fgt ftg 




5.8 2.5 51 47 2 
55 propylamycin 5.3 2.2 58 44 -2 
 
4.7 DISCUSSION AND CONCLUSION 
The calculations of side chain populations in ring I models indicate that there is a shift of 
about 4% from the gg to the gt conformation from paromomycin to propylamycin with no change 
in the population of the tg conformation. In the case of the 4-deoxy paromomycin ring I model, 
there is an 11% decrease in population of the gg conformation leading to an 7% increase in the 
population of the gt conformation, as well as a 5% increase in the population of the tg 
conformation. Considering the small difference in these values combined with the uncertainty of 
5% in the calculations there appears to be no significant change in conformation of the ring I side 
chain when changing the substituent at the 4’-position. This leads to the conclusion that the 
gauche effect, which states that electronegative atoms on neighboring carbons cause a 
preference for a gauche conformation (Figure 34),92 is the major factor in side chain populations 
and steric influence from the 4-position has a minor effect.  
 






It is noteworthy that 4-deoxy glucose is also 4-deoxy galactose, however the populations 
of the side chain in 53 resemble glucose much more closely than galactose where the ratio of 
side chain conformations is 16:53:31 gg:gt:tg.90 The gg conformation is disfavored in galactose 
and not in the 4-deoxy galactose system because of dipolar repulsion between the axial hydroxy 
group at the 4-position and the side chain hydroxy group when in the gg conformation (Figure 
35). 
 
Figure 35: The gg Conformation is Disfavored in Galactose Due to Dipolar Repulsion, This 
Effect is Absent in 4-Deoxy Galactose 
With the data suggesting that there is no significant change in the side chain conformation 
of ring I of propylamycin, 4’-deoxyparomomycin, and paromomycin, the increased 
antibacterioribosomal and antibacterial activity of propylamycin relative to the parent cannot be 
due to an increase in population of the gt conformation, and alternative explanations are 
therefore preferred. As noted above these include increased basicity of the ring oxygen, leading 
to an increase of strength of the critical hydrogen bond to A1408. The difference in 
antibacterioribosomal and antibacterial activity of propylamycin and 4’-deoxy paromomycin 
must be related to an interaction of the propyl group in propylamycin with the ribosome, possibly 







CHAPTER 5: OVERALL CONCLUSIONS 
The conformation of the ring I side chain in paromomycin has a substantial effect on the 
activity and selectivity of the drug. By fusing ring I with a second ring connecting O-4’ and C-6’, it 
has been demonstrated that the ideal bound conformation for the ring I side chain is nearly a 
perfect gt conformation as evidenced by antibacterioribosomal and antibacterial activity 
reaching a maximum in compounds determined to have side chains in the ideal gt conformation. 
Small changes in the conformation of the side chain caused by increases or decreases in the size 
of the appended ring result in large changes in activity, further affirming the importance of effects 
of the ring I side chain conformation on the activity of AGAs.  
It has been shown that alkylation at C-6’ changes the relative conformational populations 
of the side chain such that the (R) configuration increases the relative population of the gt 
conformation resulting in an increase in activity. Alkylation at C-6’ resulting in the (S) 
configuration causes a decrease in the relative population of the gt conformation, thus 
decreasing activity. Changes in the substituent at the 4’-position have a negligible effect on the 
relative populations of the side chain conformations and therefore any changes in activity of 
these AGAs are due to other factors. 
The activity of AGAs with respect to the humanized ribosomes shows little correlation to 
the conformation of the side chain, such that selectivity for bacterial over humanized ribosomes 
reaches a maximum when the side chain is in the gt conformation. Based on these trends future 
AGAs designed so as to maximize the gt conformation of the side chain will benefit from 






CHAPTER 6: EXPERIMENTAL SECTION 
GENERAL EXPERIMENTAL 
 All reagents were purchased from commercial sources and used without further 
purification unless otherwise specifies. Thin-layer chromatography was performed on Sorbtech 
glass backed silica gel XHL plates with UV 254. Chromatographic purifications were carried out in 
Fisher silica gel 60 230-400 mesh unless otherwise specified. High resolution mass spectra were 
collected on a Waters LCT Premier XE ESI-TOF mass spectrometer. Optical rotations were 
measured using a Rudolph Research Autopol III polarimeter in a 1 dm cell. NMR spectra were 
collected on an Agilent 600 MHz DD2, Agilent 500 MHz VNMRS, or an Agilent 400-MR 
spectrometer as indicated. NMR spectra were assigned with the aid of advanced 1D and 2D 
techniques including COSY, HSQC, HMBC, TOCSY, and ROESY. 
1,3,2’,2’’’,6’’’-Pentaazido-6,3’,2’’,5’’,3’’’,4’’’-hexa-O-benzyl-6’-carboxyl-1,3,2’,2’’’,6’’’-
pentadeaminoparomomycin (17). TEMPO (87.5 mg, 0.56 mmol) and BAIB (1.98 g, 6.16 mmol) 
were added to a stirred solution of 16 (3.60 g, 2.80 mmol) in 33 mL of 1:1 MeCN/H2O. After 3.5 
hours the MeCN was removed under vacuum and the aqueous solution was extracted with ethyl 
acetate. The organic layer was washed with 20% Na2S2O3 solution, 1 N HCl, and brine followed 
by drying over sodium sulfate and silica gel column chromatography in 70% EtOAc in hexanes 
with 1% AcOH to give 3.60 g (2.77 mmol, 99%) of the orange foam 17. [α]D23 = 74.99 (c = 1.0, 
CHCl3), 1H NMR (600 MHz, CD3OD/CDCl3 4:1) δ 7.40 – 7.13 (m, 30H), 6.12 (d, J = 3.6 Hz, 1H, H-1’), 
5.56 (d, J = 4.8 Hz, 1H, H-1’’), 4.90 (d, J = 11.0 Hz, 1H, PhCH2O), 4.87 (d, J = 10.8 Hz, 1H, PhCH2O), 






(d, J = 9.4 Hz, 1H, H-5’), 4.51 – 4.40 (m, 6H, PhCH2O), 4.35 (d, J = 12.2 Hz, 1H, PhCH2O), 4.33 (d, J 
= 12.2 Hz, 1H, PhCH2O), 4.19 – 4.14 (m, 2H, H-3’’, H-5’’), 3.92 (t, J = 4.6 Hz, 1H, H-2’’), 3.85 (dd, J 
= 9.9, 8.4 Hz, 1H, H-3’), 3.80 (t, J = 2.9 Hz, 1H, H-3’’’), 3.79 – 3.71 (m, 4H, H-5, H-4’, H-5’’, H-5’’’), 
3.68 (t, J = 9.4 Hz, 1H, H-4), 3.55 – 3.50 (m, 2H, H-5’’, H-6’’’), 3.50 – 3.42 (m, 2H, H-1, H-3), 3.31 
(t, J = 2.3 Hz, 1H, H-2’’’), 3.29 – 3.23 (m, 2H, H-6, H-4’’’), 3.11 (dd, J = 9.8, 3.6 Hz, 1H, H-2’), 3.03 
(dd, J = 12.9, 4.1 Hz, 1H, H-6’’’), 2.20 (dt, J = 12.8, 4.6 Hz, 1H, H-2eq), 1.39 (q, J = 12.6 Hz, 1H, H-
2ax). 13C NMR (151 MHz, CD3OD/CDCl3 4:1) δ 171.9 (C-6’), 138.2, 138.1, 138.0, 137.6, 137.4, 
137.3, 128.3, 128.2, 128.13, 128.10, 128.0, 127.94, 127.91, 127.9, 127.84, 127.82, 127.7, 127.58, 
127.55, 127.4, 127.3, 127.2 (Ar), 106.7 (C-1’’), 98.5 (C-1’’’), 96.2 (C-1’), 83.9 (C-6), 82.0 (C-3’’), 
81.8 (C-5), 81.5 (C-2’’), 78.7 (C-3’), 75.8 (C-4), 75.7 (C-4’’), 74.8 (PhCH2O), 74.6 (C-5’’), 74.2 
(PhCH2O), 73.2 (C-3’’), 73.1 (PhCH2O), 72.9 (PhCH2O), 72.3 (PhCH2O), 71.9 (C-4’’’), 71.8 (C-4’), 71.7 
(PhCH2O), 70.1 (C-5’’), 62.1 (C-2’), 60.4 (C-1), 59.7 (C-3), 57.2 (C-2’’’), 50.9 (C-6’’’), 31.8 (C-2). ESI-
HRMS: m/z calc for C69H69N15O15Na [M+Na]+ 1322.4995, found 1322.5044. 
1,3,2’,2’’’,6’’’-Pentaazido-6,3’,2’’,5’’,3’’’,4’’’-hexa-O-benzyl-6’-(N-methyl-N-
methoxy)amido-1,3,2’,2’’’,6’’’-pentadeaminoparomomycin (18). Compound 17 (4.64 g, 3.57 
mmol), DMAP (0.0911 g, 0.716 mmol) DMAP, and N,O-dimethylhydroxylamine hydrochloride 
(0.5242 g, 5.37 mmol) were stirred under argon in 30 mL DCM followed by addition of DCC 
(1.1051 g, 5.356 mmol) in 5.7 mL of DCM. After two hours DCC (0.3684 g, 1.785 mmol) in 1 mL of 
DCM was added to the reaction mixture. After another hour no starting material was detected 
by TLC and the reaction mixture was concentrated under vacuum. The crude residue was 






concentrated. The crude residue was then subjected to flash column chromatography over silica 
gel with 40% EtOAc in hexanes. Following chromatography, the product still contained some 
dicyclohexyl urea biproduct which was removed by dissolving the residue in a minimal amount 
of toluene and filtering while cold. Concentration of the filtrate gave 3.22 g (2.40 mmol 67%) of 
18 as a white foam. [α]D23 = 89.10 (c = 1.0, CHCl3) 1H NMR (600 MHz, CDCl3) δ 7.45 – 7.10 (m, 30H, 
Ar-H), 6.28 (d, J = 3.5 Hz, 1H, H-1’), 5.66 (d, J = 6.2 Hz, 1H, H-1’’), 4.97 (d, J = 10.5 Hz, 1H, PhCH2O), 
4.88 – 4.82 (m, 3H, H-1’’’, PhCH2O), 4.79 (br d, J = 9.1 Hz, 1H, H-5’), 4.67 (d, J = 10.5 Hz, 1H, 
PhCH2O), 4.61 (d, J = 12.1 Hz, 1H, PhCH2O), 4.53 (d, J = 11.7 Hz, 1H, PhCH2O), 4.50 (d, J = 11.6 Hz, 
1H, PhCH2O), 4.44 – 4.38 (m, 3H, PhCH2O), 4.30 (d, J = 12.0 Hz, 1H, PhCH2O), 4.27 – 4.23 (m, 2H, 
H-4’’’, PhCH2O), 4.22 (dd, J = 5.0, 2.0 Hz, 1H, H-3’’), 4.04 (t, J = 9.4 Hz, 1H, H-3’), 4.01 – 3.95 (m, 
2H, H-5, H-4’), 3.89 (dd, J = 6.2, 5.0 Hz, 1H, H-2’’), 3.78 – 3.73 (m, 4H, H-4, H-5’’, H-3’’’, H-5’’’), 
3.72 (s, 3H, OCH3), 3.60 (dd, J = 12.9, 8.4 Hz, 1H, H-6’’’), 3.54 (dd, J = 10.4, 3.0 Hz, 1H, H-5’’), 3.52 
– 3.42 (m, 2H, H-1, H-3), 3.32 (t, J = 2.5 Hz, 1H, H-2’’’), 3.28 (s, 3H, NCH3), 3.24 (t, J = 9.3 Hz, 1H, 
H-6), 3.11 (d, J = 2.4 Hz, 1H, H-4’’’), 3.03 (dd, J = 10.1, 3.5 Hz, 1H, H-2’), 2.89 (dd, J = 13.0, 4.1 Hz, 
1H, H-6’’’), 2.24 (dt, J = 13.1, 4.6 Hz, 1H, H-2eq), 1.33 (q, J = 12.8 Hz, 1H, H-2ax). 13C NMR (151 
MHz, CDCl3) δ 169.2 (C-6’), 138.2, 138.0, 137.8, 137.5, 137.0, 136.9, 128.7, 128.49, 128.47, 
128.43, 128.40, 128.36, 128.3, 128.24, 128.17, 128.1, 127.8, 127.62, 127.61, 127.5 (Ar), 105.8 (C-
1’’), 98.8 (C-1’’’), 96.3 (C-6), 84.5 (C-2’’), 82.5 (C-4’’), 82.2 (C-5), 81.8 (C-3’), 78.5 (C-3’’), 75.6 
(PhCH2O), 75.1 (PhCH2O), 74.6 (C-4), 74.3 (C-5’’’), 73.4 (PhCH2O), 73.3 (PhCH2O), 72.9 (C-3’’’), 72.4 
(PhCH2O), 71.9 (C-4’), 71.7 (PhCH2O), 71.4 (C-4’’’), 69.9 (C-5’’), 68.5 (C-5’), 62.2 (C-2’), 62.1 (OCH3), 
60.4 (C-1), 60.3 (C-3), 57.2 (C-2’’’), 51.0 (C-6’’’), 32.8 (C-2), 32.4 (NCH3). ESI-HRMS: m/z calc for 







trimethylsilyl-1,3,2’,2’’’,6’’’-pentadeaminoparomomycin (19). HMDS (0.55 mL, 2.6 mmol) was 
added to a stirred solution of compound 18 (1.17 g, 0.87 mmol) in 8.7 mL MeCN under argon. 
After three hours no starting material was detected by TLC. The reaction mixture was 
concentrated under vacuum and the white foam was used without further purification. ESI-
HRMS: m/z calc for C70H82N16O15SiNa [M+Na]+ 1437.5813, found 1437.5868.  0.6 mL of 3M 
MeMgCl in THF were added to a stirred solution of amide in 8.8 mL of THF at -78oC. The reaction 
mixture was stirred for 5 minutes then transferred to an ice bath and stirred for another 10 
minutes before quenching with 1 mL of NH4Cl solution. The THF was then removed under 
vacuum, diluted with Et2O, and washed with NH4Cl solution and brine. The organic layer was 
dried with Na2SO4, filtered, and concentrated. The crude residue was purified over silica gel with 
gradient elution of 0% ethyl acetate in hexanes to 80% to give 0.4673 g (0.3408 mmol, 39%) of 
ketone 19 as a white foam. [α]D23 = 104.20 (c = 1.0, CHCl3) 1H NMR (600 MHz, CDCl3) δ 7.39 – 7.15 
(m, 30H, Ar-H), 6.09 (d, J = 3.7 Hz, 1H, H-1’), 5.61 (d, J = 5.4 Hz, 1H, H-1’’), 4.93 (d, J = 10.6 Hz, 1H, 
PhCH2O), 4.88 (d, J = 1.9 Hz, 1H, H-1’’’), 4.78 (s, 2H, PhCH2O), 4.72 (d, J = 10.7 Hz, 1H, PhCH2O), 
4.62 (d, J = 12.1 Hz, 1H, PhCH2O), 4.54 (d, J = 11.7 Hz, 1H, PhCH2O), 4.51 (d, J = 11.8 Hz, 1H, 
PhCH2O), 4.47 – 4.41 (m, 3H, PhCH2O), 4.40 (d, J = 4.5 Hz, 1H, H-5’), 4.34 – 4.23 (m, 4H, H-3’’, H-
4’’, PhCH2O), 3.94 – 3.88 (m, 2H, H-5, H-2’’), 3.82 – 3.76 (m, 3H, H-3’, H-5’’, H-5’’’), 3.75 (t, J = 2.9 
Hz, 1H, H-3’’’), 3.63 (dd, J = 13.0, 8.5 Hz, 1H, H-6’’’), 3.61 – 3.58 (m, 2H, H-4, H-4’), 3.56 (dd, J = 
10.5, 3.4 Hz, 1H, H-5’’), 3.48 – 3.39 (m, 2H, H-1, H-3), 3.35 (t, J = 2.7 Hz, 1H, H-2’’’), 3.27 (t, J = 9.3 
Hz, 1H, H-6), 3.13 (d, J = 2.6 Hz, 1H, H-4’’’), 2.94 – 2.88 (m, 2H, H-2’, H-6’’’), 2.27 (dt, J = 13.2, 4.6 






MHz, CDCl3) δ 204.6 (C-6’), 138.3, 138.1, 137.8, 137.6, 137.0, 136.9, 128.7, 128.5, 128.4, 128.34, 
128.32, 128.28, 128.23, 128.18, 127.82, 127.77, 127.74, 127.71, 127.54, 127.53, 127.49, 127.47 
(Ar), 106.3 (C-1’’), 98.5 (C-1’’’), 96.3 (C-1’), 84.0 (C-6), 82.2 (C-2’’), 82.0 (C-4’’), 81.9 (C-5), 80.0 (C-
3’), 76.1 (C-5’), 75.5 (C-4), 75.4 (C-3’’), 75.2 (PhCH2O), 75.0 (PhCH2O), 74.3 (C-5’’’), 73.3 (PhCH2O), 
73.1 (PhCH2O), 72.9 (C-3’’’), 72.5 (C-4’), 72.4 (PhCH2O), 71.7 (PhCH2O), 71.5 (C-4’’’), 70.2 (C-5’’), 
62.8 (C-2’), 60.3 (C-1), 59.9 (C-3), 57.3 (C-2’’’), 51.1 (C-6’’’), 32.4 (C-2), 28.6 (CH3), 0.5 (SiCH3). ESI-
HRMS: m/z calc for C69H79N15O14SiNa [M+Na]+ 1392.5598, found 1392.5637. 
1,3,2’,2’’’,6’’’-Pentaazido-6,3’,2’’,5’’,3’’’,4’’’-hexa-O-benzyl-6’-C-methyl-4’-O-
trimethylsilyl-1,3,2’,2’’’,6’’’-pentadeaminoparomomycin (20(R) and 20(S)), NaBH4 (0.0179 g, 
.4710 mmol) was added to a stirred solution of compound 19 (0.3228 g, .2355 mmol) in 2.4 mL 
of 1:1 THF/MeOH. The reaction mixture was stirred for 20 minutes then concentrated and the 
crude residue was dissolved in EtOAc, washed with water and brine, dried over Na2SO4, and 
concentrated to afford a 1:1 mixture of isomers of 20. Silica gel chromatography eluting with 16% 
EtOAc in hexanes followed by 18% then 20% afforded the compounds 20(S) (118.6 mg, 0.0864 
mmol, 37%) and 20(R) (123.0 mg, 0.0896 mmol, 38%) both as white foams. 20(R) [α]D23 = 97.00 
(c = 1.0, CHCl3),  1H NMR (600 MHz, CDCl3) δ 7.39 – 7.15 (m, 30H, Ar-H), 6.09 (d, J = 3.8 Hz, 1H, H-
1’), 5.63 (d, J = 5.4 Hz, 1H, H-1’’), 4.95 (d, J = 10.6 Hz, 1H, PhCH2O), 4.91 (d, J = 1.9 Hz, 1H, H-1’’’), 
4.82 (d, J = 11.2 Hz, 1H, PhCH2O), 4.75 – 4.70 (m, 2H, PhCH2O), 4.62 (d, J = 12.1 Hz, 1H, PhCH2O), 
4.56 (d, J = 11.8 Hz, 1H, PhCH2O), 4.52 – 4.39 (m, 4H, PhCH2O), 4.33 – 4.30 (m, 2H, H-3’’, PhCH2O), 
4.29 (q, J = 2.8 Hz, 1H, H-4’’), 4.25 (d, J = 12.1 Hz, 1H, PhCH2O), 4.02 – 3.97 (m, 1H, H-6’), 3.96 – 






4, H-6’’’), 3.57 (dd, J = 10.5, 3.4 Hz, 1H, H-5’’), 3.50 – 3.41 (m, 2H, H-1, H-3), 3.37 (t, J = 2.6 Hz, 1H, 
H-2’’’), 3.29 (t, J = 9.3 Hz, 1H, H-6), 3.21 (dd, J = 9.9, 8.5 Hz, 1H, H-4’), 3.13 (t, J = 2.6 Hz, 1H, H-
4’’’), 2.88 (dd, J = 13.0, 3.8 Hz, 1H, H-6’’’), 2.82 (dd, J = 10.2, 3.8 Hz, 1H, H-2’), 2.24 (dt, J = 13.2, 
4.6 Hz, 1H, H-2eq), 1.42 (q, J = 12.7 Hz, 1H, H-2ax), 1.14 (d, J = 6.5 Hz, 3H, H-7’), 0.07 (s, 9H, SiCH3). 
13C NMR (151 MHz, Chloroform-d) δ 138.4, 138.2, 137.9, 137.6, 137.0, 136.9, 128.7, 128.5, 128.4, 
128.35, 128.33, 128.28, 128.2, 127.82, 127.79, 127.75, 127.71, 127.5, 127.45, 127.38, 127.37, 
127.2 (Ar), 106.3 (C-1’’), 98.5 (C-1’’’), 95.7 (C-1’), 84.1 (C-6), 82.2 (C-2’’), 81.99 (C-5), 81.96 (C-4’’), 
80.3 (C-3’), 75.4 (C-3’’), 75.02 (PhCH2O), 74.98 (C-4), 74.8 (PhCH2O), 74.4 (C-5’’’), 74.3 (C-5’), 73.23 
(C-4’), 73.21 (PhCH2O), 73.1 (PhCH2O), 72.9 (C-3’’’), 72.4 (PhCH2O), 71.7 (PhCH2O), 71.5 (C-4’’’), 
70.4 (C-5’’), 67.0 (C-6’), 63.3 (C-2’), 60.4 (C-1), 60.1 (C-3), 57.3 (C-2’’’), 51.2 (C-6’’’), 32.5 (C-2), 16.4 
(C-7’), 0.7 (SiCH3). ESI-HRMS: m/z calc for C69H81N15O14SiNa [M+Na]+ 1394.5754, found 
1394.5784.  20(S) [α]D23 = 97.20 (c = 1.0, DCM), 1H NMR (600 MHz, CDCl3) δ 7.39 – 7.16 (m, 30H, 
Ar-H), 6.11 (d, J = 3.8 Hz, 1H, H-1’), 5.68 (d, J = 5.7 Hz, 1H, H-1’’), 4.99 (d, J = 10.6 Hz, 1H, PhCH2O), 
4.95 (d, J = 1.9 Hz, 1H, H-1’’’), 4.78 (s, 2H, PhCH2O), 4.73 (d, J = 10.5 Hz, 1H, PhCH2O), 4.63 (d, J = 
12.1 Hz, 1H, PhCH2O), 4.58 (d, J = 11.9 Hz, 1H, PhCH2O), 4.52 – 4.44 (m, 3H, PhCH2O), 4.42 (d, J = 
12.0 Hz, 1H, PhCH2O), 4.36 (dd, J = 4.8, 2.5 Hz, 1H, H-3’’), 4.32 (d, J = 12.0 Hz, 1H, PhCH2O), 4.30 
(q, J = 2.5 Hz, 1H, H-4’’), 4.25 (d, J = 12.1 Hz, 1H, PhCH2O), 4.00 (dd, J = 5.7, 4.8 Hz, 1H, H-2’’), 3.94 
(t, J = 8.9 Hz, 1H, H-5), 3.93 – 3.88 (m, 1H, H-6’), 3.84 – 3.80 (m, 2H, H-5’’, H-5’’’), 3.79 – 3.75 (m, 
2H, H-3’, H-3’’’), 3.68 (dd, J = 13.0, 8.7 Hz, 1H, H-6’’’), 3.61 (d, J = 9.7 Hz, 1H, H-5’), 3.58 (dd, J = 
10.4, 2.9 Hz, 1H, H-5’’), 3.54 (dd, J = 9.8, 8.7 Hz, 1H, H-4), 3.47 – 3.41 (m, 3H, H-1, H-3, H-4’), 3.39 
– 3.36 (m, 1H, H-2’’’), 3.28 (t, J = 9.3 Hz, 1H, H-6), 3.14 – 3.12 (m, 1H, H-4’’’), 2.88 (dd, J = 13.1, 






(q, J = 12.5 Hz, 1H, H-2ax), 1.27 (d, J = 6.5 Hz, 3H, CH3), 0.10 (s, 9H, SiCH3). 13C NMR (151 MHz, 
CDCl3) δ 138.4, 138.3, 137.9, 137.6, 137.0, 136.9, 128.7, 128.5, 128.41, 128.36, 128.32, 128.27, 
128.19, 127.81, 127.79, 127.65, 127.58, 127.53, 127.51, 127.4, 127.1 (Ar), 106.2 (C-1’’), 98.6 (C-
1’’’), 95.7 (C-1’), 84.4 (C-6), 82.4 (C-2’’), 82.1 (C-4’’), 82.0 (C-5), 80.1 (C-3’), 75.4 (C-3’’), 75.1 
(PhCH2O), 75.0 (PhCH2O), 74.8 (C-4), 74.6 (C-5’), 74.5 (C-5’’’), 73.2 (PhCH2O), 73.0 (PhCH2O), 72.9 
(C-3’’’), 72.4 (PhCH2O), 71.7 (PhCH2O), 71.5 (C-4’’’), 71.3 (C-4’), 70.3 (C-5’’), 64.3 (C-6’), 63.1 (C-
2’), 60.4 (C-1), 60.1 (C-3), 57.3 (C-2’’’), 51.2 (C-6’’’), 32.7 (C-2), 20.7 (C-7’), 0.6 (SiCH3). ESI-HRMS: 
m/z calc for C69H81N15O14SiNa [M+Na]+ 1394.5754, found 1394.5760. 
6’-(R)-C-methyl-paromomycin pentaacetate salt (22(R)). 1M TBAF solution in THF (0.051 mL) 
was added dropwise to a stirred solution of compound 20(R) (26.7 mg, 0.0171 mmol) in 1.7 mL 
of THF under argon. When the starting material was no longer visible by TLC, the reaction 
mixture was diluted with Et2O and washed with of NaHCO3 solution and brine. The organic layer 
was then dried with Na2SO4, filtered, and concentrated to give the intermediate alcohol which 
was used without further purification. The previous alcohol was stirred in 0.4 mL of 1:1 
dioxane/10% AcOH in water with 58.0 mg of Pd/C under 50 psi of H2 for 18 hours. Once the 
reaction was determined to be complete by LCMS the reaction mixture was diluted with water 
and filtered through Celite. The resulting crude product was purified over a CM Sephadex C-25 
column. The column was washed with 100 mL of DI water and eluted with NH4OH in water 
starting at 0.1% and increasing stepwise by 0.1% every 20 mL to 0.8%. Lyophilization of the 
pure fractions with AcOH gave 2.6 mg (0.003 mmol) of the pentaacetate salt 22(R) as a white 






H-1’), 5.31 (d, J = 2.8 Hz, 1H, H-1’’), 5.19 (d, J = 1.8 Hz, 1H, H-1’’’), 4.44 (dd, J = 6.5, 5.0 Hz, 1H, H-
3’’), 4.28 (dd, J = 5.0, 2.8 Hz, 1H, H-2’’), 4.25 – 4.21 (m, 1H, H-5’’’), 4.16 – 4.11 (m, 3H, H-6’, H-
4’’, H-3’’’), 3.86 – 3.79 (m, 2H, H-5’ [1dTOCSY 3.82 (dd, J = 10.1, 2.5 Hz)], H-5’’), 3.77 – 3.72 (m, 
3H, H-5, H-3’, H-4’’’), 3.70 (dd, J = 12.4, 4.9 Hz, 1H, H-5’’), 3.61 (t, J = 9.4 Hz, 1H, H-4), 3.52 (dd, J 
= 10.4, 9.2 Hz, 1H, H-6), 3.48 – 3.43 (m, 1H, H-2’’’), 3.38 – 3.32 (m, 2H, H-4’, H-6’’’), 3.29 (dd, J = 
13.6, 3.9 Hz, 1H, H-6’’’), 3.20 (dd, J = 10.7, 3.9 Hz, 1H, H-2’), 3.17 – 3.06 (m, 2H, H-1, H-3), 2.20 
(dt, J = 12.8, 4.3 Hz, 1H, H-2eq), 1.84 (s, 15H, AcOH), 1.51 (q, J = 12.6 Hz, 1H, H-2ax), 1.15 (d, J = 
6.6 Hz, 3H, H-7’). 13C NMR (151 MHz, D2O) δ 181.4 (AcOH), 109.7 (C-1’’), 96.9 (C-1’), 95.9 (C-1’’’), 
84.5 (C-6), 81.3 (C-4’’), 81.0 (C-4), 75.3 (C-3’’), 75.1 (C-5’), 73.5 (C-5), 73.4 (C-2’’), 70.37 (C-4’), 
70.35 (C-3’), 70.26 (C-5’’’), 68.0 (C-3’’’), 67.5 (C-4’’’), 65.7 (C-6’), 60.3 (C-5’’), 54.3 (C-2’), 51.0 (C-
2’’’), 50.2 (C-1), 49.3 (C-3), 40.4 (C-6’’’), 31.1 (C-2), 23.3 (AcOH), 14.8 (C-7’). ESI-HRMS: m/z calc 
for C24H47N5O14 [M+H]+ 630.3198, found 630.3212. 
6’-(S)-C-methyl-paromomycin pentaacetate salt (22(S)). 1M TBAF solution in THF (0.075 mL) 
was added dropwise to a stirred solution of compound 20(S) (32.8 mg, 0.024 mmol) in 2.3 mL of 
THF under argon. When the starting material was no longer visible by TLC, the reaction mixture 
was diluted with Et2O and washed with of NaHCO3 solution and brine. The organic layer was 
then dried with Na2SO4, filtered, and concentrated to give the intermediate alcohol which was 
used without further purification. The crude alcohol was stirred in 0.4 mL of 1:1 dioxane/10% 
AcOH in water with 58.0 mg of Pd/C under 50 psi of H2 for 18 hours. Once the reaction was 
determined to be complete by LCMS the reaction mixture was diluted with water and filtered 






column was washed with 100 mL of DI water and eluted with NH4OH in water starting at 0.1% 
and increasing stepwise by 0.1% every 20 mL to 0.8%. Lyophilization of the pure fractions with 
AcOH gave 5.2 mg (0.006 mmol) of the pentaacetate salt 22(S) as a white solid in 25% yield. [α]-
D
23 = 50.87 (c = 0.6, H2O), 1H NMR (600 MHz, D2O) δ 5.61 (d, J = 3.8 Hz, 1H, H-1’), 5.31 (d, J = 2.5 
Hz, 1H, H-1’’), 5.20 (d, J = 1.8 Hz, 1H, H-1’’’), 4.46 (dd, J = 6.7, 4.9 Hz, 1H, H-3’’), 4.29 (dd, J = 5.0, 
2.5 Hz, 1H, H-2’’), 4.26 – 4.21 (m, 1H, H-5’’’), 4.17 – 4.10 (m, 3H, H-6’ [1dTOCSY 4.13 (qd, J = 6.6, 
1.6 Hz)], H-4’’, H-3’’’), 3.85 (dd, J = 12.4, 3.1 Hz, 1H, H-5’’), 3.79 (dd, J = 10.8, 8.6 Hz, 1H, H-3’), 
3.76 – 3.68 (m, 3H, H-5, H-5’’, H-4’’’), 3.59 – 3.50 (m, 4H, H-4, H-6, H-4’, H-5’), 3.49 – 3.45 (m, 
1H, H-2’’’), 3.35 (dd, J = 13.7, 6.9 Hz, 1H, H-6’’’), 3.29 (dd, J = 13.6, 3.9 Hz, 1H, H-6’’’), 3.21 (dd, J 
= 10.8, 3.8 Hz, 1H, H-2’), 3.16 (ddd, J = 12.4, 10.4, 4.2 Hz, 1H, H-1), 2.96 (ddd, J = 12.1, 9.6, 4.3 
Hz, 1H, H-3), 2.15 (dt, J = 12.9, 4.3 Hz, 1H, H-2eq), 1.84 (s, 15H, AcOH), 1.47 (q, J = 12.6 Hz, 1H, 
H-2ax), 1.21 (d, J = 6.6 Hz, 3H, H-7’). 13C NMR (151 MHz, D2O) δ 181.4 (AcOH), 109.8 (C-1’’), 96.4 
(C-1’), 95.8 (C-1’’’), 84.8 (C-5), 81.8 (C-4), 81.2 (C-4’’), 75.4 (C-5’), 75.2 (C-3’’), 73.4 (C-2’’), 73.2 
(C-6), 70.3 (C-5’’’), 69.7 (C-3’), 69.5 (C-4’), 68.0 (C-3’’’), 67.4 (C-4’’’), 64.1 (C-6’), 60.1 (C-5’’), 54.3 
(C-2’), 51.0 (C-2’’’), 50.4 (C-1), 49.4 (C-3), 40.4 (C-6’’’), 31.5 (C-2), 23.3 (AcOH), 18.9 (C-7’). ESI-
HRMS: m/z calc for C24H47N5O14 [M+H]+ 630.3198, found 630.3209. 
1,3,2’,2’’’,6’’’-Pentaazido-6,3’,2’’,5’’,3’’’,4’’’-hexa-O-benzyl-4’,6’-O-benzylidene-6’-(S)-
C-methyl-1,3,2’,2’’’,6’’’-pentadeaminoparomomycin (21). A 1 M TBAF solution in THF (0.38 mL) 
was added to a stirred solution of compound 20(S) (0.1722 g, 0.126 mmol) in THF (4.6 mL) under 
Ar. After 2 hours the reaction mixture was diluted with Et2O, washed with aqueous saturated 






0.125 mmol, 99 %) was used in the next step without purification. Benzaldehyde dimethyl acetal 
(23 µL, 0.15 mmol) was added to a stirred solution of diol (0.1631 g, 0.125 mmol) and CSA (3.2 
mg, 14 µmol) in MeCN (3.3 mL). After 30 minutes CSA (2.2 mg, 9.5 µmol) and benzaldehyde 
dimethyl acetal (22 µL, 0.15 mmol) were added and the reaction mixture was stirred for an 
additional 30 minutes monitoring by LCMS and TLC until starting material was consumed. The 
reaction was quenched with Et3N, diluted with Et2O, and washed with aqueous saturated NaHCO3 
solution and brine. The organic layer was concentrated and the resulting residue was purified 
using silica gel column chromatography in 20 % EtOAc in hexanes to give the acetal 21 (0.1004 g, 
0.0723 mmol) in 60 % yield as a white foam. [α]D23 = 66.05 (c = 1.0, CHCl3), 1H NMR (600 MHz, 
C6D6) δ 7.64 – 7.59 (m, 2H, Ar-H), 7.52 – 7.49 (m, 2H, Ar-H), 7.46 – 7.42 (m, 2H, Ar-H), 7.32 – 7.28 
(m, 4H, Ar-H), 7.20 (t, J = 7.8 Hz, 2H, Ar-H), 7.18 – 6.96 (m, 23H, Ar-H), 6.41 (d, J = 3.8 Hz, 1H, H-
1’), 5.98 (d, J = 5.5 Hz, 1H, H-1’’), 5.71 (s, 1H, PhCH(O)2), 5.06 (d, J = 11.5 Hz, 1H, PhCH2O), 5.00 
(d, J = 2.1 Hz, 1H, H-1’’’), 4.96 (d, J = 10.5 Hz, 1H, PhCH2O), 4.90 (d, J = 11.5 Hz, 1H, PhCH2O), 4.67 
(dd, J = 10.3, 5.9 Hz, 1H, H-5’), 4.63 (q, J = 6.5 Hz, 1H, H-6’), 4.60 – 4.58 (m, 2H, H-4’’, PhCH2O), 
4.50 (dd, J = 4.8, 2.7 Hz, 1H, H-3’’), 4.45 – 4.37 (m, 4H, H-3’, PhCH2O), 4.31 (d, J = 12.0 Hz, 1H, 
PhCH2O), 4.29 (d, J = 12.0 Hz, 1H, PhCH2O), 4.14 (t, J = 5.2 Hz, 1H, H-2’’), 4.08 (d, J = 11.8 Hz, 1H, 
PhCH2O), 4.00 – 3.97 (m, 2H, PhCH2O), 3.95 (dd, J = 10.5, 2.3 Hz, 1H, H-5’’), 3.83 – 3.77 (m, 2H, H-
5, H-4’), 3.75 (ddd, J = 8.4, 4.1, 2.0 Hz, 1H, H-5’’’), 3.67 (t, J = 3.1 Hz, 1H, H-3’’’), 3.59 (dd, J = 10.5, 
3.1 Hz, 1H, H-5’’), 3.56 (t, J = 9.3 Hz, 1H, H-4), 3.43 (dd, J = 12.8, 8.4 Hz, 1H, H-6’’’), 3.35 (t, J = 2.8 
Hz, 1H, H-2’’’), 3.13 (dd, J = 10.3, 3.8 Hz, 1H, H-2’), 2.96 (t, J = 2.6 Hz, 1H, H-4’’’), 2.85 (t, J = 9.5 
Hz, 1H, H-6), 2.78 – 2.68 (m, 2H, H-3, H-6’’’), 2.54 (ddd, J = 12.3, 9.7, 4.5 Hz, 1H, H-1), 1.36 (dt, J = 






(151 MHz, C6D6) δ 138.7, 138.6, 138.44, 138.35, 137.9, 137.4, 137.3, 128.44, 128.35, 128.33, 
128.24, 128.22, 128.18, 128.17, 128.15, 128.01, 128.00, 127.98, 127.90, 127.88, 127.6, 127.3, 
127.2, 126.4 (Ar), 106.3 (C-1’’), 98.8 (C-1’’’), 97.3 (C-1’), 94.0 (PhCH(O)2), 83.9 (C-6), 82.6 (C-2’’), 
82.5 (C-4’’), 81.8 (C-5), 76.3 (C-4’), 76.3 (C-3’), 75.9 (C-3’’), 75.5 (C-4), 74.94 (PhCH2O), 74.85 
(PhCH2O), 74.2 (C-5’’’), 73.5 (C-3’’’), 73.1 (PhCH2O), 72.9 (PhCH2O), 72.4 (C-4’’’), 72.2 (PhCH2O), 
71.6 (PhCH2O), 70.4 (C-5’’), 70.3 (C-6’), 65.3 (C-5’), 62.8 (C-2’), 60.0 (C-1), 59.9 (C-3), 56.7 (C-2’’’), 
51.0 (C-6’’’), 31.8 (C-2), 11.1 (C-7’). ESI-HRMS: m/z calc for C73H77N15O14Na [M+Na]+ 1410.5672, 
found 1410.5674. 
1,3,2’,2’’’,6’’’-Pentaazido-6,3’,2’’,5’’,3’’’,4’’’-hexa-O-benzyl-6’-C-dimethyl-4’-O-
trimethylsilyl-1,3,2’,2’’’,6’’’-pentadeaminoparomomycin (23). 0.1 mL of 3M MeMgCl in THF 
were added to a stirred solution of compound 19 (0.152 g, 0.111 mmol) in 1.1 mL of THF at -30oC. 
The reaction mixture was stirred for 30 minutes before quenching with 0.5 mL of NH4Cl solution. 
The reaction mixture was then diluted with Et2O then washed with NH4Cl solution and brine. The 
organic layer was dried with Na2SO4, filtered, and concentrated. The crude residue was purified 
over silica gel in 20% EtOAc in hexanes to give 0.120 g (0.087 mmol, 78%) of compound 23 as a 
white foam. [α]D23 = 102.28 (c = 1.0, CHCl3), 1H NMR (600 MHz, CDCl3) δ 7.40 – 7.15 (m, 30H, Ar-
H), 6.10 (d, J = 3.9 Hz, 1H, H-1’), 5.67 (d, J = 5.8 Hz, 1H, H-1’’), 4.97 (d, J = 1.9 Hz, 1H, H-1’’’), 4.96 
(d, J = 11.2 Hz, 1H, PhCH2O), 4.94 (d, J = 12.2 Hz, 1H, PhCH2O), 4.75 (d, J = 10.5 Hz, 1H, PhCH2O), 
4.64 (d, J = 11.5 Hz, 1H, PhCH2O), 4.63 (d, J = 12.1 Hz, 1H, PhCH2O), 4.58 (d, J = 11.9 Hz, 1H, 
PhCH2O), 4.49 – 4.41 (m, 4H, PhCH2O), 4.37 – 4.31 (m, 2H, H-3’’, PhCH2O), 4.28 (q, J = 2.7 Hz, 1H, 






H-3’’, H-5’’, H-5’’’), 3.74 (d, J = 9.6 Hz, 1H, H-5’), 3.70 (dd, J = 13.0, 8.7 Hz, 1H, H-6’’’), 3.64 (dd, J = 
9.8, 8.9 Hz, 1H, H-4), 3.58 – 3.54 (m, 2H, H-5’’, OH), 3.50 – 3.42 (m, 2H, H-1, H-3), 3.41 – 3.37 (m, 
2H, H-4’, H-2’’’), 3.28 (t, J = 9.4 Hz, 1H, H-6), 3.14 – 3.11 (m, 1H, H-4’’’), 2.86 (dd, J = 13.1, 3.6 Hz, 
1H, H-6’’’), 2.70 (dd, J = 10.0, 3.9 Hz, 1H, H-2’), 2.24 (dt, J = 13.3, 4.6 Hz, 1H, H-2eq), 1.38 (q, J = 
12.7 Hz, 1H, H-2ax), 1.26 (s, 3H, -CH3), 1.19 (s, 3H, -CH3), 0.08 (s, 9H, -OTMS). 13C NMR (151 MHz, 
CDCl3) δ 138.4, 138.3, 137.9, 137.6, 137.0, 136.9, 128.7, 128.5, 128.42, 128.38, 128.34, 128.31, 
128.2, 128.14, 127.8, 127.68, 127.56, 127.45, 127.2, 127.1, 126.9 (Ar), 106.1 (C-1’’), 98.6 (C-1’’’), 
95.6 (C-1’), 84.4 (C-6), 82.2 (C-2’’), 82.0 (C-4’’), 81.8 (C-5), 79.7 (C-3’), 75.3 (C-3’’), 75.2 (PhCH2O), 
74.9 (C-4), 74.8 (C-5’), 74.6 (C-5’’’), 73.6 (PhCH2O), 73.4 (C-4’), 73.1 (PhCH2O), 73.0 (PhCH2O), 72.8 
(C-3’’’), 72.4 (PhCH2O), 72.0 (C-6’), 71.7 (PhCH2O), 71.5 (C-4’’’), 70.4 (C-5’’), 63.5 (C-2’), 60.5 (C-
1), 60.2 (C-3), 57.2 (C-2’’’), 51.2 (C-6’’’), 32.7 (C-2), 27.0 (-CH3), 24.7 (-CH3), 0.9 (-OTMS). ESI-
HRMS: m/z calc for C70H83N15O14SiNa [M+Na]+ 1408.5911, found 1408.5900. 
6’,6’-C-dimethyl-paromomycin (24). A 1M TBAF solution in THF (0.13 mL) was added 
dropwise to a stirred solution of compound 23 (0.0564 mg, 0.0407 mmol) in 1.6 mL of THF under 
argon. When the starting material was no longer visible by TLC, the reaction mixture was diluted 
with Et2O and washed with of NaHCO3 solution and brine. The organic layer was then dried with 
Na2SO4, filtered, and concentrated to give the intermediate alcohol which was used without 
further purification. The crude alcohol was stirred in 0.6 mL of 1:1 dioxane/10% AcOH in water 
with 107.0 mg of Pd/C under 50 psi of H2 for 21 hours. Once the reaction was determined to be 
complete by LCMS the reaction mixture was diluted with water and filtered through Celite. The 






with 100 mL of DI water and eluted with NH4OH in water starting at 0.1% and increasing stepwise 
by 0.1% every 20 mL to 0.8%. Lyophilization of the pure fractions with AcOH gave 20.4 mg (0.022 
mmol) of the penta acetate salt 24 as a white solid in 54% yield. [α]D23 = 35.00 (c = 1.0, H2O), 1H 
NMR (600 MHz, D2O) δ 5.59 (d, J = 3.9 Hz, 1H, H-1’), 5.23 (d, J = 2.9 Hz, 1H, H-1’’), 5.15 (d, J = 1.8 
Hz, 1H, H-1’’’), 4.36 (t, J = 5.7 Hz, 1H, H-3’’), 4.20 (dd, J = 5.1, 3.0 Hz, 1H, H-2’’), 4.17 (td, J = 4.8, 
3.9, 2.3 Hz, 1H, H-5’’’), 4.09 (t, J = 3.2 Hz, 1H, H-3’’’), 4.08 – 4.06 (m, 1H, H-4’’), 3.77 (dd, J = 12.4, 
3.1 Hz, 1H, H-5’’), 3.74 – 3.65 (m, 4H, H-4, H-5, H-3’, H-4’’’), 3.62 (dd, J = 12.4, 4.9 Hz, 1H, H-5’’), 
3.54 – 3.49 (m, 2H, H-6, H-5’), 3.44 (br. s, 1H, H-2’’’), 3.40 (t, J = 9.3 Hz, 1H, H-4’), 3.29 (dd, J = 
13.7, 6.6 Hz, 1H, H-6’’’), 3.26 – 3.21 (m, 2H, H-2’, H-6’’’), 3.21 – 3.12 (m, 2H, H-1, H-3), 2.21 (dt, J 
= 12.8, 4.3 Hz, 1H, H-2eq), 1.77 (s, 15H, AcOH), 1.56 (q, J = 12.6 Hz, 1H, H-2ax), 1.20 (s, 3H, -CH3), 
1.14 (s, 3H, -CH3). 13C NMR (151 MHz, D2O) δ 181.2 (AcOH), 109.8 (C-1’’), 95.9 (C-1’), 95.5 (C-1’’’), 
84.4 (C-5), 81.4 (C-4’’), 79.7 (C-4), 77.2 (C-5’), 75.4 (C-3’’), 73.3 (C-2’’), 72.6 (C-6), 72.3 (C-6’), 70.7 
(C-4’), 70.2 (C-5’’’), 69.7 (C-3’), 67.6 (C-3’’’), 67.2 (C-4’’’), 60.2 (C-5’’), 53.9 (C-2’), 50.8 (C-2’’’), 49.9 
(C-1), 49.2 (C-3), 40.3 (C-6’’’), 29.8 (C-2), 26.3 (-CH3), 23.3 (-CH3), 23.1 (AcOH). ESI-HRMS: m/z calc 
for C25H50N5O14 [M+H]+ 644.3354, found 644.3358. 
1,3,2’,2’’’,6’’’-pentaazido-6,3’,2’’,5’’,3’’’,4’’’-hexa-O-benzyl-6’-O-triisopropylsilyl-
1,3,2’,2’’’,6’’’-pentadeaminoparomomycin (25). TIPSOTf (1.25 mL, 4.7 mmol) was added to a 
stirred solution of 16 (5.06 g, 3.93 mmol) and lutidine (2.3 mL, 19.7 mmol) in DCM (79 mL) under 
argon. The reaction mixture was stirred for 1 hour monitoring by TLC and LCMS then quenched 
with methanol and concentrated under vacuum. The crude residue was dissolved in EtOAc and 






Na2SO4, filtered, and concentrated. The crude product was purified over silica gel eluting with 18-
20% EtOAc in hexanes to give 25 (4.64 g, 3.22 mmol) as a white foam in 82% yield. [α]D23 = 68.1 
(c = 1.0, DCM), 1H NMR (600 MHz, CDCl3) δ 7.44 – 7.11 (m, 30H, Ar-H), 6.14 (d, J = 3.7 Hz, 1H, H-
1’), 5.67 (d, J = 5.8 Hz, 1H, H-1’’), 4.97 (d, J = 10.6 Hz, 1H, PhCH2O), 4.87 (d, J = 1.9 Hz, 1H, H-1’’’), 
4.85 (s, 2H, PhCH2O), 4.69 (d, J = 10.6 Hz, 1H, PhCH2O), 4.62 (d, J = 12.1 Hz, 1H, PhCH2O), 4.59 (d, 
J = 11.7 Hz, 1H, PhCH2O), 4.52 (d, J = 11.9 Hz, 1H, PhCH2O), 4.45 (d, J = 11.8 Hz, 1H, PhCH2O), 4.43 
(d, J = 12.0 Hz, 1H, PhCH2O), 4.40 (d, J = 12.0 Hz, 1H, PhCH2O), 4.30 (d, J = 12.1 Hz, 1H, PhCH2O), 
4.29 – 4.27 (m, 1H, H-4’’), 4.26 – 4.22 (m, 2H, H-3’’, PhCH2O), 4.01 (dt, J = 9.6, 5.7 Hz, 1H, H-5’), 
3.98 – 3.91 (m, 4H, H-5, H-3’, H-6’, H-2’’), 3.86 (dd, J = 10.1, 5.9 Hz, 1H, H-6’), 3.80 (dd, J = 10.4, 
2.3 Hz, 1H, H-5’’), 3.77 – 3.73 (m, 2H, H-3’’’, H-5’’’), 3.70 (dd, J = 9.8, 8.9 Hz, 1H, H-4), 3.63 (dd, J 
= 13.0, 8.6 Hz, 1H, H-6’’’), 3.56 (dd, J = 10.4, 3.2 Hz, 1H, H-5’’), 3.50 – 3.40 (m, 3H, H-1, H-3, H-4’), 
3.34 (t, J = 2.6 Hz, 1H, H-2’’’), 3.26 (t, J = 9.4 Hz, 1H, H-6), 3.11 (t, J = 2.5 Hz, 1H, H-4’’’), 3.03 (s, 
1H, 4’-OH), 2.96 (dd, J = 10.3, 3.7 Hz, 1H, H-2’), 2.87 (dd, J = 13.0, 3.9 Hz, 1H, H-6’’’), 2.23 (dt, J = 
13.2, 4.6 Hz, 1H, H-2eq), 1.36 (q, J = 12.8 Hz, 1H, H-2ax), 1.19 – 1.12 (m, 3H, TIPS-CH), 1.12 – 1.08 
(m, 18H, TIPS-CH3). 13C NMR (151 MHz, CDCl3) δ 138.34, 138.29, 137.9, 137.6, 137.0, 136.9, 128.7, 
128.50, 128.47, 128.42, 128.34, 128.32, 128.29, 128.24, 128.18, 127.83, 127.80, 127.77, 127.75, 
127.5, 127.4, 127.3 (Ar), 106.0 (C-1’’), 98.6 (C-1’’’), 95.7 (C-1’), 84.3 (C-6), 82.5 (C-2’’), 82.1 (C-4’’), 
81.9 (C-5), 79.4 (C-3’), 75.5 (C-3’’), 75.0 (PhCH2O), 74.6 (C-4), 74.3 (C-5’’’), 74.2 (C-4’), 73.3 
(PhCH2O), 73.2 (PhCH2O), 72.8 (C-3’’’), 72.4 (PhCH2O), 71.7 (PhCH2O), 71.5 (C-4’’’), 70.8 (C-5’), 
70.2 (C-5’’), 65.6 (C-6’), 62.5 (C-2’), 60.3 (C-1), 60.1 (C-3), 57.3 (C-2’’’), 51.1 (C-6’’’), 32.6 (C-2), 18.0 
(OTIPS-CH3), 18.0 (OTIPS-CH3), 11.8 (OTIPS-CH). ESI-HRMS: m/z calcd for C74H95N16O14Si [M + 







O-triisopropylsilyl-1,3,2’,2’’’,6’’’-pentadeaminoparomomycin (26). NaH (0.2372g, 9.88 mmol) 
and TBAI (0.1468 g, .40 mmol) were added to a stirred solution of compound 25 (5.61 g, 3.89 
mmol) in DMF (33 mL) at 0 oC. After 20 minutes PMBCl (1.6 mL, 11.70 mmol) was added and the 
reaction mixture was warmed to rt. After 1.5 hours the reaction was quenched with 2 mL of 
saturated NH4Cl solution, diluted with EtOAc and washed with saturated NH4Cl solution, water, 
and brine. The organic layer was dried with Na2SO4, filtered, and concentrated. The crude residue 
was purified over silica gel to give compound 26 (5.39g, 89%) as a white foam. [α]D23 = 64.8 (c = 
1.0, CHCl3), 1H NMR (600 MHz, CDCl3) δ 7.39 – 7.12 (m, 32H, Ar-H), 6.87 – 6.84 (m, 2H, Ar-H), 6.12 
(d, J = 3.7 Hz, 1H, H-1’), 5.65 (d, J = 5.9 Hz, 1H, H-1’’), 4.94 (d, J = 10.7 Hz, 1H, PhCH2O), 4.88 (d, J 
= 1.9 Hz, 1H, H-1’’’), 4.86 – 4.82 (m, 2H, PhCH2O), 4.77 (d, J = 11.1 Hz, 1H, PhCH2O), 4.66 (d, J = 
10.7 Hz, 1H, PhCH2O), 4.63 – 4.60 (m, 2H, PhCH2O), 4.58 – 4.54 (m, 2H, PhCH2O), 4.46 (d, J = 11.7 
Hz, 1H, PhCH2O), 4.44 – 4.39 (m, 2H, PhCH2O), 4.31 (d, J = 12.0 Hz, 1H, PhCH2O), 4.26 (q, J = 2.8 
Hz, 1H, H-4’’), 4.25 – 4.21 (m, 2H, H-3’’, PhCH2O), 4.08 (dd, J = 10.4, 9.0 Hz, 1H, H-3’), 3.99 – 3.90 
(m, 3H, H-5, H-5’, H-2’’), 3.86 (dd, J = 11.0, 1.7 Hz, 1H, H-6’), 3.80 (s, 3H, -OCH3), 3.79 – 3.72 (m, 
4H, H-4, H-5’’, H-3’’’, H-5’’’), 3.69 (dd, J = 10.9, 5.7 Hz, 1H, H-6’), 3.60 (dd, J = 12.9, 8.4 Hz, 1H, H-
6’’’), 3.55 (dd, J = 10.5, 3.3 Hz, 1H, H-5’’), 3.48 – 3.37 (m, 2H, H-1, H-3), 3.37 – 3.32 (m, 2H, H-4’, 
H-2’’’), 3.24 (t, J = 9.3 Hz, 1H, H-6), 3.11 (t, J = 2.5 Hz, 1H, H-4’’’), 3.05 (dd, J = 10.4, 3.7 Hz, 1H, H-
2’), 2.88 (dd, J = 12.9, 4.2 Hz, 1H, H-6’’’), 2.20 (dt, J = 13.1, 4.6 Hz, 1H, H-2eq), 1.35 (q, J = 12.7 Hz, 
1H, H-2ax), 1.08 (d, J = 4.5 Hz, 21H, OTIPS). 13C NMR (151 MHz, CDCl3) δ 159.2, 138.3, 138.1, 
137.9, 137.7, 137.03, 136.97, 130.5, 129.5, 128.7, 128.5, 128.41, 128.39, 128.35, 128.33, 128.31, 






1’’’), 95.5 (C-1’), 84.2 (C-6), 82.6 (C-2’’), 82.0 (C-4’’), 81.7 (C-5), 80.3 (C-3’), 77.9 (C-4’), 75.6 (C-3’’), 
75.4 (PhCH2O), 75.0 (PhCH2O), 74.4 (C-5’’’), 74.3 (C-4), 74.2 (PhCH2O), 73.3 (PhCH2O), 73.2 
(PhCH2O), 72.9 (C-3’’’), 72.7 (C-5’), 72.3 (PhCH2O), 71.7 (PhCH2O), 71.4 (C-4’’’), 70.0 (C-5’’), 63.5 
(C-2’), 63.0 (C-6’), 60.3 (C-1), 60.0 (C-3), 57.3 (C-2’’’), 55.2 (OCH3), 51.0 (C-6’’’), 32.5 (C-2), 18.12 
(OTIPS-CH3), 18.10 (OTIPS-CH3), 12.0 (OTIPS-CH). ESI-HRMS: m/z calcd for C82H99N15O15SiNa [M + 
Na]+ 1584.7112, found 1584.7095. 
1,3,2’,2’’’,6’’’-pentaazido-6,3’,2’’,5’’,3’’’,4’’’-hexa-O-benzyl-4’-O-(4-methoxybenzyl)-
1,3,2’,2’’’,6’’’-pentadeaminoparomomycin (27). A 1M solution of TBAF in THF (7.5 mL) was 
added to a stirred solution of 26 (3.92 g, 2.51 mmol) in THF (43 mL) and the reaction mixture was 
stirred under argon for 3 hours with monitoring by TLC. After completion, the reaction mixture 
was concentrated under vacuum and the residue was dissolved in ethyl acetate and washed with 
saturated aqueous NaHCO3 followed by brine. The organic layer was dried with Na2SO4, filtered, 
and concentrated under vacuum. Purification over silica gel eluting with 20-30% EtOAc in 
Hexanes gave the product 27 (3.1 g, 2.20 mmol) in 88% yield as a white foam. [α]D23 = 79.10 (c = 
1.0, CHCl3), 1H NMR (600 MHz, CDCl3) δ 7.39 – 7.13 (m, 32H, Ar-H), 6.86 – 6.83 (m, 2H, Ar-H), 6.13 
(d, J = 3.7 Hz, 1H, H-1’), 5.67 (d, J = 5.6 Hz, 1H, H-1’’), 4.97 (d, J = 10.6 Hz, 1H, PhCH2O), 4.89 (d, J 
= 1.9 Hz, 1H, H-1’’’), 4.83 (s, 2H, PhCH2O), 4.75 (d, J = 10.9 Hz, 1H, PhCH2O), 4.71 (d, J = 10.6 Hz, 
1H, PhCH2O), 4.62 (d, J = 12.0 Hz, 1H, PhCH2O), 4.57 (d, J = 11.8 Hz, 1H, PhCH2O), 4.54 (d, J = 11.0 
Hz, 1H, PhCH2O), 4.51 (d, J = 11.9 Hz, 1H, PhCH2O), 4.49 – 4.43 (m, 2H, PhCH2O), 4.40 (d, J = 12.0 
Hz, 1H, PhCH2O), 4.34 – 4.29 (m, 3H, H-3’’, H-4’’, PhCH2O), 4.24 (d, J = 12.1 Hz, 1H, PhCH2O), 4.02 






(dt, J = 10.2, 3.1 Hz, 1H, H-5’), 3.82 (dd, J = 10.5, 2.1 Hz, 1H, H-5’’), 3.80 – 3.77 (m, 4H, H-5’’’, -
OCH3), 3.76 (t, J = 2.8 Hz, 1H, H-3’’’), 3.75 – 3.72 (m, 1H, H-6’), 3.66 (dd, J = 13.0, 8.6 Hz, 1H, H-
6’’’), 3.63 – 3.56 (m, 3H, H-4, H-6’, H-5’’), 3.46 – 3.39 (m, 2H, H-1, H-3), 3.37 – 3.33 (m, 2H, H-4’, 
H-2’’’), 3.29 (t, J = 9.3 Hz, 1H, H-6), 3.11 (t, J = 2.5 Hz, 1H, H-4’’’), 2.94 (dd, J = 10.3, 3.7 Hz, 1H, H-
2’), 2.86 (dd, J = 13.0, 3.7 Hz, 1H, H-6’’’), 2.22 (dt, J = 13.2, 4.6 Hz, 1H, H-2eq), 1.39 (q, J = 12.7 Hz, 
1H, H-2ax). 13C NMR (151 MHz, CDCl3) δ 159.2, 138.3, 138.0, 137.9, 137.5, 137.0, 136.9, 130.3, 
129.4, 128.7, 128.5, 128.42, 128.40, 128.34, 128.29, 128.26, 128.20, 128.1, 127.83, 127.79, 
127.75, 127.70, 127.6, 127.5, 127.1, 113.8 (Ar), 106.2 (C-1’’), 98.6 (C-1’’’), 95.7 (C-1’), 84.2 (C-6), 
82.5 (C-2’’), 82.1 (C-4’’), 82.0 (C-5), 79.8 (C-3’), 77.4 (C-4’), 75.5 (C-3’’), 75.3 (PhCH2O), 75.0 
(PhCH2O), 74.9 (C-4), 74.4 (C-5’’’), 73.2 (PhCH2O), 72.8 (C-3’’’), 72.4 (PhCH2O), 71.7 (PhCH2O), 71.6 
(C-5’), 71.4 (C-4’’’), 70.3 (C-5’’), 63.2 (C-2’), 61.6 (C-6’), 60.3 (C-1), 60.0 (C-3), 57.3 (C-2’’’), 55.3 (-
OCH3), 51.1 (C-6’’’), 32.4 (C-2). ESI-HRMS: m/z calcd for C73H79N15O15Na [M + Na]+ 1428.5778, 
found 1428.5724. 
1,3,2’,2’’’,6’’’-Pentaazido-6,3’,2’’,5’’,3’’’,4’’’-hexa-O-benzyl-6’-C-ethyl-1,3,2’,2’’’,6’’’-
pentadeaminoparomomycin (28(R) and 28(S)). Oxalyl chloride (0.125 mL, 1.42 mmol) was added 
to a stirred solution of DMSO (0.21 mL, 2.96 mmol) in DCM (7.1 mL) at -78oC under argon. After 
15 minutes compound 27 (1.0011 g, 0.712 mmol) was dissolved in DCM (3 mL) and added to the 
cold reaction mixture dropwise. The vial containing 27 was rinsed twice with DCM (1.5 mL) to 
ensure complete transfer. After 1 hour triethylamine (0.44 mL, 3.16 mmol) was added and the 
reaction mixture was allowed to slowly warm to room temperature before dilution with ether 






Na2SO4, filtered, and concentrated to give the intermediate aldehyde as a white foam (0.9823 g, 
0.699 mmol) in 98% yield which was used in the next step without purification. Freshly prepared 
EtMgBr 1M solution (1.4 mL) was added to a stirred solution of aldehyde (0.470 g, 0.335 mmol) 
in THF (6.7 mL) at -78 oC. After 1 hour the reaction was quenched with 1 mL aqueous saturated 
NH4Cl solution, diluted with Et2O, washed with NH4Cl solution and brine, dried with Na2SO4, and 
concentrated. The crude residue was then purified using silica gel column chromatography 
eluting with 25% EtOAc in Hexanes to give the intermediate alcohols (0.303 g, 0.211 mmol, 63%) 
as an inseparable mixture of diastereomers which were used without further purification. ESI-
HRMS: m/z calcd for C75H83N15O14Na [M + Na]+ 1456.6091, found 1456.6062. TFA (0.33 mL) was 
added to a stirred solution of the alcohols (0.283g, 0.197 mmol) in DCM (3 mL) at 0 oC. After 1 
hour the reaction mixture was diluted with Et2O and washed with aqueous saturated NaHCO3 
solution and brine. The organic layer was dried with Na2SO4 and concentrated followed by 
purification using silica gel column chromatography eluting with 28% EtOAc in Hexanes to give 
28(R) (23.9 mg, 0.018) in 9% isolated yield, 28(S) (90.3 mg, 0.069) in 35% isolated yield, as well 
as a mixture of 28(R) and 28(S) (91.5 mg, 0.070 mmol) in 35% yield. 28(R) [α]D23 = 88.00 (c = 0.5, 
DCM), 1H NMR (600 MHz, CDCl3) δ 7.42 – 7.12 (m, 30H, Ar-H), 6.14 (d, J = 3.7 Hz, 1H, H-1’), 5.67 
(d, J = 5.7 Hz, 1H, H-1’’), 4.97 (d, J = 10.6 Hz, 1H, PhCH2O), 4.91 – 4.87 (m, 2H, H-1’’’, PhCH2O), 
4.72 – 4.69 (m, 2H, PhCH2O), 4.62 (d, J = 12.1 Hz, 1H, PhCH2O), 4.56 (d, J = 11.8 Hz, 1H, PhCH2O), 
4.48 (d, J = 11.7 Hz, 1H, PhCH2O), 4.46 – 4.42 (m, 2H, PhCH2O), 4.40 (d, J = 12.0 Hz, 1H, PhCH2O), 
4.32 – 4.27 (m, 3H, H-3’’, H-4’’, PhCH2O), 4.24 (d, J = 12.1 Hz, 1H, PhCH2O), 3.97 – 3.93 (m, 2H, H-
5, H-2’’), 3.88 (dd, J = 10.3, 8.6 Hz, 1H, H-3’), 3.81 (dd, J = 10.3, 1.9 Hz, 1H, H-5’’), 3.79 – 3.74 (m, 






(m, 3H, H-1, H-3, H-4’), 3.35 (t, J = 2.6 Hz, 1H, H-2’’’), 3.28 (t, J = 9.3 Hz, 1H, H-6), 3.12 (t, J = 2.6 
Hz, 1H, H-4’’’), 2.89 – 2.85 (m, 2H, H-2’, H-6’’’), 2.24 (dt, J = 13.3, 4.6 Hz, 1H, H-2eq), 1.76 (dqd, J 
= 14.4, 7.5, 3.5 Hz, 1H, H-7’), 1.49 (ddd, J = 14.4, 8.6, 7.1 Hz, 1H, H-7’), 1.38 (q, J = 12.8 Hz, 1H, H-
2ax), 1.02 (t, J = 7.4 Hz, 3H, H-8’). 13C NMR (151 MHz, Chloroform-d) δ 138.2, 138.1, 137.9, 137.5, 
137.0, 136.9, 128.7, 128.6, 128.5, 128.4, 128.33, 128.32, 128.28, 128.26, 128.18, 128.15, 128.0, 
127.80, 127.78, 127.76, 127.72, 127.5, 127.4, 127.2 (Ar), 106.1 (C-1’’), 98.6 (C-1’’’), 95.6 (C-1’), 
84.3 (C-6), 82.4 (C-2’’), 82.1 (C-4’’), 81.9 (C-5), 79.6 (C-3’), 75.5 (C-3’’), 75.4 (C-6’), 75.1 (PhCH2O), 
75.04 (PhCH2O), 75.01 (C-4), 74.4 (C-5’’’), 73.7 (C-4’), 73.2 (PhCH2O), 73.1 (PhCH2O), 72.9 (C-3’’’), 
72.4 (PhCH2O), 72.1 (C-5’), 71.7 (PhCH2O), 71.5 (C-4’’’), 70.3 (C-5’’), 62.5 (C-2’), 60.4 (C-1), 60.3 
(C-3), 57.2 (C-2’’’), 51.1 (C-6’’’), 32.6 (C-2), 25.6 (C-7’), 9.8 (C-8’). ESI-HRMS: m/z calcd for 
C67H75N15O14Na [M + Na]+ 1336.5516, found 1336.5537. 28(S) [α]D23 = 74.30 (c = 1.0, DCM), 1H 
NMR (600 MHz, CDCl3) δ 7.40 – 7.15 (m, 30H, Ar-H), 6.17 (d, J = 3.6 Hz, 1H, H-1’), 5.70 (d, J = 5.9 
Hz, 1H, H-1’’), 5.01 (d, J = 10.5 Hz, 1H, PhCH2O), 4.94 – 4.90 (m, 2H, PhCH2O), 4.72 (d, J = 10.5 Hz, 
1H, PhCH2O), 4.68 (d, J = 11.4 Hz, 1H, PhCH2O), 4.63 (d, J = 12.1 Hz, 1H, PhCH2O), 4.59 (d, J = 11.9 
Hz, 1H, PhCH2O), 4.49 (d, J = 11.9 Hz, 1H, PhCH2O), 4.47 (s, 2H, PhCH2O), 4.41 (d, J = 12.0 Hz, 1H, 
PhCH2O), 4.34 – 4.30 (m, 3H, H-3’’, H-4’’, PhCH2O), 4.25 (d, J = 12.1 Hz, 1H, PhCH2O), 4.00 (dd, J = 
6.0, 4.6 Hz, 1H, H-2’’), 3.96 (t, J = 8.9 Hz, 1H, H-5), 3.88 (dd, J = 10.3, 8.9 Hz, 1H, H-3’), 3.84 (dd, J 
= 10.4, 2.2 Hz, 1H, H-5’’), 3.80 (ddd, J = 8.7, 3.8, 1.9 Hz, 1H, H-5’’’), 3.77 (t, J = 2.9 Hz, 1H, H-3’’’), 
3.73 (dd, J = 9.8, 1.4 Hz, 1H, H-5’), 3.70 – 3.64 (m, 2H, H-6’, H-6’’’), 3.59 (dd, J = 10.4, 2.7 Hz, 1H, 
H-5’’), 3.54 (t, J = 9.3 Hz, 1H, H-4), 3.52 – 3.49 (m, 1H, H-4’), 3.49 – 3.41 (m, 2H, H-1, H-3), 3.37 (t, 
J = 2.6 Hz, 1H, H-2’’’), 3.29 (t, J = 9.4 Hz, 1H, H-6), 3.14 – 3.11 (m, 1H, H-4’’’), 2.87 (dd, J = 13.0, 3.8 






(m, 2H, H-7’, -OH), 1.52 (dqd, J = 14.7, 7.5, 4.7 Hz, 1H, H-7’), 1.34 (q, J = 12.8 Hz, 1H, H-2ax), 1.02 
(t, J = 7.4 Hz, 3H, H-8’). 13C NMR (151 MHz, CDCl3) δ 138.3, 138.1, 137.9, 137.5, 137.0, 136.9, 
128.7, 128.6, 128.5, 128.41, 128.36, 128.33, 128.26, 128.2, 128.1, 128.0, 127.8, 127.7, 127.6, 
127.5, 127.0 (Ar), 106.1 (C-1’’), 98.7 (C-1’’’), 95.9 (C-1’), 84.4 (C-6), 82.5 (C-2’’), 82.2 (C-4’’), 82.0 
(C-5), 79.8 (C-3’), 75.5 (C-3’’), 75.1 (PhCH2O), 74.9 (PhCH2O), 74.8 (C-4), 74.5 (C-5’’’), 73.1 
(PhCH2O), 72.9 (C-3’’’), 72.7 (C-5’), 72.4 (PhCH2O), 71.7 (PhCH2O), 71.5 (C-4’’’), 70.7 (C-6’), 70.2 
(C-5’’), 70.0 (C-4’), 62.5 (C-2’), 60.4 (C-1), 60.3 (C-3), 57.2 (C-2’’’), 51.2 (C-6’’’), 32.7 (C-2), 27.0 (C-
7’), 10.5 (C-8’). ESI-HRMS: m/z calcd for C67H75N15O14Na [M + Na]+ 1336.5516, found 1336.5549. 
6’-(R)-C-ethyl-paromomycin (29(R)). Compound 28(R) (18.8 mg, 0.0143 mmol) was added to a 
16 mm test tube followed by 0.2 mL of dioxane and 0.2 mL of 10% AcOH in water. 38 mg of 
Pd/C were added to the tube and the reaction mixture was subjected to 48 psi H2 for 48 hours. 
Once the reaction was determined to be complete by LCMS the reaction mixture was diluted 
with water and filtered through Celite. The resulting crude product was purified using a CM 
Sephadex C-25 column. The column was washed with 50 mL of DI water and eluted with NH4OH 
in water starting at 0.1% and increasing stepwise by 0.1% every 20 mL to 0.8%. Lyophilization 
with AcOH gave the acetate salt 29(R) (2.3 mg, 0.0024 mmol) in 34% yield as a white powder. 
[α]D23 = 57.61 (c = 0.1, H2O), 1H NMR (600 MHz, D2O) δ 5.53 (d, J = 4.0 Hz, 1H, H-1’), 5.24 (d, J = 
2.8 Hz, 1H, H-1’’), 5.16 (d, J = 1.8 Hz, 1H, H-1’’’), 4.38 (t, 1H, H-3’’), 4.22 (dd, J = 5.1, 2.9 Hz, 1H, 
H-2’’), 4.20 – 4.16 (m, 1H, H-5’’’), 4.10 (t, J = 3.1 Hz, 1H, H-3’’’), 4.09 – 4.06 (m, 1H, H-4’’), 3.81 – 
3.68 (m, 7H, H-4, H-5, H-3’, H-5’ [J5’,6’ = 2.5 Hz extracted from HSQC], H-6’, H-5’’, H-4’’’), 3.64 






J = 9.5 Hz, 1H, H-4’), 3.36 – 3.15 (m, 5H, H-1, H-3, H-2’, H-6’’’, H-6’’’), 2.29 (dt, J = 13.2, 4.1 Hz, 
1H, H-2eq), 1.80 (s, 15H, AcOH), 1.65 (q, J = 12.5 Hz, 1H, H-2ax), 1.54 – 1.44 (m, 1H, H-7’), 1.43 – 
1.33 (m, 1H, H-7’), 0.84 (t, J = 7.4 Hz, 3H, H-8’). 13C NMR (151 MHz, D2O) δ 180.5 (AcOH), 109.7 
(C-1’’), 96.5 (C-1’), 95.4 (C-1’’’), 84.1 (C-5), 81.3 (C-4’’), 79.2 (C-4), 75.6 (C-5’), 75.2 (C-3’’), 73.4 
(C-2’’), 72.5 (C-6), 71.1 (C-6’), 70.1 (C-5’’’), 69.7 (C-4’), 69.5 (C-3’), 67.6 (C-3’’’), 67.2 (C-4’’’), 60.0 
(C-5’’), 53.8 (C-2’), 50.8 (C-2’’’), 49.7 (C-1), 49.0 (C-3), 40.4 (C-6’’’), 28.9 (C-2), 22.7 (AcOH), 22.2 
(C-7’), 9.8 (C-8’). ESI-HRMS: m/z calcd for C25H49N5O14 [M + H]+ 644.3354, found 644.3358. 
6’-(S)-C-ethyl-paromomycin (29(S)). Compound 28(S) (38.1 mg, 0.029 mmol) was added 
to a 16 mm test tube followed by 0.4 mL of dioxane and 0.4 mL of 10% AcOH in water. 77.5 mg 
of Pd/C were added to the tube and the reaction mixture was subjected to 50 psi H2 for 48 hours. 
Once the reaction was determined to be complete by LCMS the reaction mixture was diluted with 
water and filtered through Celite. The resulting crude product was purified using a CM Sephadex 
C-25 column. The column was washed with 250 mL of DI water and eluted with NH4OH in water 
starting at 0.1% and increasing stepwise by 0.1% every 20 mL to 0.8%. Lyophilization with AcOH 
gave the acetate salt 29(S) (9.5 mg, 0.010 mmol) in 35% yield as a white powder. [α]D23 = 41.32 
(c = 0.4, H2O), 1H NMR (600 MHz, D2O) δ 5.65 (d, J = 3.8 Hz, 1H, H-1’), 5.26 (d, J = 2.6 Hz, 1H, H-
1’’), 5.16 (d, J = 1.8 Hz, 1H, H-1’’’), 4.39 (dd, J = 6.6, 5.0 Hz, 1H, H-3’’), 4.23 (dd, J = 5.0, 2.6 Hz, 1H, 
H-2’’), 4.20 – 4.16 (m, 1H, H-5’’’), 4.10 (t, J = 3.1 Hz, 1H, H-3’’’), 4.08 (ddd, J = 7.1, 4.5, 3.2 Hz, 1H, 
H-4’’), 3.80 – 3.70 (m, 5H, H-4, H-5, H-3’, H-6’ [1dTOCSY 3.73, dd, J = 9.9, 3.9 Hz], H-5’’), 3.69 – 
3.68 (m, 1H, H-4’’’), 3.64 (dd, J = 12.4, 4.7 Hz, 1H, H-5’’), 3.57 – 3.50 (m, 3H, H-6, H-4’, H-5’), 3.46 






6’’’), 2.25 (dt, J = 12.1, 3.5 Hz, 1H, H-2eq), 1.81 (s, 15H, AcOH), 1.62 (q, J = 12.7 Hz, 1H, H-2ax), 
1.52 (ddq, J = 14.6, 9.3, 7.3 Hz, 1H, H-7’), 1.38 (dqd, J = 14.6, 7.3, 3.7 Hz, 1H, H-7’), 0.83 (t, J = 7.5 
Hz, 3H, H-8’). 13C NMR (151 MHz, D2O) δ 180.3 (AcOH), 109.7 (C-1’’), 95.8 (C-1’), 95.3 (C-1’’’), 84.2 
(C-5), 81.3 (C-4’’), 78.8 (C-4), 75.23 (C-5’), 75.19 (C-3’’), 73.4 (C-2’’), 72.4 (C-6), 70.1 (C-5’’’), 69.7 
(C-6’), 69.2 (C-4’), 68.9 (C-3’), 67.6 (C-3’’’), 67.2 (C-4’’’), 60.0 (C-5’’), 53.8 (C-2’), 50.8 (C-2’’’), 49.9 
(C-1), 49.2 (C-3), 40.3 (C-6’’’), 29.1 (C-2), 26.1 (C-7’), 22.6 (AcOH), 9.9 (C-8’). ESI-HRMS: m/z calcd 
for C25H49N5O14 [M + H]+ 644.3354, found 644.3369. 
1,3,2’,2’’’,6’’’-Pentaazido-6,3’,2’’,5’’,3’’’,4’’’-hexa-O-benzyl-4’,6’-O-benzylidene-(R)-6’-
C-ethyl-1,3,2’,2’’’,6’’’-pentadeaminoparomomycin (30). Benzaldehyde dimethyl acetal (1.0 µL, 
67 µmol) was added to a stirred solution of 28(R) (24.3 mg, 18.5 µmol) and CSA (3.0 mg, 13 µmol) 
in MeCN (0.5 mL) under argon. The reaction mixture was stirred for 1 hour monitoring by LCMS 
and TLC then quenched with Et3N. The reaction mixture was diluted with Et2O, washed with 
aqueous saturated NaHCO3 solution and brine, dried with Na2SO4, and concentrated. The crude 
residue was purified using silica gel column chromatography with 18 % EtOAc in hexanes to give 
acetal 30 (12.3 mg, 8.8 µmol) in 47 % yield as a white foam. [α]D23 = 92.76 (c = 0.2, CHCl3), 1H NMR 
(600 MHz, CDCl3) δ 7.49 (d, J = 7.3 Hz, 2H, Ar-H), 7.40 – 7.13 (m, 33H, Ar-H), 6.19 (d, J = 3.9 Hz, 
1H, H-1’), 5.66 (d, J = 5.6 Hz, 1H, H-1’’), 5.56 (s, 1H, PhCH(O)2), 4.97 (d, J = 10.6 Hz, 1H, PhCH2O), 
4.92 (d, J = 11.2 Hz, 1H, PhCH2O), 4.88 (d, J = 1.9 Hz, 1H, H-1’’’), 4.76 (d, J = 11.2 Hz, 1H, PhCH2O), 
4.72 (d, J = 10.6 Hz, 1H, PhCH2O), 4.62 (d, J = 12.0 Hz, 1H, PhCH2O), 4.56 (d, J = 11.8 Hz, 1H, 
PhCH2O), 4.52 (d, J = 11.9 Hz, 1H, PhCH2O), 4.47 – 4.42 (m, 2H, PhCH2O), 4.40 (d, J = 11.9 Hz, 1H, 






9.6 Hz, 1H, H-3’), 4.00 – 3.92 (m, 2H, H-5, H-2’’), 3.82 – 3.74 (m, 3H, H-5’’, H-3’’’, H-5’’’), 3.69 (t, J 
= 9.3 Hz, 1H, H-5’), 3.64 (dd, J = 12.9, 8.6 Hz, 1H, H-6’’’), 3.60 (t, J = 9.2 Hz, 1H, H-4), 3.58 – 3.51 
(m, 2H, H-6’, H-5’’), 3.49 – 3.40 (m, 3H, H-1, H-3, H-4’), 3.35 (t, J = 2.4 Hz, 1H, H-2’’’), 3.29 (t, J = 
9.3 Hz, 1H, H-6), 3.12 (br s, 1H, H-4’’’), 3.06 (dd, J = 10.1, 3.9 Hz, 1H, H-2’), 2.88 (dd, J = 13.0, 3.9 
Hz, 1H, H-6’’’), 2.23 (dt, J = 13.4, 4.7 Hz, 1H, H-2eq), 1.96 (dtt, J = 15.3, 7.9, 4.6 Hz, 1H, H-7’), 1.62 
(dp, J = 15.5, 7.7 Hz, 1H, H-7’), 1.37 (q, J = 12.7 Hz, 1H, H-2ax), 1.10 (t, J = 7.4 Hz, 3H, H-8’). 13C 
NMR (151 MHz, CDCl3) δ 138.3, 138.1, 137.9, 137.8, 137.6, 137.0, 136.9, 128.72, 128.66, 128.5, 
128.4, 128.33, 128.31, 128.27, 128.21, 128.18, 128.14, 127.81, 127.77, 127.74, 127.73, 127.67, 
127.5, 127.4, 127.3, 126.1 (Ar), 106.1 (C-1’’), 100.8 (PhCH(O)2), 98.6 (C-1’’’), 96.1 (C-1’), 84.3 (C-
6), 82.4 (C-2’’), 82.1 (C-4’’), 81.8 (C-5), 81.7 (C-4’), 80.5 (C-6’), 76.1 (C-3’), 75.5 (C-3’’), 75.2 (C-4), 
75.0 (PhCH2O), 74.9 (PhCH2O), 74.4 (C-5’’’), 73.2 (PhCH2O), 73.1 (PhCH2O), 72.9 (C-3’’’), 72.4 
(PhCH2O), 71.7 (PhCH2O), 71.5 (C-4’’’), 70.3 (C-5’’), 67.2 (C-5’), 62.8 (C-2’), 60.4 (C-1), 60.0 (C-3), 
57.3 (C-2’’’), 51.1 (C-6’’’), 32.6 (C-2), 24.7 (C-7’), 9.6 (C-8’). ESI-HRMS: m/z calcd for 
C74H79N15O14Na [M + Na]+ 1424.5829, found 1424.5809. 
6’-(R)-C-propyl-paromomycin (32(R)). Compound 31(R) (33.2 mg, 0.0251 mmol) was 
added to a 16 mm test tube followed by 0.4 mL of dioxane and 0.4 mL of 10% AcOH in water. 
67.4 mg of Pd/C were added to the tube and the reaction mixture was subjected to 48 psi H2 for 
22 hours. Once the reaction was determined to be complete by LCMS the reaction mixture was 
diluted with water and filtered through Celite. The resulting crude product was purified using a 
CM Sephadex C-25 column. The column was washed with 50 mL of DI water and eluted with 






Lyophilization with AcOH gave the acetate salt 32(R) (10.0 mg, 0.0104 mmol) in 42% yield as a 
white powder. [α]D23 = 48.83 (c = 0.3, H2O), 1H NMR (600 MHz, D2O) δ 5.52 (d, J = 4.0 Hz, 1H, H-
1’), 5.24 (d, J = 2.9 Hz, 1H, H-1’’), 5.16 (d, J = 1.8 Hz, 1H, H-1’’’), 4.38 (t, J = 5.7 Hz, 1H, H-3’’), 4.21 
(dd, J = 5.2, 2.9 Hz, 1H, H-2’’), 4.20 – 4.15 (m, 1H, H-5’’’), 4.10 (t, J = 3.2 Hz, 1H, H-3’’’), 4.09 – 4.06 
(m, 1H, H-4’’), 3.92 – 3.88 (m, 1H, H-6’), 3.82 (t, J = 9.5 Hz, 1H, H-4), 3.79 – 3.68 (m, 5H, H-5, H-3’, 
H-5’ [J5’,6’ = 2.7 Hz extracted from HSQC trace], H-5’’, H-4’’’), 3.64 (dd, J = 12.4, 4.6 Hz, 1H, H-5’’), 
3.56 (t, J = 9.8 Hz, 1H, H-6), 3.46 (s, 1H, H-2’’’), 3.42 – 3.36 (m, 2H, H-3, H-4’), 3.32 – 3.17 (m, 4H, 
H-1, H-2’, H-6’’’), 2.32 (dt, J = 11.4, 4.0 Hz, 1H, H-2eq), 1.82 (s, 15H, AcOH), 1.69 (q, J = 12.8 Hz, 
1H, H-2ax), 1.44 – 1.32 (m, 3H, H-7’, H-8’), 1.27 – 1.15 (m, 1H, H-8’), 0.78 (t, J = 7.0 Hz, 3H, H-9’). 
13C NMR (151 MHz, D2O) δ 179.9 (AcOH), 109.7 (C-1’’), 96.6 (C-1’), 95.5 (C-1’’’), 84.0 (C-5), 81.4 
(C-4’’), 78.9 (C-4), 75.9 (C-5’), 75.2 (C-3’’), 73.4 (C-2’’), 72.3 (C-6), 70.1 (C-5’’’), 69.7 (C-4’), 69.4 (C-
3’), 69.0 (C-6’), 67.6 (C-3’’’), 67.2 (C-4’’’), 59.9 (C-5’’), 53.8 (C-2’), 50.8 (C-2’’’), 49.6 (C-1), 49.0 (C-
3), 40.3 (C-6’’’), 31.0 (C-7’), 28.4 (C-2), 22.5 (AcOH), 18.5 (C-8’), 13.0 (C-9’). ESI-HRMS: m/z calcd 
for C26H51N5O14 [M + H]+ 658.3511, found 658.3529. 
6’-(S)-C-propyl-paromomycin (32(S)). Compound 31(S) (33.3 mg, 0.0251 mmol) was 
added to a 16 mm test tube followed by 0.4 mL of dioxane and 0.4 mL of 10% AcOH in water. 
64.8 mg of Pd/C were added to the tube and the reaction mixture was subjected to 50 psi H2 for 
22 hours. Once the reaction was determined to be complete by LCMS the reaction mixture was 
diluted with water and filtered through Celite. The resulting crude product was purified using a 
CM Sephadex C-25 column. The column was washed with 250 mL of DI water and eluted with 






Lyophilization with AcOH gave the acetate salt 32(S) (11.9 mg, 0.0124 mmol) in 49% yield as a 
white powder. [α]D23 = 40.60 (c = 0.4, H2O), 1H NMR (600 MHz, D2O) δ 5.65 (d, J = 3.9 Hz, 1H, H-
1’), 5.26 (d, J = 2.5 Hz, 1H, H-1’’), 5.16 (d, J = 1.9 Hz, 1H, H-1’’’), 4.39 (dd, J = 6.6, 4.9 Hz, 1H, H-3’’), 
4.23 (dd, J = 5.0, 2.5 Hz, 1H, H-2’’), 4.17 (ddd, J = 6.4, 4.1, 1.5 Hz, 1H, H-5’’’), 4.09 (t, J = 3.1 Hz, 
1H, H-3’’’), 4.07 (ddd, J = 7.0, 4.4, 3.0 Hz, 1H, H-4’’), 3.85 (ddd, J = 9.8, 3.4, 1.7 Hz, 1H, H-6’), 3.79 
– 3.74 (m, 2H, H-3’, H-5’’), 3.74 – 3.70 (m, 2H, H-4, H-5), 3.70 – 3.68 (m, 1H, H-4’’’), 3.64 (dd, J = 
12.4, 4.6 Hz, 1H, H-5’’), 3.56 – 3.47 (m, 3H, H-6, H-4’, H-5’), 3.45 (dt, J = 3.0, 1.4 Hz, 1H, H-2’’’), 
3.29 (dd, J = 13.7, 6.6 Hz, 1H, H-6’’’), 3.25 – 3.15 (m, 4H, H-1, H-3, H-2’, H-6’’’), 2.25 (dt, J = 12.8, 
4.3 Hz, 1H, H-2eq), 1.81 (s, 15H, AcOH), 1.63 (q, J = 12.7 Hz, 1H, H-2ax), 1.53 (dtd, J = 13.7, 9.7, 
9.1, 4.3 Hz, 1H, H-7’), 1.40 – 1.26 (m, 2H, H-7’, H-8’), 1.26 – 1.19 (m, 1H, H-8’), 0.78 (t, J = 7.2 Hz, 
3H, H-9’). 13C NMR (151 MHz, D2O) δ 180.3 (AcOH), 109.7 (C-1’’), 95.8 (C-1’), 95.4 (C-1’’’), 84.2 (C-
5), 81.3 (C-4’’), 78.9 (C-4), 75.6 (C-5’), 75.2 (C-3’’), 73.4 (C-2’’), 72.4 (C-6), 70.1 (C-5’’’), 69.2 (C-4’), 
68.9 (C-3’), 67.62 (C-3’’’), 67.58 (C-6’), 67.2 (C-4’’’), 60.0 (C-5’’), 53.7 (C-2’), 50.8 (C-2’’’), 49.9 (C-
1), 49.1 (C-3), 40.3 (C-6’’’), 34.9 (C-7’), 29.1 (C-2), 22.6 (AcOH), 18.6 (C-8’), 12.9 (C-9’). ESI-HRMS: 
m/z calcd for C26H51N5O14 [M + H]+ 658.3511, found 658.3528. 
1,3,2’,6’,2’’’,6’’’-hexaazido-6,3’,2’’,5’’,3’’’,4’’’-hexa-O-benzyl-1,3,2’,6’,2’’’,6’’’-
hexaadeaminoneomycin (33). Trifluoromethanesulfonic anhydride (35 µL, 0.24 mmol) was 
added to a stirred solution of 20(R) (0.151 g, 0.110 mmol) and pyridine (0.09 mL, 1.1 mmol) in 
DCM (2.2 mL) at 0 oC.  After 20 minutes the reaction was quenched with MeOH (0.02 mL, 0.49 
mmol) and concentrated under vacuum. The resulting triflate was dissolved in DMF (1.1 mL) and 






washed with 1N HCl and brine, and concentrated. The crude residue was purified using silica gel 
column chromatography in 22% EtOAc in hexanes to give 33 (58.6 mg, 0.044 mmol) in 40% yield. 
[α]D23 = 90.60 (c = 0.7, CHCl3), 1H NMR (600 MHz, CDCl3) δ 7.39 – 7.15 (m, 30H, Ar-H), 6.16 (d, J = 
3.7 Hz, 1H, H-1’), 5.64 (d, J = 5.7 Hz, 1H, H-1’’), 4.96 (d, J = 10.6 Hz, 1H, PhCH2O), 4.93 (d, J = 11.4 
Hz, 1H, PhCH2O), 4.87 (d, J = 2.0 Hz, 1H, H-1’’’), 4.71 (d, J = 10.6 Hz, 1H, PhCH2O), 4.63 – 4.60 (m, 
2H, PhCH2O), 4.58 (d, J = 11.7 Hz, 1H, PhCH2O), 4.54 (d, J = 11.9 Hz, 1H, PhCH2O), 4.47 – 4.43 (m, 
2H, PhCH2O), 4.40 (d, J = 11.9 Hz, 1H, PhCH2O), 4.31 (d, J = 12.0 Hz, 1H, PhCH2O), 4.27 (q, J = 2.9 
Hz, 1H, H-4’’), 4.26 – 4.23 (m, 2H, H-3’’, PhCH2O), 3.97 – 3.92 (m, 2H, H-5, H-2’’), 3.83 – 3.72 (m, 
6H, H-3’, H-5’, H-6’, H-5’’, H-3’’’, H-5’’’), 3.61 (dd, J = 13.0, 8.4 Hz, 1H, H-6’’’), 3.59 – 3.54 (m, 2H, 
H-4, H-5’’), 3.51 (td, J = 9.3, 2.8 Hz, 1H, H-4’), 3.49 – 3.40 (m, 2H, H-1, H-3), 3.34 (t, J = 2.6 Hz, 1H, 
H-2’’’), 3.27 (t, J = 9.3 Hz, 1H, H-6), 3.13 (d, J = 2.6 Hz, 1H, H-4’’’), 2.95 (dd, J = 10.3, 3.8 Hz, 1H, H-
2’), 2.91 (dd, J = 12.9, 4.1 Hz, 1H, H-6’’’), 2.24 (dt, J = 13.2, 4.6 Hz, 1H, H-2eq), 2.07 (d, J = 3.1 Hz, 
1H, 4’-OH), 1.44 (d, J = 6.9 Hz, 3H, H-7’), 1.35 (q, J = 12.7 Hz, 1H, H-2ax). 13C NMR (151 MHz, CDCl3) 
δ 138.2, 138.0, 137.8, 137.6, 137.0, 136.9, 128.70, 128.66, 128.5, 128.41, 128.39, 128.34, 128.31, 
128.28, 128.16, 128.12, 128.08, 127.81, 127.80, 127.79, 127.77, 127.6, 127.5 (Ar), 106.1 (C-1’’), 
98.7 (C-1’’’), 95.9 (C-1’), 84.3 (C-6), 82.3 (C-2’’), 82.0 (C-4’’), 81.7 (C-5), 80.0 (C-3’), 75.5 (C-3’’), 
75.1 (C-4), 75.1 (PhCH2O), 74.8 (PhCH2O), 74.3 (C-5’’’), 73.6 (C-5’), 73.3 (PhCH2O), 73.2 (PhCH2O), 
72.9 (C-3’’’), 72.4 (PhCH2O), 71.7 (PhCH2O), 71.5 (C-4’’’), 70.4 (C-4’), 70.0 (C-5’’), 62.4 (C-2’), 60.4 
(C-1), 60.2 (C-3), 57.3 (C-2’’’), 55.0 (C-6’), 51.0 (C-6’’’), 32.7 (C-2), 15.3 (C-7’). ESI-HRMS: m/z calcd 







1,3,2’,6’,2’’’,6’’’-hexaadeaminoneomycin (35(R) and 35(S)). Hydroxylamine hydrochloride 
(0.125 g, 1.80 mmol) was added to a stirred solution of 19 (0.507 g, 0.370 mmol) in 1:1 
DCM/MeOH (7.4 mL). After 3 hours the reaction mixture was diluted with Et2O, washed with 1 N 
HCl and brine, dried with Na2SO4, and concentrated. The resulting oxime was used in the next 
step without further purification. 10% HCl MeOH solution (0.5 mL) was added to a stirred solution 
of oxime and NaBH3CN (0.114 g, 1.81 mmol) in MeOH (7.4 mL) at 60 oC. HCl MeOH solution was 
added at 20 minutes (1 mL), 50 minutes (0.5 mL), and 1 hour (0.4 mL) to ensure reaction mixture 
was acidic. NaBH3CN (0.113 g, 1.80 mmol) was added at 30 minutes. After 1.5 hours the reaction 
mixture was diluted with Et2O, washed with aqueous saturated NaHCO3 and brine, dried with 
Na2SO4, and concentrated. The crude residue was purified using silica gel column 
chromatography in 40-60 % EtOAc in hexanes to give 35(R) (0.192 g, 0.146 mmol) in 39% yield 
and 35(S) (0.114 g, 0.087 mmol) in 23% yield. 35(R) [α]D23 = 83.24 (c = 1.0, CHCl3), 1H NMR (600 
MHz, CDCl3) δ 7.42 – 7.13 (m, 30H, Ar-H), 6.15 (d, J = 3.7 Hz, 1H, H-1’), 5.68 (d, J = 5.9 Hz, 1H, H-
1’’), 4.99 (d, J = 10.6 Hz, 1H, PhCH2O), 4.900 (d, J = 11.1 Hz, 1H, PhCH2O), 4.897 (d, 1.8 Hz, 1H, H-
1’’’), 4.75 – 4.69 (m, 2H, PhCH2O), 4.63 (d, J = 12.0 Hz, 1H, PhCH2O), 4.58 (d, J = 11.8 Hz, 1H, 
PhCH2O), 4.50 (d, J = 11.8 Hz, 1H, PhCH2O), 4.48 – 4.39 (m, 3H, PhCH2O), 4.33 – 4.28 (m, 3H, H-
3’’, H-4’’, PhCH2O), 4.25 (d, J = 12.1 Hz, 1H, PhCH2O), 4.08 (dd, J = 10.0, 4.4 Hz, 1H, H-5’), 3.97 – 
3.93 (m, 2H, H-5, H-2’’), 3.90 (dd, J = 10.3, 8.7 Hz, 1H, H-3’), 3.83 (dd, J = 10.4, 2.2 Hz, 1H, H-5’’), 
3.80 – 3.75 (m, 2H, H-3’’’, H-5’’’), 3.73 (t, J = 9.3 Hz, 1H, H-4), 3.67 (dd, J = 13.0, 8.6 Hz, 1H, H-6’’’), 
3.58 (dd, J = 10.4, 3.1 Hz, 1H, H-5’’), 3.49 – 3.38 (m, 2H, H-1, H-3), 3.37 (t, J = 2.4 Hz, 1H, H-2’’’), 






2.20 (dt, J = 13.1, 4.6 Hz, 1H, H-2eq), 1.40 (q, J = 12.8 Hz, 1H, H-2ax), 1.09 (d, J = 6.7 Hz, 3H, H-7’). 
13C NMR (151 MHz, CDCl3) δ 138.3, 138.05, 137.96, 137.5, 137.0, 136.9, 128.7, 128.6, 128.5, 
128.43, 128.36, 128.34, 128.27, 128.22, 128.0, 127.83, 127.82, 127.79, 127.78, 127.5, 127.2 (Ar), 
106.1 (C-1’’), 98.6 (C-1’’’), 95.7 (C-1’), 84.3 (C-6), 82.4 (C-2’’), 82.1 (C-4’’), 82.0 (C-5), 80.0 (C-3’), 
75.5 (C-3’’), 75.1 (PhCH2O), 74.6 (PhCH2O), 74.4 (C-5’’’), 73.24 (PhCH2O), 73.18 (PhCH2O), 72.8 (C-
3’’’), 72.6 (PhCH2O), 72.4 (C-4’), 71.7 (PhCH2O), 71.5 (C-4’’’), 70.3 (C-5’’), 69.1 (C-5’), 62.7 (C-2’), 
60.4 (C-1), 60.3 (C-3), 58.3 (C-6’), 57.2 (C-2’’’), 51.1 (C-6’’’), 32.6 (C-2), 12.0 (C-7’). ESI-HRMS: m/z 
calcd for C66H75N16O14 [M + H]+ 1315.5649, found 1315.5668. 35(S) [α]D23 = 82.66 (c = 1.0, CHCl3), 
1H NMR (600 MHz, CDCl3) δ 7.46 – 7.12 (m, 30H, Ar-H), 6.09 (d, J = 3.8 Hz, 1H, H-1’), 5.67 (d, J = 
5.6 Hz, 1H, H-1’’), 4.97 (d, J = 10.6 Hz, 1H, PhCH2O), 4.88 (d, J = 1.9 Hz, 1H, H-1’’’), 4.86 (d, J = 11.1 
Hz, 1H, PhCH2O), 4.82 (d, J = 11.2 Hz, 1H, PhCH2O), 4.71 (d, J = 10.6 Hz, 1H, PhCH2O), 4.62 (d, J = 
12.1 Hz, 1H, PhCH2O), 4.56 (d, J = 11.7 Hz, 1H, PhCH2O), 4.50 (d, J = 11.8 Hz, 1H, PhCH2O), 4.47 – 
4.42 (m, 2H, PhCH2O), 4.41 (d, J = 11.9 Hz, 1H, PhCH2O), 4.34 – 4.28 (m, 3H, H-3’’, H-4’’, PhCH2O), 
4.25 (d, J = 12.1 Hz, 1H, PhCH2O), 4.10 (dd, J = 10.1, 3.2 Hz, 1H, H-5’), 3.97 (dd, J = 5.7, 4.4 Hz, 1H, 
H-2’’), 3.93 (t, J = 8.9 Hz, 1H, H-5), 3.88 (dd, J = 10.3, 8.7 Hz, 1H, H-3’), 3.82 (dd, J = 10.4, 2.0 Hz, 
1H, H-5’’), 3.79 – 3.74 (m, 2H, H-3’’’, H-5’’’), 3.69 – 3.59 (m, 3H, H-4, H-4’, H-6’’’), 3.57 (dd, J = 
10.7, 2.9 Hz, 1H, H-5’’), 3.47 – 3.38 (m, 3H, H-1, H-3, H-6’), 3.35 (t, J = 2.4 Hz, 1H, H-2’’’), 3.27 (t, J 
= 9.3 Hz, 1H, H-6), 3.12 (t, J = 2.3 Hz, 1H, H-4’’’), 2.92 (dd, J = 10.3, 3.8 Hz, 1H, H-2’), 2.87 (dd, J = 
13.0, 3.8 Hz, 1H, H-6’’’), 2.21 (dt, J = 13.1, 4.6 Hz, 1H, H-2eq), 1.39 (q, J = 12.8 Hz, 1H, H-2ax), 1.13 
(d, J = 6.8 Hz, 3H, H-7’). 13C NMR (151 MHz, CDCl3) δ 138.3, 138.2, 137.9, 137.6, 137.0, 136.9, 
128.7, 128.51, 128.48, 128.4, 128.34, 128.27, 128.19, 128.17, 127.83, 127.79, 127.75, 127.51, 






(C-5), 79.7 (C-3’), 75.5 (C-3’’), 75.12 (PhCH2O), 75.06 (C-4), 74.4 (C-5’’’), 73.2 (PhCH2O), 73.1 
(PhCH2O), 72.8 (C-3’’’), 72.4 (PhCH2O), 71.8 (C-4’), 71.7 (PhCH2O), 71.5 (C-4’’’), 70.3 (C-5’’), 69.9 
(C-5’), 62.6 (C-2’), 60.4 (C-1), 60.1 (C-3), 58.0 (C-6’), 57.3 (C-2’’’), 51.1 (C-6’’’), 32.5 (C-2), 13.0 (C-
7’). ESI-HRMS: m/z calcd for C66H75N16O14 [M + H]+ 1315.5649, found 1315.5677. 
6’-(R)-C-methyl-neomycin (34(R)). Compound 35(R) (43.7 mg, 0.0332 mmol) was stirred 
in 0.4 mL of 1:1 dioxane/10% AcOH in water with 79.0 mg of Pd/C under 50 psi of H2 for 12 hours. 
Once the reaction was determined to be complete by LCMS the reaction mixture was diluted with 
water and filtered through Celite. The resulting crude product was purified over a CM Sephadex 
C-25 column. The column was washed with 250 mL of DI water and eluted with NH4OH in water 
starting at 0.1% and increasing stepwise by 0.1% every 20 mL to 0.8%. Lyophilization with AcOH 
gave the acetate salt 34(R) (11.8 mg, 0.0119 mmol) as a white solid in 36% yield. [α]D23 = 44.86 (c 
= 0.4, H2O), 1H NMR (600 MHz, D2O) δ 5.92 (d, J = 3.9 Hz, 1H, H-1’), 5.29 (d, J = 2.8 Hz, 1H, H-1’’), 
5.16 (d, J = 1.8 Hz, 1H, H-1’’’), 4.34 (dd, J = 6.2, 5.0 Hz, 1H, H-3’’), 4.24 (dd, J = 5.1, 2.8 Hz, 1H, H-
2’’), 4.18 (ddd, J = 6.0, 4.1, 1.5 Hz, 1H, H-5’’’), 4.12 – 4.08 (m, 2H, H-4’’, H-3’’’), 3.88 – 3.81 (m, 2H, 
H-3’, H-5’), 3.80 – 3.73 (m, 2H, H-5, H-5’’), 3.71 – 3.66 (m, 3H, H-4, H-6’, H-4’’’), 3.60 (dd, J = 12.3, 
5.4 Hz, 1H, H-5’’), 3.51 (dd, J = 10.6, 9.0 Hz, 1H, H-6), 3.45 (t, J = 1.2 Hz, 1H, H-2’’’), 3.38 (t, J = 9.5 
Hz, 1H, H-4’), 3.32 – 3.21 (m, 3H, H-2’, H-6’’’), 3.20 – 3.12 (m, 2H, H-1, H-3), 2.20 (dt, J = 12.6, 4.3 
Hz, 1H, H-2eq), 1.79 (s, 18H, AcOH), 1.58 (q, J = 12.6 Hz, 1H, H-2ax), 1.19 (d, J = 6.9 Hz, 3H, H-7’). 
13C NMR (151 MHz, D2O) δ 180.6 (AcOH), 110.1 (C-1’’), 95.5 (C-1’), 95.1 (C-1’’’), 85.2 (C-5), 81.5 
(C-4’’), 77.1 (C-4), 75.5 (C-3’’), 73.6 (C-2’’), 72.8 (C-6), 71.4 (C-5’), 70.1 (C-5’’’), 69.8 (C-4’), 68.5 (C-






6’), 40.4 (C-6’’’), 29.9 (C-2), 22.8 (AcOH), 11.2 (C-7’). ESI-HRMS: m/z calcd for C24H48N6O13 [M+H]+ 
629.3358, found 629.3362. 
6’-(S)-C-methyl-neomycin (34(S)). Compound 35(S) (32.6 mg, 0.0248 mmol) was stirred 
in 0.4 mL of 1:1 dioxane/10% AcOH in water with 65.0 mg of Pd/C under 50 psi of H2 for 12 hours. 
Once the reaction was determined to be complete by LCMS the reaction mixture was diluted with 
water and filtered through Celite. The resulting crude product was purified over a CM Sephadex 
C-25 column. The column was washed with 250 mL of DI water and eluted with NH4OH in water 
starting at 0.1% and increasing stepwise by 0.1% every 20 mL to 0.8%. Lyophilization with AcOH 
gave the acetate salt 34(S) (8.3 mg, 0.0084 mmol) as a white solid in 34% yield. [α]D23 = 40.36 (c 
= 0.3, H2O), 1H NMR (600 MHz, D2O) δ 5.78 (d, J = 3.9 Hz, 1H, H-1’), 5.27 (d, J = 2.8 Hz, 1H, H-1’’), 
5.16 (d, J = 1.8 Hz, 1H, H-1’’’), 4.36 (dd, J = 6.3, 5.0 Hz, 1H, H-3’’), 4.24 (dd, J = 5.0, 2.8 Hz, 1H, H-
2’’), 4.18 (td, J = 5.1, 4.7, 2.3 Hz, 1H, H-5’’’), 4.12 – 4.07 (m, 2H, H-4’’, H-3’’’), 3.83 – 3.71 (m, 4H, 
H-5, H-3’, H-5’, H-5’’), 3.70 – 3.69 (m, 1H, H-4’’’), 3.69 – 3.64 (m, 2H, H-4, H-6’), 3.62 (dd, J = 12.4, 
5.0 Hz, 1H, H-5’’), 3.52 (dd, J = 10.5, 9.1 Hz, 1H, H-6), 3.47 – 3.42 (m, 2H, H-4’, H-2’’’), 3.30 (dd, J 
= 13.7, 6.4 Hz, 1H, H-6’’’), 3.27 – 3.22 (m, 2H, H-2’, H-6’’’), 3.19 – 3.14 (m, 1H, H-1), 3.13 – 3.08 
(m, 1H, H-3), 2.19 (dt, J = 12.9, 4.3 Hz, 1H, H-2eq), 1.80 (s, 18H, AcOH), 1.54 (q, J = 12.6 Hz, 1H, H-
2ax), 1.29 (d, J = 6.9 Hz, 3H, H-7’). 13C NMR (151 MHz, D2O) δ 180.5 (AcOH), 109.9 (C-1’’), 95.6 (C-
1’), 95.5 (C-1’’’), 84.9 (C-5), 81.5 (C-4’’), 79.0 (C-4), 75.4 (C-3’’), 73.5 (C-2’’), 72.8 (C-6), 72.0 (C-5’), 
70.1 (C-5’’’), 69.9 (C-4’), 68.8 (C-3’), 67.6 (C-3’’’), 67.3 (C-4’’’), 60.2 (C-5’’), 53.5 (C-2’), 50.8 (C-2’’’), 
50.1 (C-1), 48.8 (C-3), 47.3 (C-6’), 40.4 (C-6’’’), 30.1 (C-2), 22.8 (AcOH), 14.9 (C-7’). ESI-HRMS: m/z 






Compound 35(S) (0.039 mg, 0.030 mmol) was stirred in 0.8 mL of 1:1 dioxane/10% AcOH 
in water with 77.4 mg of Pd/C under 50 psi of H2 for 72 hours. Once the reaction was determined 
to be complete by LCMS the reaction mixture was diluted with water and filtered through Celite. 
The resulting crude product was purified over a CM Sephadex C-25 column. The column was 
washed with 250 mL of DI water and eluted with NH4OH in water starting at 0.1% and increasing 
stepwise by 0.1% every 20 mL to 0.8%. Lyophilization with AcOH gave the acetate salt 2 (10.5 mg, 
0.0167 mmol) as a white solid in 56% yield. 
1,3,2’,2’’’,6’’’-Pentaazido-6,3’,6’,2’’,5’’,3’’’,4’’’-hepta-O-benzyl-6’-C-vinyl-1,3,2’,2’’’,6’’’-
6’-paratoluenesulfonylmethyl-pentadeaminoparomomycin (41(R) and 41(S)). To a stirred 
solution of DMSO (0.22 mL 3.1 mmol) in 1 mL DCM at -78oC under argon was added oxalyl 
chloride (0.125 mL, 1.46 mmol). After stirring for 10 minutes compound 27 (1.00 g, 0.71 mmol) 
was dissolved in DCM (6 mL) and added dropwise. After an additional 45 minutes Et3N (0.45 mL, 
3.2 mmol) was added. The reaction mixture was stirred for an additional 2 hours then diluted 
with Et2O, washed with aqueous NH4Cl solution, DI water, and brine. The organic layer was 
concentrated under vacuum to give the intermediate aldehyde as a white foam which was used 
in the next step without further purification. ESI-HRMS: m/z calc for C74H79N15O14Na [M+Na]+ 
1424.5829, found 1424.5815. To a stirred solution of aldehyde in THF (14.5 mL) at -78oC was 
added vinylMgBr solution (2.9 mL, 1 M in THF). After stirring for 45 minutes the reaction was 
quenched with aqueous saturated NH4Cl solution, diluted with Et2O, washed with aqueous 
saturated NH4Cl solution, brine, dried with Na2SO4, and concentrated to give an inseparable 






further purification. ESI-HRMS: m/z calc for C74H79N15O14Na [M+Na]+ 1424.5829, found 
1424.5815. To a solution of alcohols in DMF (4.7 mL) at 0oC under argon was added NaH (60 % in 
mineral oil, 0.188 g, 7.78 mmol). After 15 minutes TBAI (0.118 g, 0.319 mmol) and BnBr (1.1 mL, 
9.3 mmol) were added to the reaction mixture and stirring was continued for 40 minutes before 
quenching with aqueous saturated NH4Cl solution. The reaction mixture was diluted with Et2O, 
washed with aqueous saturated NH4Cl solution followed by brine, dried with Na2SO4, and 
concentrated. The crude residue was purified over silica gel to give compounds 40 (0.650 g, 0.427 
mmol, 60%) as an inseparable mixture of diastereomers. 1H NMR (600 MHz, CDCl3) δ 7.43 – 7.12 
(m, 70H, Ar-H), 7.11 – 7.07 (m, 2H, Ar-H), 7.07 – 7.03 (m, 2H, Ar-H), 6.84 – 6.79 (m, 4H, Ar-H), 
6.18 – 6.09 (m, 2H, H-1’a, H-7’a), 6.08 (d, J = 3.7 Hz, 1H, H-1’b), 5.95 (ddd, J = 17.4, 10.3, 8.7 Hz, 
1H, H-7’b), 5.64 (d, J = 5.7 Hz, 1H, H-1’’a), 5.61 (d, J = 5.7 Hz, 1H, H-1’’b), 5.43 – 5.37 (m, 2H), 5.32 
(dd, J = 10.3, 1.9 Hz, 1H), 5.10 (dd, J = 17.3, 1.9 Hz, 1H), 4.97 (d, J = 10.7 Hz, 1H), 4.94 (d, J = 10.7 
Hz, 1H), 4.88 – 4.75 (m, 5H), 4.75 – 4.71 (m, 2H), 4.71 – 4.51 (m, 10H), 4.50 – 4.44 (m, 4H), 4.44 – 
4.38 (m, 4H), 4.35 – 4.24 (m, 9H), 4.23 – 4.20 (m, 2H), 4.14 – 4.03 (m, 5H), 3.98 – 3.95 (m, 1H), 
3.94 – 3.88 (m, 3H), 3.85 – 3.81 (m, 2H), 3.80 (s, 3H), 3.79 – 3.71 (m, 9H), 3.65 (dd, J = 12.9, 8.5 
Hz, 1H), 3.63 – 3.51 (m, 4H), 3.50 – 3.37 (m, 4H), 3.35 (t, J = 2.5 Hz, 1H), 3.33 (t, J = 2.5 Hz, 1H), 
3.26 (t, J = 9.2 Hz, 1H), 3.24 – 3.19 (m, 2H), 3.17 (dd, J = 10.4, 3.7 Hz, 1H), 3.13 (t, J = 2.7 Hz, 1H), 
3.12 (t, J = 2.3 Hz, 1H), 2.97 – 2.93 (m, 2H), 2.89 (dd, J = 13.0, 4.0 Hz, 1H), 2.23 – 2.17 (m, 2H, H-
2eqa, H-2eqb), 1.35 – 1.23 (m, 2H, H-2axa, H-2axb). 13C NMR (151 MHz, CDCl3) δ 159.09, 159.04, 
138.7, 138.4, 138.3, 138.1, 138.0, 137.9, 137.62, 137.61, 137.1, 137.04, 137.00, 136.97 (Ar), 136.2 
(C-7’a), 134.0 (C-7’b), 130.7, 130.5, 128.93, 128.88, 128.67, 128.66, 128.49, 128.48, 128.41, 






127.83, 127.82, 127.78, 127.74, 127.72, 127.65, 127.61, 127.48, 127.45, 127.40, 127.37, 127.31, 
120.26, 118.7, 113.74, 113.70 (Ar), 106.1 (C-1’’a), 105.9 (C-1’’b), 98.7 (C-1’’’b), 98.6 (C-1’’’a), 96.0 
(C-1’b), 95.7 (C-1’b), 84.12, 84.05, 82.4, 82.1, 82.0, 81.93, 81.87, 81.6, 80.70, 80.67, 79.4, 78.2, 
77.8, 77.7, 75.60, 75.59, 75.4, 74.99, 74.97, 74.8, 74.4, 74.3, 74.13, 74.07, 73.86, 73.84, 73.29, 
73.28, 73.19, 73.11, 73.01, 72.95, 72.90, 72.39, 72.37, 71.8, 71.7, 71.5, 70.5, 70.3, 70.2, 69.8, 
63.3, 63.2, 60.40, 60.39, 60.0, 59.7, 57.4, 57.3, 55.3, 55.2, 51.1, 50.9, 32.5 (C-2). ESI-HRMS: m/z 
calc for C82H87N15O15Na [M+Na]+ 1544.6404, found 1544.6403. Ozone gas was bubbled through 
a solution of mixture 40 (0.650 g, 0.427 mmol) in 23.2 mL 4:1 DCM/MeOH at -78oC. After 30 
minutes the solution turned pale blue and the reaction mixture was sparged with argon followed 
by addition of NaBH4 (59 mg, 1.6 mmol). After 1 hour the reaction was quenched with acetone 
and concentrated under vacuum. The crude residue was dissolved in Et2O, washed with NH4Cl 
solution followed by brine, dried with Na2SO4, and concentrated to give the alcohols as an 
inseparable mixture of diastereomers which were used without further purification. To a stirred 
solution of 7’-alcohols in pyridine (4.1 mL) was added TsCl (0.120 g, 0.629 mmol). After 19 hours 
TsCl (0.022 g, 0.115 mmol) and DMAP (5.9 mg 0.05 mmol) were added. After stirring for an 
additional 5 hours the reaction mixture was diluted with Et2O, washed with 1 N HCl, saturated 
aqueous NaHCO3 solution, and brine. The organic layer was dried with Na2SO4 and concentrated 
to give the tosylates as an inseparable mixture of diastereomers which were used in the next step 
without further purification. TFA (0.89 mL) was added to a stirred solution of tosylates in DCM (8 
mL) at 0oC. After 30 minutes the reaction mixture was diluted with Et2O and washed with DI 
water, aqueous saturated NaHCO3 solution, and brine. The organic layer was dried with Na2SO4, 






diastereomers (0.367 g, 0.235 mmol, 55%). The mixture of diastereomers was then purified using 
silica gel HPLC to give 41(R) (91.5 mg 0.059 mmol) in 14% isolated yield and 41(S) (95.2 mg, 0.061 
mmol) in 14% isolated yield. 41(R) [α]D23 = 60.29 (c = 1.0, CHCl3), 1H NMR (600 MHz, CDCl3) δ 7.80 
(d, J = 8.3 Hz, 2H, ArH), 7.40 – 7.13 (m, 37H, ArH), 6.11 (d, J = 3.5 Hz, 1H, H-1’), 5.68 (d, J = 6.1 Hz, 
1H, H-1’’), 4.97 (d, J = 10.7 Hz, 1H, PhCH2O), 4.95 (d, J = 1.9 Hz, 1H, H-1’’’), 4.83 (d, J = 11.2 Hz, 1H, 
PhCH2O), 4.78 (d, J = 11.2 Hz, 1H, PhCH2O), 4.70 (d, J = 10.6 Hz, 1H, PhCH2O), 4.66 – 4.60 (m, 2H, 
PhCH2O), 4.53 – 4.49 (m, 2H, PhCH2O), 4.47 – 4.40 (m, 4H, PhCH2O), 4.31 (d, J = 12.0 Hz, 1H, 
PhCH2O), 4.30 – 4.27 (m, 3H, H-7’, H-3’’, H-4’’), 4.24 (d, J = 12.1 Hz, 1H, PhCH2O), 4.21 (dd, J = 
11.1, 2.6 Hz, 1H, H-7’), 4.09 (dd, J = 9.7, 5.2 Hz, 1H, H-5’), 3.95 (dd, J = 6.1, 4.8 Hz, 1H, H-2’’), 3.90 
(m, 2H, H-5, H-3’), 3.80 (m, 2H, H-5’’, H-5’), 3.76 (t, J = 2.8 Hz, 1H, H-3’’’), 3.73 – 3.64 (m, 3H, H-4, 
H-6’, H-6’’’), 3.55 (dd, J = 10.4, 2.8 Hz, 1H, H-5’’), 3.45 – 3.29 (m, 5H, H-1, H-3, H-6, H-4’, H-2’’’), 
3.11 (t, J = 2.4 Hz, 1H, H-4’’’), 2.85 (dd, J = 13.0, 3.7 Hz, 1H, H-6’’’), 2.80 (dd, J = 10.4, 3.5 Hz, 1H, 
H-2’), 2.41 (s, 3H, Ar-CH3), 2.14 (dt, J = 13.2, 4.6 Hz, 1H, H-2eq), 1.37 (q, J = 12.7 Hz, 1H, H-2ax). 
13C NMR (151 MHz, CDCl3) δ 144.9, 138.3, 138.2, 138.1, 137.7, 137.0, 136.95, 136.91, 133.1, 
133.0, 129.9, 128.7, 128.6, 128.52, 128.50, 128.42, 128.35, 128.32, 128.28, 128.21, 128.18, 
128.15, 128.11, 127.90, 127.86, 127.81, 127.75, 127.4, 127.1 (Ar), 106.0 (C-1’’), 98.7 (C-1’’’), 95.4 
(C-1’), 84.1 (C-6), 82.6 (C-2’’), 82.1 (C-4’’), 81.9 (C-5), 79.3 (C-3’), 78.6 (C-6’), 75.5 (C-3’’), 75.2 
(PhCH2O), 75.0 (PhCH2O), 74.4 (C-5’’’), 74.2 (C-4), 73.2 (C-4’), 73.1 (PhCH2O), 72.8 (C-3’’’), 72.3 
(PhCH2O), 72.2 (PhCH2O), 71.7 (PhCH2O), 71.5 (C-4’’’), 70.2 (C-5’’), 69.3 (C-5’), 67.9 (C-7’), 62.2 (C-
2’), 60.45 (C-1), 60.41 (C-3), 57.2 (C-2’’’), 51.1 (C-6’’’), 32.2 (C-2), 21.6 (OTs-CH3). ESI-HRMS: m/z 
calc for C80H85N15O17SNa [M+Na]+ 1582.5866, found 1582.5872.  41(S) [α]D23 = 58.69 (c = 1.0, 






(d, J = 3.6 Hz, 1H, H-1’), 5.65 (d, J = 6.0 Hz, 1H, H-1’’), 4.97 (d, J = 10.7 Hz, 1H, PhCH2O-), 4.89 – 
4.86 (m, 2H, H-1’’’, PhCH2O-), 4.70 (d, J = 10.6 Hz, 1H, PhCH2O-), 4.66 – 4.58 (m, 4H, PhCH2O-), 
4.54 – 4.47 (m, 3H, PhCH2O-), 4.42 – 4.37 (m, 2H, PhCH2O-), 4.34 (dd, J = 9.9, 6.2 Hz, 1H, H-7’), 
4.30 (d, J = 12.0 Hz, 1H, PhCH2O-), 4.26 – 4.22 (m, 2H, H-4’’, PhCH2O-), 4.20 (dd, J = 5.0, 2.5 Hz, 
1H, H-3’’), 4.10 (dd, J = 10.0, 6.5 Hz, 1H, H-7’), 3.99 (dd, J = 9.9, 2.3 Hz, 1H, H-5’), 3.93 – 3.90 (m, 
2H, H-5, H-6’), 3.88 (dd, J = 4.8, 1.2 Hz, 1H, H-2’’), 3.86 (d, J = 9.6 Hz, 1H, H-3’), 3.76 – 3.71 (m, 3H, 
H-5’’, H-3’’’, H-5’’’), 3.62 (t, J = 9.4 Hz, 1H, H-4), 3.59 – 3.51 (m, 3H, H-4’, H-5’’, H-6’’’), 3.48 – 3.37 
(m, 2H, H-1, H-3), 3.35 (t, J = 9.3 Hz, 1H, H-6), 3.32 (t, J = 2.4 Hz, 1H, H-2’’’), 3.11 (t, J = 2.5 Hz, 1H, 
H-4’’’), 2.93 (dd, J = 10.3, 3.6 Hz, 1H, H-2’), 2.90 (dd, J = 12.9, 4.3 Hz, 1H, H-6’’’), 2.43 (s, 3H, Ar-
CH3), 2.17 (dt, J = 13.2, 4.6 Hz, 1H, H-2eq), 1.51 (q, J = 12.7 Hz, 1H, H-2ax). 13C NMR (151 MHz, 
CDCl3) δ 144.9, 138.2, 138.0, 137.6, 137.5, 137.04, 136.98, 129.9, 128.7, 128.6, 128.47, 128.45, 
128.43, 128.39, 128.33, 128.29, 128.22, 128.14, 128.09, 127.96, 127.91, 127.80, 127.78, 127.73, 
127.43, 127.40 (Ar), 105.9 (C-1’’), 98.7 (C-1’’’), 96.0 (C-1’), 84.0 (C-6), 82.2 (C-2’’), 81.9 (C-4’’), 81.7 
(C-5), 79.9 (C-3’), 75.5 (C-3’’), 75.1 (PhCH2O), 75.0 (PhCH2O), 74.4 (C-4), 74.2 (C-3’’’), 74.0 
(PhCH2O), 73.6 (C-6’), 73.23 (PhCH2O), 73.17 (PhCH2O), 72.9 (C-5’’’), 72.3 (PhCH2O), 71.7 
(PhCH2O), 71.4 (C-4’’’), 70.3 (C-5’), 69.9 (C-5’’), 69.7 (C-4’), 68.6 (C-7’), 62.5 (C-2’), 60.5 (C-1), 60.4 
(C-3), 57.2 (C-2’’’), 50.9 (C-6’’’), 32.2 (C-2), 21.7 (Ar-CH3). ESI-HRMS: m/z calc for C80H85N15O17SNa 
[M+Na]+ 1582.5866, found 1582.5854. 
4-O-(2-azido-3,6-di-O-benzyl-4,7-anhydro-2,7-dideoxy-D-glycero-α-D-gluco-
heptapyranosyl)-5-O-[3-O-(2,6-diazido-3,4-di-O-benzyl-2,6-dideoxy-β-L-idopyranosyl)-2,5-di-






solution of compound 41(R) (41.8 mg, 0.027 mmol) in DMF (1.1 mL) was added NaH (60% in 
mineral oil, 2.2 mg, 0.055 mmol). The reaction mixture was stirred for 1 hour, then quenched 
with aqueous saturated NH4Cl solution, diluted with Et2O, washed with brine, dried with Na2SO4, 
and concentrated under vacuum. The crude residue was purified using silica gel column 
chromatography (20 % EtOAc in hexanes) to obtain compound 42(ax) (19.5 mg, 0.014 mmol) as 
a white foam in 52% yield. [α]D23 = 72.00 (c = 1.0, CHCl3), 1H NMR (600 MHz, C6D6) δ 7.54 – 7.46 
(m, 4H, ArH), 7.33 – 7.29 (m, 2H, ArH), 7.28 – 7.22 (m, 4H, ArH), 7.18 – 6.94 (m, 25H, ArH), 6.46 
(d, J = 3.8 Hz, 1H, H-1’), 5.98 (d, J = 5.4 Hz, 1H, H-1’’), 5.14 (d, J = 11.7 Hz, 1H, PhCH2O), 4.99 (d, J 
= 2.1 Hz, 1H, H-1’’’), 4.97 (d, J = 10.6 Hz, 1H, PhCH2O), 4.89 (d, J = 11.7 Hz, 1H, PhCH2O), 4.74 (d, 
J = 12.0 Hz, 1H, PhCH2O), 4.61 (d, J = 10.5 Hz, 1H, PhCH2O), 4.57 (q, J = 2.9 Hz, 1H, H-4’’), 4.49 (dd, 
J = 4.9, 2.8 Hz, 1H, H-3’’), 4.41 – 4.35 (m, 5H, PhCH2O), 4.34 (d, J = 9.4 Hz, 1H, PhCH2O), 4.30 (d, J 
= 11.8 Hz, 1H, PhCH2O), 4.25 (d, J = 11.9 Hz, 1H, PhCH2O), 4.21 (dd, J = 10.3, 4.3 Hz, 1H, H-5’), 4.12 
(t, J = 5.2 Hz, 1H, H-2’’), 4.11 – 4.05 (m, 2H, H-4’, PhCH2O), 4.00 – 3.88 (m, 5H, H-6’, H-7’, PhCH2O), 
3.86 (dd, J = 10.5, 2.5 Hz, 1H, H-5’’), 3.81 (t, J = 8.9 Hz, 1H, H-5), 3.73 (ddd, J = 8.3, 4.6, 2.1 Hz, 1H, 
H-5’’’), 3.69 – 3.64 (m, 2H, H-4, H-3’’’), 3.56 (dd, J = 10.5, 3.2 Hz, 1H, H-5’’), 3.39 (dd, J = 12.8, 8.2 
Hz, 1H, H-6’’’), 3.34 (t, J = 2.7 Hz, 1H, H-2’’’), 3.18 (dd, J = 9.9, 3.9 Hz, 1H, H-2’), 2.97 – 2.95 (m, 
1H, H-4’’’), 2.88 (t, J = 9.4 Hz, 1H, H-6), 2.75 (dd, J = 12.9, 4.6 Hz, 1H, H-6’’’), 2.71 (ddd, J = 12.8, 
9.6, 4.6 Hz, 1H, H-3), 2.57 (ddd, J = 12.4, 9.6, 4.5 Hz, 1H, H-1), 1.41 (dt, J = 12.9, 4.6 Hz, 1H, H-
2eq), 0.88 (q, J = 12.7 Hz, 1H, H-2ax). 13C NMR (151 MHz, C6D6) δ 138.6, 138.4, 138.3, 138.0, 137.4, 
137.3, 128.4, 128.35, 128.26, 128.22, 128.19, 128.00, 127.98, 127.94, 127.89, 127.6, 127.41, 
127.37, 127.35 (Ar), 106.3 (C-1’’), 98.8 (C-1’, C-1’’’), 83.9 (C-6), 82.4 (C-4’’), 82.4 (C-2’’), 81.6 (C-






5’’’), 73.6 (C-3’’’), 73.1 (PhCH2O), 73.0 (PhCH2O), 72.7 (PhCH2O), 72.4 (C-4’’’), 72.2 (PhCH2O), 71.9 
(PhCH2O), 71.6 (PhCH2O), 70.0 (C-5’’), 62.5 (C-2’), 59.9 (C-1), 59.8 (C-3), 56.8 (C-2’’’), 50.9 (C-6’’’), 
31.8 (C-2). ESI-HRMS: m/z calc for C73H77N15O14Na [M+Na]+ 1410.5672, found 1410.5699. 
4-O-(2-Amino-4,7-anhydro-2,7-dideoxy-D-glycero-α-D-gluco-heptapyranosyl)-5-O-[3-
O-(2,6-diamino-2,6-dideoxy-β-L-idopyranosyl)-β-D-ribofuranosyl]-2-deoxystreptamine 
pentaacetate salt (43(ax)). To a solution of compound 42(ax) (19.5 mg, 0.014 mmol) in 1:1 1,4-
dioxane/10% aqueous AcOH (0.6 mL) was added Pd/C (10 wt%, 40.6 mg). The reaction mixture 
was stirred under 50 psi H2 for 30 hours before filtration through Celtie and concentration. The 
crude residue was purified using CM Sephadex ion exchange column chromatography (0.1-0.8% 
aqueous NH4OH) followed by lyophilization with acetic acid to give the pentaacetate salt 43(ax) 
(5.9 mg, 0.0064 mmol) in 46% yield as a white powder. [α]D23 = 38.64 (c = 0.2, water) 1H NMR 
(600 MHz, D2O) δ 5.67 (d, J = 4.2 Hz, 1H, H-1’), 5.22 (d, J = 1.9 Hz, 1H, H-1’’), 5.11 (d, J = 1.8 Hz, 
1H, H-1’’’), 4.37 (dd, J = 7.2, 4.8 Hz, 1H, H-3’’), 4.33 (t, J = 4.5 Hz, 1H, H-6’), 4.25 (dd, J = 4.9, 2.0 
Hz, 1H, H-2’’), 4.19 – 4.12 (m, 2H, H-7’, H-5’’’), 4.06 – 4.02 (m, 2H, H-4’’, H-3’’’), 3.91 (t, J = 9.9 Hz, 
1H, H-3’), 3.77 – 3.70 (m, 3H, H-5’, H-7’, H-5’’), 3.67 (t, J = 9.1 Hz, 1H, H-5), 3.65 – 3.63 (m, 1H, H-
4’’’), 3.62 – 3.56 (m, 2H, H-4, H-5’’), 3.51 (t, J = 9.9 Hz, 1H, H-4’), 3.44 (t, J = 9.8 Hz, 1H, H-6), 3.40 
– 3.37 (m, 1H, H-2’’’), 3.25 (dd, J = 13.6, 6.8 Hz, 1H, H-6’’’), 3.19 (dd, J = 13.6, 3.8 Hz, 1H, H-6’’’), 
3.13 (dd, J = 10.2, 4.2 Hz, 1H, H-2’), 3.10 – 3.05 (m, 1H, H-1), 3.04 – 2.98 (m, 1H, H-3), 2.12 (dt, J 
= 12.9, 4.4 Hz, 1H, H-2eq), 1.73 (d, J = 1.1 Hz, 15H, AcOH), 1.44 (q, J = 12.6 Hz, 1H, H-2ax). 13C 
NMR (151 MHz, D2O) δ 181.3 (AcOH), 110.0 (C-1’’), 98.3 (C-1’), 95.3 (C-1’’’), 85.1 (C-5), 81.0 (C-






69.9 (C-5’’’), 67.7 (C-3’), 67.6 (C-3’’’), 67.3 (C-6’), 59.8 (C-4’’’), 54.6 (C-5’’), 50.9 (C-2’), 50.2 (C-2’’’), 
48.5 (C-1), 40.3 (C-3), 30.7 (C-2), 23.2 (AcOH). ESI-HRMS: m/z calc for C24H46N5O14 [M+H]+ 
628.3041, found 628.3060. 
4-O-(2-azido-3,6-di-O-benzyl-4,7-anhydro-2,7-dideoxy-L-glycero-α-D-gluco-
heptapyranosyl)-5-O-[3-O-(2,6-diazido-3,4-di-O-benzyl-2,6-dideoxy-β-L-idopyranosyl)-2,5-di-
O-benzyl-β-D-ribofuranosyl]-1,3-diazido-6-O-benzyl-2-deoxystreptamine (42(eq)). To a stirred 
solution of compound 41(S) (39.8 mg, 0.026 mmol) in DMF (1.0 mL) was added NaH (60% in 
mineral oil, 2.5 mg, 0.062 mmol). After stirring for 3 hours the reaction was not complete and 
NaH (2.5 mg, 0.062 mmol) was added. After an additional 30 minutes the reaction was quenched 
with aqueous saturated NH4Cl solution, diluted with Et2O, washed with brine, dried with Na2SO4, 
and concentrated under vacuum. The crude residue was purified using silica gel column 
chromatography (20 % EtOAc in hexanes) to obtain compound 42(eq) (24.4 mg, 0.018 mmol) as 
a white foam in 69% yield. [α]D23 = 76.40 (c = 1.0, CHCl3) 1H NMR (600 MHz, C6D6) δ 7.52 – 7.45 
(m, 4H, ArH), 7.36 – 7.26 (m, 6H, ArH), 7.21 – 6.95 (m, 25H, ArH), 6.57 (d, J = 3.9 Hz, 1H, H-1’), 
5.99 (d, J = 5.6 Hz, 1H, H-1’’), 5.08 (d, J = 11.6 Hz, 1H, PhCH2O), 5.02 (d, J = 1.8 Hz, 1H, H-1’’’), 4.93 
(d, J = 10.5 Hz, 1H, PhCH2O), 4.87 (d, J = 11.6 Hz, 1H, PhCH2O), 4.68 (d, J = 11.6 Hz, 1H, PhCH2O), 
4.58 – 4.55 (m, 2H, H-4’’, PhCH2O), 4.54 – 4.45 (m, 3H, H-3’, H-5’, H-3’’), 4.41 – 4.36 (m, 2H, 
PhCH2O), 4.36 – 4.32 (m, 2H, PhCH2O), 4.31 – 4.26 (m, 2H, PhCH2O), 4.13 (t, J = 5.2 Hz, 1H, H-2’’), 
4.06 (d, J = 11.8 Hz, 1H, PhCH2O), 4.02 (td, J = 7.6, 5.3 Hz, 1H, H-6’), 3.99 – 3.95 (m, 2H, PhCH2O), 
3.94 – 3.89 (m, 2H, H-7’, H-5’’), 3.85 – 3.80 (m, 2H, H-4, H-7’), 3.77 – 3.70 (m, 2H, H-5, H-5’’’), 3.66 






3.36 – 3.33 (m, 1H, H-2’’’), 3.26 (t, J = 9.7 Hz, 1H, H-4’), 3.09 (dd, J = 9.8, 3.9 Hz, 1H, H-2’), 2.96 – 
2.93 (m, 1H, H-4’’’), 2.86 (t, J = 9.4 Hz, 1H, H-6), 2.78 (ddd, J = 12.7, 9.8, 4.6 Hz, 1H, H-3), 2.71 (dd, 
J = 12.8, 4.2 Hz, 1H, H-6’’’), 2.56 (ddd, J = 12.5, 9.9, 4.4 Hz, 1H, H-1), 1.38 (dt, J = 12.7, 4.4 Hz, 1H, 
H-2eq), 0.86 (q, J = 12.7 Hz, 1H, H-2ax). 13C NMR (151 MHz, C6D6) δ 138.6, 138.4, 138.34, 138.27, 
138.0, 137.4, 137.3, 128.43, 128.35, 128.27, 128.22, 128.1, 128.00, 127.96, 127.94, 127.6, 127.31, 
127.28 (Ar), 106.4 (C-1’’), 98.8 (C-1’’’), 98.3 (C-1’), 84.1 (C-6), 82.6 (C-2’’), 82.4 (C-4’’), 82.0 (C-4), 
81.8 (C-4’), 78.9 (C-6’), 77.1 (C-5’), 77.0 (C-3’), 75.9 (C-3’’), 75.7 (C-5), 75.0 (PhCH2O), 74.2 (C-5’’’), 
73.5 (C-3’’’), 73.3 (PhCH2O), 73.1 (PhCH2O), 72.8 (PhCH2O), 72.3 (C-7’), 72.2 (C-4’’’), 71.8 
(PhCH2O), 71.6 (PhCH2O), 70.3 (C-5’’), 62.7 (C-2’), 60.0 (C-1), 59.9 (C-3), 56.7 (C-2’’’), 51.0 (C-6’’’), 
32.0 (C-2). ESI-HRMS: m/z calc for C73H77N15O14Na [M+Na]+ 1410.5672, found 1410.5570. 
4-O-(2-Amino-4,7-anhydro-2,7-dideoxy-L-glycero-α-D-gluco-heptapyranosyl)-5-O-[3-O-
(2,6-diamino-2,6-dideoxy-β-L-idopyranosyl)-β-D-ribofuranosyl]-2-deoxystreptamine 
pentaacetate salt (43(eq)). To a solution of compound 42(eq) (24.4 mg, 0.018 mmol) in 1:1 1,4-
dioxane/10% aqueous AcOH (0.6 mL) was added Pd/C (10 wt%, 47.8 mg). The reaction mixture 
was stirred under 50 psi H2 for 30 hours before filtration through Celtie and concentration. The 
crude residue was purified using CM Sephadex ion exchange column chromatography (0.1-0.6% 
aqueous NH4OH) followed by lyophilization with acetic acid to give the pentaacetate salt 43(eq) 
(3.1 mg, 0.0033 mmol) in 18% yield as a white powder. [α]D23 = 54.64 (c = 0.1, water) 1H NMR 
(600 MHz, D2O) δ 5.58 (d, J = 4.3 Hz, 1H, H-1’), 5.23 (d, J = 2.1 Hz, 1H, H-1’’), 5.11 (d, J = 1.8 Hz, 
1H, H-1’’’), 4.42 (td, J = 8.0, 5.5 Hz, 1H, H-6’), 4.38 (dd, J = 7.0, 4.8 Hz, 1H, H-3’’), 4.24 (dd, J = 4.9, 






Hz, 1H, H-3’), 3.83 (dd, J = 10.1, 7.9 Hz, 1H, H-5’), 3.75 (dd, J = 12.4, 3.1 Hz, 1H, H-5’’), 3.68 (t, J = 
9.2 Hz, 1H, H-5), 3.66 – 3.64 (m, 1H, H-4’’’), 3.64 – 3.58 (m, 2H, H-7’, H-5’’), 3.56 (t, J = 9.4 Hz, 1H, 
H-4), 3.43 (t, J = 9.8 Hz, 1H, H-6), 3.39 – 3.34 (m, 2H, H-4’, H-2’’’), 3.26 (dd, J = 13.6, 6.8 Hz, 1H, H-
6’’’), 3.20 (dd, J = 13.6, 3.9 Hz, 1H, H-6’’’), 3.10 – 3.03 (m, 2H, H-1, H-2’), 3.02 – 2.96 (m, 1H, H-3), 
2.11 (dt, J = 12.9, 4.3 Hz, 1H, H-2eq), 1.75 (s, 13H, AcOH), 1.41 (q, J = 12.6 Hz, 1H, H-2ax). 13C NMR 
(151 MHz, D2O) δ 181.3 (AcOH), 109.8 (C-1’’), 98.6 (C-1’), 95.6 (C-1’’’), 84.9 (C-5), 81.1 (C-4’’), 80.4 
(C-4), 78.8 (C-4’), 77.1 (C-5’), 75.0 (C-3’’), 73.5 (C-6), 73.4 (C-2’’), 73.0 (C-7’), 70.8 (C-6’), 70.3 (C-
5’’’), 69.7 (C-3’), 67.9 (C-3’’’), 67.4 (C-4’’’), 59.9 (C-5’’), 54.7 (C-2’), 51.0 (C-2’’’), 50.3 (C-1), 48.8 (C-




benzyl-β-D-ribofuranosyl]-1,3-diazido-6-O-benzyl-2-deoxystreptamine (45(ax)), and 4-O-(2-
azido-3,6-di-O-benzyl-4,8-anhydro-2,7-dideoxy-L-glycero-α-D-gluco-octapyranosyl)-5-O-[3-O-
(2,6-diazido-3,4-di-O-benzyl-2,6-dideoxy-β-L-idopyranosyl)-2,5-di-O-benzyl-β-D-
ribofuranosyl]-1,3-diazido-6-O-benzyl-2-deoxystreptamine (45(eq)). 1 M BH3 complex with THF 
(0.5 mL, 0.5 mmol) was added to a stirred solution of compounds 40 (0.69 g, 0.45 mmol) in THF 
(4.5 mL) at 0 oC. After 4 hours more BH3 complex with THF (0.1 mL, 0.1 mmol) was added. After 
2 more hours aqueous saturated NaHCO3 solution (1.2 mL) and 30% hydrogen peroxide solution 
(0.46 mL) were added dropwise. After an additional hour the reaction mixture was diluted with 






residue was purified using silica gel column chromatography in 25 to 35% EtOAc in hexanes to 
give compounds 44 (0.292 g, 0.190 mmol) in 42% yield as an inseparable mixture of 
diastereomers. 1H NMR (600 MHz, CDCl3) δ 7.40 – 7.09 (m, 74H, Ar-H), 6.84 – 6.80 (m, 4H, Ar-H), 
6.19 (d, J = 3.7 Hz, 1H, H-1’a), 6.16 (d, J = 3.7 Hz, 1H, H-1’b), 5.65 (d, J = 6.6 Hz, 1H, H-1’’a), 5.63 
(d, J = 6.3 Hz, 1H, H-1’’b), 4.98 – 4.94 (m, 2H), 4.89 – 4.72 (m, 10H), 4.67 (d, J = 10.7 Hz, 1H), 4.64 
– 4.56 (m, 6H), 4.54 (d, J = 11.9 Hz, 1H), 4.51 (d, J = 11.8 Hz, 1H), 4.49 (d, J = 1.8 Hz, 1H), 4.47 (d, 
J = 1.6 Hz, 1H), 4.47 – 4.37 (m, 8H), 4.33 – 4.21 (m, 11H), 4.19 (dd, J = 5.0, 2.5 Hz, 1H), 4.11 (td, J 
= 10.6, 8.7 Hz, 2H), 4.06 – 4.03 (m, 1H), 4.02 – 4.00 (m, 1H), 3.97 – 3.88 (m, 4H), 3.87 – 3.81 (m, 
2H), 3.80 (s, 3H), 3.77 (s, 3H), 3.73 (dt, J = 9.1, 2.8 Hz, 3H), 3.70 – 3.63 (m, 4H), 3.59 – 3.51 (m, 
5H), 3.51 – 3.40 (m, 3H), 3.38 – 3.32 (m, 2H), 3.32 – 3.30 (m, 1H), 3.28 (d, J = 9.3 Hz, 1H), 3.17 (t, 
J = 9.5 Hz, 1H), 3.13 – 3.07 (m, 4H), 2.92 – 2.87 (m, 2H), 2.82 (dd, J = 13.0, 3.7 Hz, 1H), 2.23 (dt, J 
= 13.1, 4.6 Hz, 1H, H-2eq a), 2.09 (dt, J = 13.5, 4.8 Hz, 1H, H-2eq b), 2.07 – 2.00 (m, 2H, H-7’a, H-
7’b), 1.87 (m, 2H, H-7’a, H-7’b), 1.36 (q, J = 12.7 Hz, 1H, H-2ax a), 1.00 (q, J = 12.8 Hz, 1H, H-2ax 
b). 13C NMR (151 MHz, CDCl3) δ 159.3, 159.0, 138.3, 138.2, 138.14, 138.12, 138.0, 137.92, 137.87, 
137.6, 137.5, 137.03, 137.00, 136.96, 136.94, 129.8, 128.8, 128.66, 128.65, 128.50, 128.47, 
128.41, 128.39, 128.36, 128.34, 128.31, 128.22, 128.17, 128.16, 128.11, 127.90, 127.85, 127.81, 
127.77, 127.74, 127.5, 127.2, 113.8, 113.7 (Ar), 106.0 (C-1’a), 105.9 (C-1’b), 98.67 (C-1’’’a, C-1’’’b), 
95.84 (C-1’b), 95.43 (C-1’a), 84.14, 84.10, 82.59, 82.25, 82.10, 81.97, 81.70, 80.77, 80.49, 77.87, 
77.52, 75.88, 75.62, 75.56, 75.39, 75.32, 75.03, 75.00, 74.92, 74.52, 74.37, 74.15, 73.97, 73.90, 
73.85, 73.42, 73.28, 73.20, 72.93, 72.84, 72.60, 72.36, 72.34, 71.78, 71.73, 71.66, 71.44, 70.94, 
70.34, 70.29, 69.93, 63.22, 63.06, 60.67, 60.42, 60.37, 60.29, 59.58, 57.27, 57.21, 55.28, 55.23, 






[M + Na]+ 1562.6509, found 1562.6514. TsCl (58.3 mg, 0.306 mmol) was added to a stirred 
solution of compounds 44 (0.292 g, 0.190 mmol) and Hunig’s base (0.07 mL, 0.4 mmol) in DCM 
(1.9 mL). After 28 hours Hunig’s base (0.12 mL, 0.67 mmol) and TsCl (0.117 g, 0.614 mmol) were 
added. After 24 additional hours TsCl (59.2 mg, 0.311 mmol) was added. After 28 additional hours 
TsCl (50.8 mg, 0.266 mmol) and Hunig’s base (0.07 mL, 0.4 mmol) were added. After 18 additional 
hours the reaction mixture was diluted with Et2O and washed with 1N HCl, NaHCO3 solution, and 
brine. The organic layer was dried with Na2SO4, filtered, and concentrated. The crude residue was 
passed through silica gel and used in the next step without further purification. ESI-HRMS: m/z 
calcd for C89H95N15O18SNa [M + Na]+ 1717.6628, found 1717.6620. To a stirred solution of the 8’-
OTs compounds in DCM (1.68 mL) at 0 oC was added TFA (0.19 mL). After 50 minutes the reaction 
mixture was diluted with Et2O and washed with water, saturated NaHCO3 solution, and brine. 
The organic layer was dried with Na2SO4, filtered, and concentrated to give a mixture of 
diastereomers which were passed through silica gel and used in the next step without further 
purification. ESI-HRMS: m/z calcd for C81H87N15O17SNa [M + Na]+ 1596.6023, found 1596.6086. 
The crude residue was stirred in DMF at 0 oC followed by addition of 60% NaH in mineral oil (8.0 
mg, 0.2 mmol). After 1.5 hours the reaction was quenched with NH4Cl solution (1 mL), diluted 
with Et2O, and washed with DI water and brine. The organic layer was dried with Na2SO4 and 
concentrated. The crude residue was purified using silica gel column chromatography in 12.5% 
EtOAc in hexanes to give 45(ax) (22.6 mg, 0.0161 mmol) in 9% yield as the less polar diastereomer 
and 45(eq) (26.4 mg, 0.0188 mmol) in 10% yield as the more polar diastereomer. 45(ax) [α]D23 = 
71.46 (c = 1.0, DCM), 1H NMR (600 MHz, CDCl3) δ 7.42 – 7.10 (m, 35H, Ar-H), 6.03 (d, J = 3.8 Hz, 






PhCH2O), 4.82 (d, J = 1.9 Hz, 1H, H-1’’’), 4.76 – 4.72 (m, 2H, PhCH2O), 4.71 (d, J = 10.8 Hz, 1H, 
PhCH2O), 4.63 (d, J = 12.2 Hz, 1H, PhCH2O), 4.60 (d, J = 12.1 Hz, 1H, PhCH2O), 4.54 (d, J = 10.9 Hz, 
1H, PhCH2O), 4.52 (d, J = 10.4 Hz, 1H, PhCH2O), 4.44 – 4.38 (m, 3H, PhCH2O), 4.31 (d, J = 12.0 Hz, 
1H, PhCH2O), 4.29 – 4.23 (m, 3H, H-3’’, H-4’’, PhCH2O), 4.02 – 3.88 (m, 5H, H-5, H-3’, H-5’, H-6’, 
H-2’’), 3.85 – 3.80 (m, 2H, H-4’, H-8’), 3.78 – 3.71 (m, 4H, H-8’, H-5’’, H-3’’’, H-5’’’), 3.65 (dd, J = 
9.8, 8.6 Hz, 1H, H-4), 3.60 – 3.53 (m, 2H, H-5’’, H-6’’’), 3.45 – 3.38 (m, 2H, H-1, H-3), 3.33 (t, J = 2.7 
Hz, 1H, H-2’’’), 3.28 (t, J = 9.2 Hz, 1H, H-6), 3.14 (dd, J = 10.2, 3.8 Hz, 1H, H-2’), 3.12 (t, J = 2.8 Hz, 
1H, H-4’’’), 2.92 (dd, J = 12.9, 4.3 Hz, 1H, H-6’’’), 2.23 (dt, J = 13.1, 4.6 Hz, 1H, H-2eq), 1.93 – 1.88 
(m, 1H, H-7’eq), 1.78 (tdd, J = 13.9, 5.5, 2.2 Hz, 1H, H-7’ax), 1.41 (q, J = 12.7 Hz, 1H, H-2ax). 13C 
NMR (151 MHz, CDCl3) δ 139.1, 138.5, 138.2, 137.8, 137.6, 137.03, 136.95, 128.7, 128.5, 128.4, 
128.33, 128.30, 128.29, 128.25, 128.15, 128.0, 127.8, 127.7, 127.54, 127.48, 127.46, 127.41, 
127.3, 127.1 (Ar), 106.2 (C-1’’), 98.6 (C-1’’’), 96.8 (C-1’), 83.8 (C-6), 82.1 (C-2’’), 82.0 (C-4’’), 81.5 
(C-5), 77.7 (C-3’), 76.3 (C-4’), 75.5 (C-3’’), 75.4 (C-4), 75.0 (PhCH2O), 74.8 (PhCH2O), 74.2 (C-5’’’), 
73.2 (PhCH2O), 73.02 (PhCH2O), 72.97 (C-3’’’), 72.4 (PhCH2O), 72.3 (C-6’), 71.9 (PhCH2O), 71.8 
(PhCH2O), 71.5 (C-4’’’), 70.6 (C-5’), 70.0 (C-5’’), 62.6 (C-2’), 62.3 (C-8’), 60.3 (C-1), 59.9 (C-3), 57.4 
(C-2’’’), 51.0 (C-6’’’), 32.4 (C-2), 31.1 (C-7’). ESI-HRMS: m/z calcd for C74H83N16O14 [M + NH4]+ 
1419.6275, found 1419.6295. 45(eq) [α]D23 = 79.48 (c = 1.0, DCM), 1H NMR (600 MHz, CDCl3) δ 
7.44 – 7.05 (m, 35H, Ar-H), 6.25 (d, J = 3.8 Hz, 1H, H-1’), 5.68 (d, J = 6.2 Hz, 1H, H-1’’), 4.94 – 4.88 
(m, 4H, H-1’’’, PhCH2O), 4.77 (d, J = 11.8 Hz, 1H, PhCH2O), 4.71 (d, J = 11.1 Hz, 1H, PhCH2O), 4.63 
– 4.59 (m, 2H, PhCH2O), 4.58 (d, J = 11.8 Hz, 1H, PhCH2O), 4.52 (d, J = 11.7 Hz, 1H, PhCH2O), 4.46 
– 4.41 (m, 2H, PhCH2O) 4.40 (d, J = 12.0 Hz, 1H, PhCH2O), 4.30 (d, J = 12.0 Hz, 1H, PhCH2O), 4.28 






H-2’’), 3.82 (t, J = 9.3 Hz, 1H, H-5’), 3.79 (dd, J = 10.4, 2.1 Hz, 1H, H-5’’), 3.77 – 3.73 (m, 2H, H-3’’’, 
H-5’’’), 3.72 (t, J = 9.4 Hz, 1H, H-4), 3.64 (dd, J = 13.0, 8.6 Hz, 1H, H-6’’’), 3.56 (dd, J = 10.4, 2.8 Hz, 
1H, H-5’’), 3.51 (ddd, J = 11.1, 8.8, 5.2 Hz, 1H, H-6’), 3.44 (ddd, J = 12.6, 9.8, 4.5 Hz, 1H, H-3), 3.40 
– 3.32 (m, 3H, H-1, H-8’, H-2’’’), 3.09 (t, J = 2.4 Hz, 1H, H-4’’’), 3.03 – 2.99 (m, 2H, H-6, H-2’), 2.95 
(t, J = 9.4 Hz, 1H, H-4’), 2.82 (dd, J = 13.0, 3.7 Hz, 1H, H-6’’’), 2.14 (dt, J = 13.2, 4.6 Hz, 1H, H-2eq), 
2.07 – 2.03 (m, 1H, H-7’eq), 1.78 (tdd, J = 13.0, 11.1, 5.1 Hz, 1H, H-7’ax), 1.22 (q, J = 12.7 Hz, 1H, 
H-2ax). 13C NMR (151 MHz, Chloroform-d) δ 139.3, 138.4, 138.3, 138.0, 137.4, 137.0, 136.9, 
128.7, 128.5, 128.43, 128.41, 128.32, 128.27, 128.22, 128.17, 128.0, 127.81, 127.77, 127.70, 
127.6, 127.5, 127.4, 127.2, 127.1 (Ar), 105.8 (C-1’’), 98.6 (C-1’’’), 95.3 (C-1’), 84.3 (C-6), 82.8 (C-
2’’), 82.1 (C-4’’), 81.6 (C-5), 80.8 (C-4’), 77.3 (C-3’), 76.8 (C-6’), 75.5 (C-3’’), 75.00 (PhCH2O), 74.96 
(PhCH2O), 74.4 (C-5’’’), 74.1 (C-4), 73.4 (PhCH2O), 73.2 (PhCH2O), 73.0 (C-5’), 72.8 (C-3’’’), 72.3 
(PhCH2O), 72.1 (PhCH2O), 71.7 (PhCH2O), 71.4 (C-4’’’), 70.3 (C-5’’), 66.1 (C-8’), 62.9 (C-2’), 60.3 (C-
1), 60.0 (C-3), 57.2 (C-2’’’), 51.1 (C-6’’’), 32.5 (C-2), 32.1 (C-7’). ESI-HRMS: m/z calcd for 
C74H79N15O14 [M + Na]+ 1424.5829, found 1424.5869. 
4-O-(2-Amino-4,8-anhydro-2,7-dideoxy-D-glycero-α-D-gluco-octapyranosyl)-5-O-[3-O-
(2,6-diamino-2,6-dideoxy-β-L-idopyranosyl)-β-D-ribofuranosyl]-2-deoxystreptamine (46(ax)). 
To a solution of compound 45(ax) (21.1 mg, 0.015 mmol) in 1:1 1,4-dioxane/10% aqueous AcOH 
(0.6 mL) was added Pd/C (10 wt%, 43.4 mg). The reaction mixture was stirred under 50 psi H2 for 
19 hours before filtration through Celtie and concentration. The crude residue was purified using 
CM Sephadex ion exchange column chromatography (0.1-0.8% aqueous NH4OH) followed by 






in 43% yield as a white powder. [α]D23 = 22.07 (c = 0.1, water), 1H NMR (600 MHz, D2O) δ 5.62 (d, 
J = 4.1 Hz, 1H, H-1’), 5.23 (d, J = 2.2 Hz, 1H, H-1’’), 5.13 (d, J = 1.8 Hz, 1H, H-1’’’), 4.38 (dd, J = 7.0, 
4.9 Hz, 1H, H-3’’), 4.24 (dd, J = 4.8, 2.1 Hz, 1H, H-2’’), 4.17 – 4.14 (m, 1H, H-5’’’), 4.10 – 4.03 (m, 
3H, H-6’, H-4’’, H-3’’’), 3.81 (t, J = 10.1 Hz, 1H, H-3’), 3.77 (dd, J = 12.4, 2.9 Hz, 1H, H-5’’), 3.72 – 
3.65 (m, 3H, H-5, H-8’, H-4’’’), 3.65 – 3.58 (m, 3H, H-5’, H-8’, H-5’’), 3.56 (t, J = 9.4 Hz, 1H, H-4), 
3.48 – 3.38 (m, 3H, H-6, H-4’, H-2’’’), 3.27 (dd, J = 13.6, 6.8 Hz, 1H, H-6’’’), 3.24 – 3.17 (m, 2H, H-
2’, H-6’’’), 3.13 – 3.06 (m, 1H, H-1), 3.06 – 2.99 (m, 1H, H-3), 2.13 (dt, J = 12.8, 4.1 Hz, 1H, H-2eq), 
1.76 (s, 16H, H-7’ax, AcOH), 1.71 – 1.66 (m, 1H, H-7’eq), 1.45 (q, J = 12.5 Hz, 1H, H-2ax). 13C NMR 
(151 MHz, D2O) δ 181.2 (AcOH), 109.9 (C-1’’), 96.5 (C-1’), 95.4 (C-1’’’), 85.0 (C-5), 81.0 (C-4’’), 79.4 
(C-4), 74.9 (C-3’’), 73.8 (C-4’), 73.4 (C-2’’), 73.1 (C-6), 70.2 (C-5’, C-5’’’), 67.7 (C-3’’’), 67.6 (C-3’), 
67.3 (C-4’’’), 63.8 (C-6’), 62.3 (C-8’), 59.9 (C-5’’), 54.5 (C-2’), 50.9 (C-2’’’), 50.2 (C-1), 48.8 (C-3), 
40.3 (C-6’’’), 31.6 (C-7’), 30.7 (C-2), 23.1 (AcOH). ESI-HRMS: m/z calcd for C25H47N5O14 [M + H]+ 
642.3198, found 642.3193. 
4-O-(2-Amino-4,8-anhydro-2,7-dideoxy-L-glycerol-α-D-gluco-octapyranosyl)-5-O-[3-O-
(2,6-diamino-2,6-dideoxy-β-L-idopyranosyl)-β-D-ribofuranosyl]-2-deoxystreptamine (46(eq)). 
To a solution of compound 45(eq) (26.4 mg, 0.019 mmol) in 1:1 1,4-dioxane/10% aqueous AcOH 
(0.6 mL) was added Pd/C (10 wt%, 43.4 mg). The reaction mixture was stirred under 50 psi H2 for 
19 hours before filtration through Celtie and concentration. The crude residue was purified using 
CM Sephadex ion exchange column chromatography (0.1-0.8% aqueous NH4OH) followed by 
lyophilization with excess acetic acid to give the pentaacetate salt 46(eq) (9.1 mg, 0.0097 mmol) 






J = 4.1 Hz, 1H, H-1’), 5.22 (d, J = 2.7 Hz, 1H, H-1’’), 5.13 (d, J = 1.8 Hz, 1H, H-1’’’), 4.36 (dd, J = 6.6, 
5.1 Hz, 1H, H-3’’), 4.20 (dd, J = 5.0, 2.7 Hz, 1H, H-2’’), 4.15 (ddd, J = 6.6, 4.1, 1.5 Hz, 1H, H-5’’’), 
4.07 (t, J = 3.1 Hz, 1H, H-3’’’), 4.05 – 4.02 (m, 1H, H-4’’), 3.89 – 3.85 (m, 1H, H-8’), 3.82 (t, J = 10.0 
Hz, 1H, H-3’), 3.77 – 3.69 (m, 4H, H-4, H-5, H-6’, H-5’’), 3.66 (dt, J = 3.0, 1.4 Hz, 1H, H-4’’’), 3.61 
(dd, J = 12.4, 4.6 Hz, 1H, H-5’’), 3.50 (dd, J = 10.4, 8.7 Hz, 1H, H-6), 3.44 – 3.37 (m, 3H, H-5’, H-8’, 
H-2’’’), 3.29 – 3.17 (m, 4H, H-3, H-2’, H-6’’’, H-6’’’), 3.14 (td, J = 11.5, 10.7, 4.0 Hz, 1H, H-1), 3.06 
(t, J = 9.5 Hz, 1H, H-4’), 2.24 (dt, J = 13.0, 4.3 Hz, 1H, H-2eq), 1.93 – 1.87 (m, 1H, H-7’eq), 1.75 (s, 
15H, AcOH), 1.62 – 1.50 (m, 2H, H-2ax, H-7’ax). 13C NMR (151 MHz, D2O) δ 181.0 (AcOH), 109.7 
(C-1’’), 96.7 (C-1’), 95.4 (C-1’’’), 84.2 (C-5), 81.3 (C-4’’), 79.6 (C-4), 78.1 (C-4’), 75.1 (C-3’’), 73.6 (C-
5’), 73.3 (C-2’’), 72.7 (C-6), 70.2 (C-5’’’), 68.5 (C-6’), 67.6 (C-3’’’), 67.4 (C-3’), 67.2 (C-4’’’), 66.0 (C-
8’), 59.9 (C-5’’), 54.4 (C-2’), 50.8 (C-2’’’), 49.8 (C-1), 49.0 (C-3), 40.3 (C-6’’’), 33.1 (C-7’), 29.4 (C-2), 
23.1 (AcOH). ESI-HRMS: m/z calcd for C25H47N5O14 [M + H]+ 642.3198, found 642.3199. 
4’-O-allyl-1,3,2’,2’’’,6’’’-Pentaazido-6,3’,2’’,5’’,3’’’,4’’’-hexa-O-benzyl-6’-O-
triisopropylsilyl-1,3,2’,2’’’,6’’’-pentadeaminoparomomycin (47). To a stirred solution of 
compound 25 (2.51 g 1.73 mmol) in DMF (34 mL) was added NaH (0.140 g, 3.50 mmol) and the 
reaction mixture was stirred for 20 minutes. TBAI (0.200 g, 0.541 mmol) and allylBr (0.30 mL, 3.5 
mmol) were added and stirring was continued. After 3 hours the reaction was quenched with 
aqueous saturated NH4Cl solution, diluted with Et2O, washed with DI water and brine, dried with 
Na2SO4, and concentrated. The crude residue was purified using silica gel column 
chromatography (10% EtOAc in hexanes) to give compound 47 (1.94 g, 1.31 mmol) as a white 






ArH), 7.36 – 7.23 (m, 18H, ArH), 7.22 – 7.14 (m, 10H, ArH), 6.10 (d, J = 3.7 Hz, 1H, H-1’), 5.91 (ddt, 
J = 17.3, 10.7, 5.5 Hz, 1H, -CH2-CH=CH2), 5.65 (d, J = 5.9 Hz, 1H, H-1’’), 5.25 (dq, J = 17.2, 1.7 Hz, 
1H, -CH2-CH=CH2), 5.14 (dq, J = 10.4, 1.5 Hz, 1H, -CH2-CH=CH2), 4.94 (d, J = 10.7 Hz, 1H, PhCH2O), 
4.87 (d, J = 1.9 Hz, 1H, H-1’’’), 4.83 (d, J = 10.7 Hz, 1H, PhCH2O), 4.80 (d, J = 10.7 Hz, 1H, PhCH2O), 
4.67 (d, J = 10.7 Hz, 1H, PhCH2O), 4.613 (d, J = 11.9, 1H, PhCH2O), 4.610 (d, J = 12.1, 1H, PhCH2O), 
4.55 (d, J = 12.0 Hz, 1H, PhCH2O), 4.46 (d, J = 11.7 Hz, 1H, PhCH2O), 4.409 (d, J = 12.0, 1H, PhCH2O), 
4.403 (d, J = 12.0, 1H, PhCH2O), 4.33 – 4.21 (m, 5H, H-3’’, H-4’’, -CH2-CH=CH2, PhCH2O), 4.13 (ddt, 
J = 12.7, 5.6, 1.5 Hz, 1H, -CH2-CH=CH2), 4.03 (dd, J = 10.4, 9.0 Hz, 1H, H-3’), 3.98 – 3.91 (m, 4H, H-
5, H-5’, H-6’, H-2’’), 3.84 (dd, J = 5.5, 11.1 Hz, 1H, H-6’), 3.76 – 3.71 (m, 4H, H-4, H-5’’, H-3’’’, H-
5’’’), 3.59 (dd, J = 12.9, 8.4 Hz, 1H, H-6’’’), 3.54 (dd, J = 10.4, 3.3 Hz, 1H, H-5’’), 3.45 (ddd, J = 12.4, 
9.7, 4.6 Hz, 1H, H-3), 3.45 (ddd, J = 12.4, 9.7, 4.6 Hz, 1H, H-1), 3.34 – 3.31 (m, 1H, H-2’’’), 3.28 (t, 
J = 9.3 Hz, 1H, H-4’), 3.25 (t, J = 9.4 Hz, 1H, H-6), 3.12 – 3.10 (m, 1H, H-4’’’), 3.04 (dd, J = 10.4, 3.7 
Hz, 1H, H-2’), 2.89 (dd, J = 12.9, 4.2 Hz, 1H, H-6’’’), 2.22 (dt, J = 13.1, 4.6 Hz, 1H, H-2eq), 1.36 (q, J 
= 12.7 Hz, 1H, H-2ax), 1.17 – 1.06 (m, 21H, OTIPS). 13C NMR (151 MHz, CDCl3) δ 138.3, 138.1, 
137.9, 137.7, 137.07, 136.93 (Ar), 134.9 (-CH2-CH=CH2), 128.7, 128.5, 128.41, 128.38, 128.35, 
128.32, 128.31, 128.28, 128.23, 128.16, 127.82, 127.76, 127.73, 127.48, 127.46, 127.42 (Ar), 
116.5 (-CH2-CH=CH2), 105.9 (C-1’’), 98.6 (C-1’’’), 95.6 (C-1’), 84.2 (C-6), 82.6 (C-2’’), 82.0 (C-4’’), 
81.7 (C-5), 80.1 (C-3’), 78.1 (C-4’), 75.6 (C-3’’), 75.4 (PhCH2O), 75.0 (PhCH2O), 74.5 (C-4), 74.2 (C-
5’’’), 73.5 (-CH2-CH=CH2), 73.3 (PhCH2O), 73.2 (PhCH2O), 72.9 (C-3’’’), 72.7 (C-5’), 72.4 (PhCH2O), 
71.7 (PhCH2O), 71.4 (C-4’’’), 69.9 (C-5’’), 63.4 (C-2’), 62.9 (C-6’), 60.4 (C-1), 60.0 (C-3), 57.3 (C-2’’’), 
51.0 (C-6’’’), 32.6 (C-2), 18.1 (iPr-CH3), 18.1 (iPr-CH3), 12.0 (iPr-CH-). ESI-HRMS: m/z calc for 







pentadeaminoparomomycin (48). To a stirred solution of 47 (2.60 g, 1.75 mmol) in THF (33 mL) 
was added TBAF solution (1 M in THF, 10.5 mL). The reaction mixture was stirred under argon for 
1 hour with monitoring by TLC. After completion, the reaction mixture was concentrated under 
vacuum and the residue was dissolved in ethyl acetate and washed with saturated aqueous 
NaHCO3 followed by brine. The organic layer was dried with Na2SO4, filtered, and concentrated 
under vacuum. Purification using silica gel column chromatography (15-30% EtOAc in hexanes) 
gave the product 48 (2.03 g, 1.53 mmol) in 87% yield as a white foam. [α]D23 = 85.20 (c = 1.0, 
DCM), 1H NMR (600 MHz, CDCl3) δ 7.41 – 7.38 (m, 2H, ArH), 7.36 – 7.24 (m, 19H, ArH), 7.22 – 7.13 
(m, 9H, ArH), 6.13 (d, J = 3.7 Hz, 1H, H-1’), 5.89 (ddt, J = 17.2, 10.8, 5.5 Hz, 1H, -CH2-CH=CH2), 5.68 
(d, J = 5.7 Hz, 1H, H-1’’), 5.25 (dq, J = 17.2, 1.7 Hz, 1H, -CH2-CH=CH2), 5.14 (dq, J = 10.5, 1.4 Hz, 
1H, -CH2-CH=CH2), 4.98 (d, J = 10.6 Hz, 1H, PhCH2O), 4.90 (d, J = 1.9 Hz, 1H, H-1’’’), 4.82 (d, J = 
10.8 Hz, 1H, PhCH2O), 4.79 (d, J = 10.8 Hz, 1H, PhCH2O), 4.72 (d, J = 10.6 Hz, 1H, PhCH2O), 4.62 (d, 
J = 12.1 Hz, 1H, PhCH2O), 4.58 (d, J = 11.8 Hz, 1H, PhCH2O), 4.49 (d, J = 11.9 Hz, 1H, PhCH2O), 
4.464 (d, J = 11.8 Hz, 1H, PhCH2O), 4.460 (d, J = 11.8 Hz, 1H, PhCH2O), 4.40 (d, J = 12.0 Hz, 1H, 
PhCH2O), 4.34 – 4.29 (m, 3H, H-3’’, H-4’’, PhCH2O), 4.28 – 4.22 (m, 2H, -CH2-CH=CH2, PhCH2O), 
4.11 (ddt, J = 12.7, 5.7, 1.5 Hz, 1H, -CH2-CH=CH2), 4.01 – 3.96 (m, 2H, H-3’, H-2’’), 3.95 (t, J = 9.0 
Hz, 1H, H-5), 3.88 (dt, J = 10.0, 3.0 Hz, 1H, H-5’), 3.82 (dd, J = 10.4, 2.0 Hz, 1H, H-5’’), 3.80 – 3.75 
(m, 3H, H-6’, H-3’’’, H-5’’’), 3.69 – 3.64 (m, 2H, H-6’, H-6’’’), 3.63 – 3.57 (m, 2H, H-4, H-5’’), 3.46-
3.41 (m, 2H, H-1, H-3), 3.37 – 3.35 (m, 1H, H-2’’’), 3.30 (t, J = 9.3 Hz, 1H, H-6), 3.25 (dd, J = 10.0, 
9.0 Hz, 1H, H-4’), 3.13 – 3.10 (m, 1H, H-4’’’), 2.90 (dd, J = 10.4, 3.7 Hz, 1H, H-2’), 2.86 (dd, J = 13.0, 






(151 MHz, CDCl3) δ 138.3, 138.0, 137.9, 137.5, 137.0, 136.9 (Ar), 134.7 (-CH2-CH=CH2), 128.7, 
128.5, 128.42, 128.39, 128.34, 128.27, 128.26, 128.19, 127.83, 127.79, 127.75, 127.70, 127.55, 
127.49, 127.1 (Ar), 116.8 (-CH2-CH=CH2), 106.2 (C-1’’), 98.6 (C-1’’’), 95.7 (C-1’), 84.2 (C-6), 82.5 (C-
2’’), 82.1 (C-3’’), 82.0 (C-5), 79.5 (C-3’), 77.5 (C-4’), 75.5 (C-4’’), 75.3 (PhCH2O), 75.0 (PhCH2O), 
74.9 (C-4), 74.4 (C-5’’’), 73.6 (PhCH2O), 73.2 (PhCH2O), 73.1 (PhCH2O), 72.8 (C-3’’’), 72.4 (PhCH2O), 
71.7 (PhCH2O), 71.6 (C-5’), 71.5 (PhCH2O), 70.3 (C-5’’), 63.1 (C-2’), 61.5 (C-6’), 60.3 (C-1), 60.1 (C-
3), 57.3 (C-2’’’), 51.1 (C-6’’’), 32.5 (C-2). ESI-HRMS: m/z calc for C68H75N15O14Na [M+Na]+ 
1348.5516, found 1348.5515. 
4-O-(2-azido-3-O-benzyl-4,8-anhydro-2,7-dideoxy-D-glycero-α-D-gluco-nona-7-
enopyranosyl)-5-O-[3-O-(2,6-diazido-3,4-di-O-benzyl-2,6-dideoxy-β-L-idopyranosyl)-2,5-di-O-
benzyl-β-D-ribofuranosyl]-1,3-diazido-6-O-benzyl-2-deoxystreptamine (50(ax)), and 4-O-(2-
azido-3-O-benzyl-4,8-anhydro-2,7-dideoxy-L-glycero-α-D-gluco-nona-7-enopyranosyl)-5-O-[3-
O-(2,6-diazido-3,4-di-O-benzyl-2,6-dideoxy-β-L-idopyranosyl)-2,5-di-O-benzyl-β-D-
ribofuranosyl]-1,3-diazido-6-O-benzyl-2-deoxystreptamine (50(eq)). To a stirred solution of 
DMSO (0.38 mL 5.4 mmol) in 2 mL DCM at -78oC under argon was added oxalyl chloride (0.22 mL, 
2.6 mmol). After stirring for 10 minutes, compound 48 (1.70 g, 1.28 mmol) was dissolved in DCM 
(11 mL) and added dropwise. After an additional 3 hours Et3N (0.75 mL, 5.4 mmol) was added. 
The reaction mixture was stirred for an additional 2 hours then diluted with Et2O, washed with 
aqueous NH4Cl solution, DI water, and brine. The organic layer was concentrated under vacuum 
to give the intermediate aldehyde as a white foam which was used in the next step without 






1378.5647. To a stirred solution of aldehyde in THF (26 mL) at -78oC was added vinylMgBr 
solution (5.2 mL, 1 M in THF). After stirring for 1 hour the reaction was quenched with aqueous 
saturated NH4Cl solution, diluted with Et2O, washed with aqueous saturated NH4Cl solution, 
brine, dried with Na2SO4, and concentrated. The crude residue was purified using silica gel 
column chromatography (15-25% EtOAc in hexanes) to give the inseparable mixture of 
diastereomers 49 (0.83 g, 0.614 mmol) in 48% yield. 49: 1H NMR (600 MHz, CDCl3) δ 7.45 – 7.17 
(m, 60H, Ar-H), 6.13 – 6.10 (m, 2H, H-1’a, H-1’b), 6.03 – 5.84 (m, 4H, CH2=CH-), 5.70 (d, J = 5.7 Hz, 
1H, H-1’b), 5.68 (d, J = 5.5 Hz, 1H, H-1’a), 5.43 – 5.38 (m, 1H, CH2=CH-CH2), 5.36 (dt, J = 17.4, 1.6 
Hz, 1H, CH2=CH-CH2), 5.31 – 5.22 (m, 5H), 5.19 – 5.14 (m, 2H), 5.03 – 4.98 (m, 2H), 4.96 – 4.91 (m, 
2H), 4.86 – 4.82 (m, 3H), 4.79 (d, J = 10.7 Hz, 1H), 4.77 – 4.72 (m, 2H), 4.67 – 4.63 (m, 2H), 4.62 – 
4.57 (m, 2H), 4.54 (d, J = 11.7 Hz, 1H), 4.52 – 4.47 (m, 4H), 4.47 – 4.45 (m, 1H), 4.45 – 4.42 (m, 
2H), 4.39 – 4.25 (m, 13H), 4.22 – 4.16 (m, 1H), 4.12 (dd, J = 10.1, 3.2 Hz, 1H), 4.10 – 4.06 (m, 1H), 
4.04 – 3.98 (m, 4H), 3.98 – 3.91 (m, 3H), 3.87 – 3.77 (m, 6H), 3.72 – 3.64 (m, 3H), 3.63 – 3.59 (m, 
2H), 3.55 (t, J = 9.3 Hz, 1H), 3.50 – 3.42 (m, 4H), 3.39 (m, 2H, H-2’’’a, H-2’’’b), 3.37 – 3.27 (m, 3H), 
3.21 – 3.16 (m, 1H), 3.15 (m, 2H, H-4’’’a, H-4’’’b), 2.96 (dd, J = 10.3, 3.7 Hz, 1H), 2.92 – 2.87 (m, 
3H), 2.25 (m, 2H, H-2eqa, H-2eq b), 1.44 (q, J = 12.7 Hz, 1H, H-2ax a), 1.36 (q, J = 12.7 Hz, 1H, H-
2axb). 13C NMR (151 MHz, CDCl3) δ 138.6, 138.4, 138.1, 138.0, 137.6, 137.02, 136.95, 136.0, 
134.7, 134.5, 128.7, 128.54, 128.45, 128.43, 128.38, 128.30, 128.23, 128.19, 128.15, 127.86, 
127.84, 127.83, 127.78, 127.71, 127.6, 127.5, 127.2, 127.1 (Ar), 117.0 (CH2=CH-CH2), 116.8 
(CH2=CH-CH2), 116.6 (CH2=CH-CH2), 115.4 (CH2=CH-CH2), 106.3 (C-1’’), 106.2 (C-1’’), 98.7 (C-1’’’), 
98.6 (C-1’’’), 95.73 (C-1’), 95.66 (C-1’), 84.3, 84.1, 82.4, 82.3, 82.2, 82.1, 82.08, 81.97, 80.2, 79.8, 






72.96, 72.90, 72.42, 72.41, 71.7, 71.5, 70.33, 70.27, 70.0, 63.1 (C-2’), 63.0 (C-2’), 60.43 (C-1), 60.39 
(C-1), 60.08 (C-3), 60.06 (C-3), 57.3 (C-2’’’), 51.2 (C-6’’’), 32.6 (C-2), 32.5 (C-2). ESI-HRMS: m/z calc 
for C70H77N15O14Na [M+Na]+ 1374.5672, found 1374.5682. To a stirred solution of compounds 49 
(0.83 g 0.614 mmol) in DCM (6.1 mL) was added Hoveyda-Grubbs generation II catalyst (39.2 mg, 
0.038 mmol). The reaction mixture was heated to reflux for 8 hours followed by addition of more 
catalyst (10.7 mg, 0.010 mmol). After an additional 30 minutes the reaction mixture was filtered 
through silica gel and concentrated. The crude residue was purified using silica gel column 
chromatography (25-27.5% EtOAc in hexanes) to give 50(ax) (0.132 g, 0.100 mmol) in 16% 
isolated yield, 50(eq) (0.150 g, 0.113 mmol) in 18% isolated yield, and a mixture of diastereomers 
(0.120 g, 0.091 mmol) in 15% yield. 50(ax) [α]D23 = 82.92 (c = 0.2, DCM), 1H NMR (600 MHz, CDCl3) 
δ 7.40 – 7.23 (m, 21H, ArH), 7.20 – 7.13 (m, 9H, ArH), 6.10 (d, J = 3.6 Hz, 1H, H-1’), 5.98 (ddd, J = 
12.0, 5.7, 2.9 Hz, 1H, H-8’), 5.90 (ddd, J = 12.0, 7.2, 2.4 Hz, 1H, H-7’), 5.70 (d, J = 6.0 Hz, 1H, H-1’’), 
5.00 (d, J = 10.6 Hz, 1H, PhCH2O), 4.90 (d, J = 1.9 Hz, 1H, H-1’’’), 4.87 (d, J = 11.1 Hz, 1H, PhCH2O), 
4.78 (d, J = 11.2 Hz, 1H, PhCH2O), 4.69 (d, J = 10.6 Hz, 1H, PhCH2O), 4.61 (t, J = 11.7 Hz, 2H, 
PhCH2O), 4.49 (d, J = 11.8 Hz, 1H, PhCH2O), 4.47 (s, 2H, PhCH2O), 4.39 (d, J = 12.0 Hz, 1H, PhCH2O), 
4.35 (dt, J = 7.2, 2.4 Hz, 1H, H-6’), 4.34 – 4.28 (m, 3H, 3’’, 4’’, PhCH2O), 4.23 (d, J = 12.1 Hz, 1H, 
PhCH2O), 4.20 (dd, J = 16.1, 5.7 Hz, 1H, H-9’), 4.08 (dt, J = 16.1, 2.8 Hz, 1H, H-9’), 4.04 – 3.99 (m, 
3H, H-3’, H-5’, H-2’’), 3.96 (t, J = 8.9 Hz, 1H, H-5), 3.85 (dd, J = 10.4, 2.0 Hz, 1H, H-5’’), 3.78 (ddd, J 
= 8.7, 3.7, 1.9 Hz, 1H, H-5’’’), 3.75 (t, J = 2.9 Hz, 1H, H-3’’’), 3.73 (dd, J = 9.6, 8.6 Hz, 1H, H-4’), 3.66 
(dd, J = 13.0, 8.7 Hz, 1H, H-6’’’), 3.61 – 3.55 (m, 2H, 4, H-5’’), 3.46 – 3.38 (m, 2H, H-1, H-3), 3.36 – 
3.33 (m, 1H, H-2’’’), 3.29 (t, J = 9.3 Hz, 1H, H-6), 3.11 – 3.08 (m, 1H, H-4’’’), 2.90 (dd, J = 10.5, 3.6 






= 2.4 Hz, 1H, 6’-OH), 1.38 (q, J = 12.8 Hz, 1H, H-2ax). 13C NMR (151 MHz, CDCl3) δ 138.5, 138.3, 
137.9, 137.5, 137.0, 136.9, 135.4 (C-8’), 128.7, 128.5, 128.4, 128.33, 128.30, 128.29, 128.23, 
128.19, 128.0, 127.81, 127.76, 127.69, 127.63, 127.58, 127.46 (Ar), 127.0 (C-7’), 126.9 (Ar), 106.0 
(C-1’’), 98.7 (C-1’’’), 95.7 (C-1’), 84.3 (C-6), 82.6 (C-2’’), 82.3 (C-3’’), 81.9 (C-3’’), 79.4 (C-5), 77.8 
(C-4’), 75.6 (C-4’’), 75.4 (PhCH2O), 75.0 (PhCH2O), 74.8 (C-4), 74.4 (C-5’’’), 73.2 (PhCH2O), 73.1 
(PhCH2O), 72.8 (C-3’’’), 72.4 (C-5’), 72.3 (PhCH2O), 71.7 (PhCH2O), 71.4 (C-4’’’), 70.3 (C-5’’), 68.7 
(C-6’), 67.5 (C-9’), 62.2 (C-2’), 60.3 (C-1), 60.2 (C-3), 57.2 (2’’’), 51.1 (C-6’’’), 32.6 (C-2). ESI-HRMS: 
m/z calc for C68H73N15O14Na [M+Na]+ 1346.5359, found 1346.5327.  50(eq) [α]D23 = 67.96 (c = 1.0, 
CHCl3), 1H NMR (600 MHz, CHCl3) δ 7.39 – 7.23 (m, 21H, ArH), 7.22 – 7.15 (m, 9H, ArH), 6.18 (d, J 
= 3.6 Hz, 1H, H-1’), 5.85 (ddt, J = 12.2, 6.0, 3.0 Hz, 1H, H-8’), 5.79 (dt, J = 12.2, 2.2 Hz, 1H, H-7’), 
5.68 (d, J = 5.7 Hz, 1H, H-1’’), 4.98 (d, J = 10.6 Hz, 1H, PhCH2O), 4.90 (d, J = 1.9 Hz, 1H, H-1’’’), 4.87 
(d, J = 11.0 Hz, 1H, PhCH2O), 4.77 (d, J = 11.1 Hz, 1H, PhCH2O), 4.73 (d, J = 10.6 Hz, 1H, PhCH2O), 
4.63 (d, J = 12.1 Hz, 1H, PhCH2O), 4.56 (d, J = 11.8 Hz, 1H, PhCH2O), 4.49 (d, J = 11.8 Hz, 1H, 
PhCH2O), 4.45 (d, J = 11.7 Hz, 2H, PhCH2O), 4.41 (d, J = 12.0 Hz, 1H, PhCH2O), 4.32 (dd, J = 7.6, 4.3 
Hz, 3H, H-3’’, H-4’’), 4.28 – 4.23 (m, 2H, 9’, PhCH2O), 4.19 – 4.15 (m, 1H, H-6’), 4.01 – 3.93 (m, 3H, 
H-5, H-3’, H-2’’), 3.86 (dq, J = 15.7, 2.6 Hz, 1H, H-9’), 3.83 – 3.78 (m, 2H, H-5’’, H-5’’’), 3.77 – 3.72 
(m, 2H, H-5’, H-3’’’), 3.67 (dd, J = 13.0, 8.7 Hz, 1H, H-6’’’), 3.62 – 3.56 (m, 2H, H-4, H-5’’), 3.48 – 
3.40 (m, 2H, H-1, H-3), 3.38 – 3.36 (m, 1H, H-2’’’), 3.30 (t, J = 9.3 Hz, 1H, H-6), 3.17 (dd, J = 9.6, 8.5 
Hz, 1H, H-4’), 3.12 (t, J = 2.7 Hz, 1H, H-4’’’), 3.00 (dd, J = 10.4, 3.6 Hz, 1H, H-2’), 2.86 (dd, J = 13.0, 
3.7 Hz, 2H, H-6’’’), 2.22 (dt, J = 13.2, 4.6 Hz, 1H, H-2eq), 1.42 (q, J = 12.7 Hz, 1H, H-2ax) 13C NMR 
(151 MHz, CDCl3) δ 138.4, 138.3, 137.9, 137.5, 137.0, 136.9, 132.7 (C-7’), 128.7 (Ar), 128.6 (C-8’), 






127.51, 127.50, 127.2 (Ar), 106.1 (C-1’’), 98.6 (C-1’’’), 94.8 (C-1’), 84.2 (C-6), 83.8 (C-4’), 82.4 (C-
2’’), 82.1 (C-3’’), 82.0 (C-5), 77.8 (C-3’), 75.6 (PhCH2O), 75.4 (C-4’’), 75.0 (C-4), 74.5 (C-5’’’), 73.7 
(C-6’), 73.2 (PhCH2O), 73.1 (PhCH2O), 72.8 (C-3’’’), 72.4 (PhCH2O), 72.0 (C-5’), 71.7 (PhCH2O), 71.5 
(C-4’’’), 70.3 (C-5’’), 67.7 (C-9’), 62.5 (C-2’), 60.3 (C-3), 60.2 (C-2), 57.2 (C-2’’’), 51.1 (C-6’’’), 32.4 
(C-2). ESI-HRMS: m/z calc for C68H73N15O14Na [M+Na]+ 1346.5359, found 1346.5348. 
4-O-(2-amino-4,9-anhydro-2,7,8-trideoxy-D-glycero-α-D-gluco-nonapyranosyl)-5-O-[3-
O-(2,6-diamino-2,6-dideoxy-β-L-idopyranosyl)-β-D-ribofuranosyl]-2-deoxystreptamine 
(51(ax)). To a solution of compound 50(ax) (30.0 mg, 0.023 mmol) in 1:1 1,4-dioxane/10% 
aqueous AcOH (0.6 mL) was added Pd/C (10 wt%, 64.8 mg). The reaction mixture was stirred 
under 50 psi H2 for 26 hours before filtration through Celtie and concentration. The crude residue 
was purified using CM Sephadex ion exchange column chromatography (0.1-0.7% aqueous 
NH4OH) followed by lyophilization with acetic acid to give the pentaacetate salt 51(ax) (6.8 mg, 
0.0071 mmol) in 31% yield as a white powder. [α]D23 = 13.33 (c = 0.03, water), 1H NMR (600 MHz, 
D2O) δ 5.64 (d, J = 3.9 Hz, 1H, H-1’), 5.22 (d, J = 2.3 Hz, 1H, H-1’’), 5.12 (d, J = 1.8 Hz, 1H, H-1’’’), 
4.36 (dd, J = 6.9, 4.9 Hz, 1H, H-3’’), 4.23 (dd, J = 4.9, 2.3 Hz, 1H, H-2’’), 4.14 (ddd, J = 6.9, 4.0, 1.5 
Hz, 1H, H-5’’’), 4.05-4.08 (m, 3H, H-6’, H-4’’, H-3’’’), 3.77 – 3.73 (m, 2H, H-3’, H-5’’), 3.72 – 3.67 
(m, 2H, H-5, H-9’), 3.67 – 3.59 (m, 3H, H-4, H-5’’, H-4’’’), 3.50 (dd, J = 10.0, 3.4 Hz, 1H, H-5’), 3.47 
(dd, J = 10.5, 9.1 Hz, 1H, H-6), 3.41 (dt, J = 3.0, 1.3 Hz, 1H, H-2’’’), 3.36 (t, J = 9.4 Hz, 1H, H-4’), 3.26 
(dd, J = 13.7, 6.7 Hz, 1H, H-6’’’), 3.20 (dd, J = 13.7, 3.9 Hz, 1H, H-6’’’), 3.16 (dd, J = 11.0, 3.9 Hz, 1H, 
H-2’), 3.11 (m, 2H, H-1, H-3), 2.17 (dt, J = 12.7, 4.3 Hz, 1H, H-2eq), 1.93 (m, 1H, H-8’), 1.84 – 1.77 






δ 179.7 (AcOH), 108.6 (C-1’’), 94.3 (C-1’), 94.0 (C-1’’’), 83.6 (C-5), 79.7 (C-4’’), 77.0 (C-4), 73.6 (C-
3’’), 73.4 (C-5’), 72.9 (C-4’), 72.0 (C-2’’), 71.5 (C-6), 68.8 (C-5’’’), 67.7 (C-9’), 66.5 (C-6’), 66.4 (C-
3’), 66.3 (C-3’’’), 65.9 (C-4’’’), 58.5 (C-5’’), 52.3 (C-2’), 49.4 (C-2’’’), 48.7 (C-1), 47.4 (C-3), 39.0 (C-
6’’’), 28.6 (C-2), 24.5 (C-7’), 21.7 (AcOH), 17.7 (C-8’). ESI-HRMS: m/z calc for C26H50N5O14 [M+H]+ 
656.3354, found 656.3372. 
4-O-(2-amino-4,9-anhydro-2,7,8-trideoxy-L-glycero-α-D-gluco-nonapyranosyl)-5-O-[3-
O-(2,6-diamino-2,6-dideoxy-β-L-idopyranosyl)-β-D-ribofuranosyl]-2-deoxystreptamine 
(51(eq)). To a solution of compound 50(eq) (22.8 mg, 0.017 mmol) in 1:1 1,4-dioxane/10% 
aqueous AcOH (0.6 mL) was added Pd/C (10 wt%, 48.2 mg). The reaction mixture was stirred 
under 50 psi H2 for 23 hours before filtration through Celtie and concentration. The crude residue 
was purified using CM Sephadex ion exchange column chromatography (0.1-0.8% aqueous 
NH4OH) followed by lyophilization with acetic acid to give the pentaacetate salt 51(eq) (2.9 mg, 
0.0030 mmol) in 18% yield as a white powder. [α]D23 = 80.43 (c = 0.05, water), 1H NMR (600 MHz, 
D2O) δ 5.40 (d, J = 3.8 Hz, 1H, H-1’), 5.22 (d, J = 3.2 Hz, 1H, H-1’’), 5.14 (d, J = 1.9 Hz, 1H, H-1’’’), 
4.36 (t, J = 5.7 Hz, 1H, H-3’’), 4.19 – 4.15 (m, 2H, H-2’’, H-5’’’), 4.08 (t, J = 3.2 Hz, 1H, H-3’’’), 4.07 
– 4.04 (m, 1H, H-4’’), 3.75 (dd, J = 12.4, 3.2 Hz, 1H, H-5’’), 3.74 – 3.58 (m, 6H, H-4, H-5, H-3’, H-9’, 
H-5’’, H-4’’’), 3.53 – 3.39 (m, 4H, H-6, H-5’, H-6’, H2’’’), 3.29 (dd, J = 13.6, 6.8 Hz, 1H, H-6’’’), 3.25 
– 3.18 (m, 2H, H-4’, H-6’’’), 3.15 (dd, J = 10.8, 3.8 Hz, 1H, H-2’), 3.13 – 3.07 (m, 2H, H-1, H-3), 2.16 
(dt, J = 12.9, 4.3 Hz, 1H, H-2eq), 1.81 – 1.61 (m, 18H, H-7’, H-8’, AcOH), 1.57 – 1.44 (m, 2H, H-2ax, 
H-7’). 13C NMR (151 MHz, D2O) δ 181.3 (AcOH), 109.5 (C-1’’), 96.8 (C-1’), 95.8 (C-1’’’), 84.1 (C-5), 






70.2 (C-5’’’), 68.9 (C-3’), 68.5 (C-9’), 67.8 (C-3’’’), 67.3 (C-4’’’), 60.1 (C-5’’), 54.1 (C-2’), 50.9 (C-2’’’), 
50.0 (C-1), 49.3 (C-3), 40.4 (C-6’’’), 30.6 (C-2), 28.1 (C-7’), 23.1 (AcOH), 21.9 (C-8’). ESI-HRMS: m/z 
calc for C26H50N5O14 [M+H]+ 656.3354, found 656.3359. 
Methyl 2-amino-2,4-dideoxy-α-D-xylopyranoside (53). Compound 57 (93.8 mg, 0.30 
mmol) was dissolved in 0.8 mL of a 1:1 mixture of 1,4-Dioxane and 10% aqueous AcOH followed 
by addition of Pd/C (20.8 mg). The reaction mixture was stirred under 50 psi H2 for 5 hours 
followed by filtration over Celite® and lyophilization to obtain 53 as an off white solid (69.1 mg, 
97%). [α]D23 = 110.56 (c = 0.14, water), 1H NMR (600 MHz, D2O) δ 4.86 (d, J = 3.7 Hz, 1H, H1), 3.91 
(td, J = 11.0, 5.1 Hz, 1H, H3), 3.79 (ddt, J = 11.8, 5.8, 2.5 Hz, 1H, H5), 3.51 (dd, J = 12.1, 3.1 Hz, 1H, 
H6), 3.43 (dd, J = 12.1, 6.2 Hz, 1H, H6’), 3.24 (s, 3H, OMe), 3.02 (dd, J = 10.5, 3.6 Hz, 1H, H2), 1.86 
(ddd, J = 12.8, 5.1, 2.1 Hz, 1H, H4eq), 1.76 (s, 3H, AcOH), 1.33 (q, J = 12.0 Hz, 1H, H4ax). 13C NMR 
(151 MHz, D2O) δ 180.4 (AcOH), 96.6 (C1), 68.8 (C5), 64.3 (C3), 63.3 (C6), 55.2 (C2), 55.0 (OMe), 
34.2 (C4), 22.6 (AcOH). ESI-HRMS: m/z calcd for C7H15NO4Na [M + Na]+ 200.0899, found 200.0891. 
4-C-Allyl-1,6-anhydro-2-N-benzyl-2,4-dideoxy-β-D-glucopyranose (59). A solution of 58 
(0.3188 g, 1.90 mmol) in benzylamine (5.0 ml) was stirred for 3 days at 155°C. After concentration 
under reduced pressure the crude residue was purified by Flash column chromatography on silica 
gel eluting with 40% ethyl acetate in hexanes with 1% triethylamine added to afford 59 (0.4020 
g, 77%). [α]23D  = -49.4 (c = 1.00, CHCl3). 1H NMR (500 MHz, CDCl3) δ 7.38 – 7.23 (m, 5H: aromatic), 
5.83 (ddq, J = 16.4, 14.4, 6.2, 5.3 Hz, 1H: CH2CHCH2-C4), 5.47 (s, 1H: H1), 5.21 – 5.10 (m, 2H: 
CH2CHCH2-C4), 4.40 (d, J = 5.0 Hz, 1H: H5), 4.06 (d, J = 7.0 Hz, 1H: H6a), 3.93 – 3.85 (m, 5H: PhCH2), 






2H: CH2CHCH2-C4), 1.77 (t, J = 7.2 Hz, 1H: H4). 13C NMR (125 MHz, CDCl3) δ 139.9, 136.1 
(CH2CHCH2-C4), 128.5, 128.1, 127.2, 117.5 (CH2CHCH2-C4), 102.6 (C1), 74.6 (C5), 70.3 (C3), 68.5 
(C6), 62.2 (C2), 51.7 (PhCH2), 44.6 (C4), 36.5 (CH2CHCH2-C4). ESI-HRMS: m/z calcd for 
C16H22NO3Na [M+Na]+ 276.1600, found 276.1600. 
 2-amino-1,6-anhydro-2,4-dideoxy-4-C-propyl-β-D-glucopyranose acetate salt (60). 
Compound 59 (0.4020 g, 1.46 mmol) and Pd/C (0.1316 g) were stirred in a 1:2 mixture of 10% 
aqueous acetic acid and 1,4-dioxane (6 mL) under 40 psi H2 for 7 hours. Pd/C (0.23 g) was added 
after 7 hours and the reaction mixture was stirred for an additional 14 hours before final addition 
of Pd/C (0.39 g). After an additional 28 hours the reaction mixture was filtered through Celite® 
and concentrated to give the product 60 (0.2858 g, 79%). [α]D23 = -45.9 (c = 1.0, MeOH), 1H NMR 
(600 MHz, CD3OD) δ 5.32 (s, 1H, H-1), 4.41 (d, J = 5.2 Hz, 1H, H-5), 3.98 (d, J = 6.8 Hz, 1H, H-6a), 
3.68 (dd, J = 6.9, 5.3 Hz, 1H, H-6b), 3.43 (t, J = 4.0 Hz, 1H, H-3), 2.82 (d, J = 4.0 Hz, 1H, H-2), 1.92 
(s, 3H, AcOH), 1.64 – 1.47 (m, 4H, H-4, -CH2CH2-), 1.45 – 1.34 (m, 1H, -CH2CH2-), 0.97 (t, J = 7.3 Hz, 
3H, -CH3). 13C NMR (151 MHz, CD3OD) δ 104.9 (C-1), 79.1 (C-5), 74.6 (C-6), 72.6 (C-3), 60.7 (C-2), 
48.8 (C-4), 37.9 (-CH2CH2CH3), 25.4 (AcOH), 23.9 (-CH2CH2CH3), 16.9 (-CH2CH2CH3). ESI-HRMS: m/z 
calcd for C9H18NO3 [M + H]+ 188.1287, found 188.1286. 
 1,6-anhydro-2-azido-2,4-dideoxy-4-C-propyl-β-D-glucopyranose (61). Stick’s reagent 
(0.4664 g, 2.23 mmol) was added to an ice cold stirred solution of CuSO4 (0.0237 g, 0.148 mmol), 
triethylamine (0.62 mL, 4.5 mmol), and compound 60 (0.2778 g, 1.12 mmol) in 4:1 MeCN/water 
(14.8 mL). The reaction mixture was stirred for 1 hour before MeCN was removed under vacuum 






brine. The organic layer was dried with Na2SO4 and concentrated to give 61 as a colorless gum 
(0.2186 g, 91%). [α]D23 = -113.2 (c = 1.0, CHCl3) 1H NMR (499 MHz, CDCl3) δ 5.46 (t, J = 1.4 Hz, 1H, 
H-1), 4.43 (d, J = 5.1 Hz, 1H, H-5), 4.10 (dd, J = 7.0, 0.8 Hz, 1H, H-6a), 3.78 (dd, J = 7.1, 5.1 Hz, 1H, 
H-6b), 3.65 (tt, J = 2.4, 1.2 Hz, 1H, H-3), 3.47 (t, J = 2.0 Hz, 1H, H-2), 1.72 – 1.56 (m, 3H, H-4, -
CH2CH2CH3), 1.55 – 1.45 (m, 1H, -CH2CH2CH3), 1.44 – 1.34 (m, 1H, -CH2CH2CH3), 0.97 (t, J = 7.2 Hz, 
3H, -CH2CH2CH3). 13C NMR (126 MHz, CDCl3) δ 100.6 (C-1), 75.0 (C-5), 71.2 (C-3), 68.6 (C-6), 63.6 
(C-2), 44.3 (C-4), 33.3 (CH3CH2CH2-), 20.5 (CH3CH2CH2-), 14.0 (CH3CH2CH2-).  Compound not visible 
by ESIMS 
Methyl 2-azido-2,4-dideoxy-4-C-propyl-D-glucopyranoside (62α and 62β). Compound 
61 (0.219 g, 0.857 mmol) was dissolved in 8.6 mL Ac2O followed by addition of 0.86 mL TFA and 
stirred under argon for 45 minutes. The reaction mixture was then diluted with Et2O and washed 
with saturated NaHCO3 solution and brine, dried with Na2SO4, filtered, and concentrated. The 
crude residue was then dissolved in 10% HCl MeOH solution (7 mL) and heated to reflux for 4.5 
hours followed by concentration under vacuum. The resulting residue was subjected to flash 
column chromatography over silica gel in 45% to 50% ethyl acetate in hexanes which afforded 55 
mg 62α (22%) and 31 mg 62β (12%). 62α: [α]D23 = 125.4 (c = 1.0, MeOH), 1H NMR (600 MHz, 
CD3OD) δ 4.76 (d, J = 3.5 Hz, 1H, H1), 3.78 (t, J = 10.2 Hz, 1H, H3), 3.74 – 3.68 (m, 1H, H6), 3.62 – 
3.54 (m, 2H, H5, H6), 3.37 (s, 3H, OMe), 3.10 (dd, J = 10.0, 3.5 Hz, 1H, H2), 1.62 – 1.50 (m, 2H, H4, 
-CH2CH2-), 1.49 – 1.28 (m, 3H, -CH2CH2-), 0.91 (t, J = 7.1 Hz, 3H, CH3). 13C NMR (151 MHz, CD3OD) 
δ 99.2 (C1), 71.8 (C5), 68.5 (C3), 65.2 (C2), 61.8 (C6), 53.9 (OMe), 43.1 (C4), 28.8 (-CH2CH2-), 18.7 






268.1273. 62β: [α]D23 = -31.8 (c = 1.0, MeOH), 1H NMR (600 MHz, CD3OD) δ 4.13 (d, J = 8.1 Hz, 1H, 
H1), 3.77 (dd, J = 12.1, 2.1 Hz, 1H, H6), 3.59 (dd, J = 12.1, 5.5 Hz, 1H, H6), 3.52 (s, 3H, OMe), 3.32 
– 3.24 (m, 2H, H3, H5), 3.03 (dd, J = 9.5, 8.1 Hz, 1H, H2), 1.58 – 1.25 (m, 5H, H4, -CH2CH2-), 0.90 
(t, J = 7.2 Hz, 3H, -CH3). 13C NMR (151 MHz, CD3OD) δ 102.7 (C1), 76.2 (C5), 72.6 (C3), 68.6 (C2), 
61.8 (C6), 55.6 (OMe), 42.6 (C4), 28.7 (-CH2CH2-), 18.6 (-CH2CH2-), 13.7 (-CH3). ESI-HRMS: m/z 
calcd for C10H19N3O4Na [M + Na]+ 268.1273, found 268.1261. 
Methyl 2-amino-2,4-dideoxy-4-C-propyl-α-D-glucopyranoside (55). Compound 62α 
(13.6 mg, 0.30 mmol) was dissolved in 0.6 mL of a 1:1 mixture of 1,4-Dioxane and 10% aqueous 
AcOH followed by addition of Pd/C (2.9 mg). The reaction mixture was stirred under 50 psi H2 for 
1.5 hours followed by filtration over Celite® and lyophilization to obtain 55 as an off white solid 
(15.4 mg, 99%). [α]D23 = 80.5 (c = 0.7, water), 1H NMR (600 MHz, D2O) δ 4.84 (d, J = 3.6 Hz, 1H, 
H1), 3.70 (t, J = 10.6 Hz, 1H, H3), 3.66 (dd, J = 12.3, 2.2 Hz, 1H, H6), 3.62 (ddd, J = 10.9, 5.3, 2.2 
Hz, 1H, H5), 3.54 (dd, J = 12.3, 5.3 Hz, 1H, H6), 3.24 (s, 3H, OMe), 3.07 (dd, J = 10.3, 3.6 Hz, 1H, 
H2), 1.79 (s, 3H, AcOH), 1.49 (tt, J = 10.8, 4.0 Hz, 1H, H4), 1.41 – 1.32 (m, 1H, -CH2CH2-), 1.32 – 
1.24 (m, 1H, -CH2CH2-), 1.23 – 1.06 (m, 2H, -CH2CH2-), 0.71 (t, J = 7.2 Hz, 3H, -CH3). 13C NMR (151 
MHz, D2O) δ 96.3 (C1), 71.6 (H5), 67.0 (C3), 61.1 (6), 55.3 (C2), 54.9 (OMe), 42.0 (C4), 27.7 (-
CH2CH2-), 17.8 (-CH2CH2-), 13.8 (-CH3). ESI-HRMS: m/z calcd for C10H22NO4 [M + H]+ 220.1549, 
found 220.1539. 
1,6-Anhydro-4-deoxy-2-O-p-toluenesulfonyl-6-(S)-deuterio-β-D-glucopyranose (68). 
NaBH4 (0.43 g, 11.4 mmol) and BF3∙OEt2 (0.85 mL, 6.9 mmol) were added to an ice cold solution 






with Et2O and washed with saturated NaHCO3 solution and brine then dried with Na2SO4 and 
concentrated under vacuum to give 68 as a clear gum (0.85 g, 2.8 mmol 99%) which was used in 
the next step without purification. [α]D23 = -27.02 (c = 1.0, CHCl3), 1H NMR (600 MHz, CDCl3) δ 
7.81 (d, J = 8.3 Hz, 2H, Ar-H), 7.36 – 7.33 (m, 2H, Ar-H), 5.27 (d, J = 1.9 Hz, 1H, H-1), 4.52 (d, J = 
4.1 Hz, 1H, H-5), 4.20 (q, J = 1.7 Hz, 1H, H-2), 4.09 (s, 1H, H-6), 3.92 (t, J = 6.3 Hz, 1H, H-3), 2.46 (d, 
J = 6.3 Hz, 1H, -OH), 2.44 (s, 3H, Ar-CH3), 2.31 (ddd, J = 15.0, 5.7, 4.5 Hz, 1H, H-4ax), 1.70 (ddt, J = 
15.0, 1.9, 1.0 Hz, 1H, H-4eq). 13C NMR (151 MHz, CDCl3) δ 145.3, 133.2, 130.1, 127.9 (Ar), 99.3 (C-
1), 76.8 (C-2), 71.3 (C-5), 67.5 (t, J = 23.3 Hz, C-6), 66.5 (C-3), 32.5 (C-4), 21.7 (Ar-CH3). ESI-HRMS: 
m/z calcd for C13H15DO6SNa [M + Na]+ 324.0628, found 324.0627. 
1,6;2,3-Bisanhydro-4-deoxy-6-(S)-deuterio-D-lyxopyranose (69). NaOMe (0.34 g, 6.3 
mmol) was added to an ice cold stirred solution of 68 (0.824 g, 2.73 mmol) in 1:1 CHCl3/MeOH 
(13.6 mL). After 4 hours the reaction mixture was diluted with DCM and washed with water. The 
aqueous phase was back extracted with DCM and the combined organic layers were washed with 
brine then dried with Na2SO4 and concentrated under vacuum to give 69 as a colorless oil (0.351 
g, 99%). [α]D23 = -28.60 (c = 1.0, DCM), 1H NMR (400 MHz, CDCl3) δ 5.64 (dd, J = 3.2, 1.0 Hz, 1H, 
H-1), 4.38 (br d, J = 6.0 Hz, 1H, H-5), 3.63 (d, J = 1.7 Hz, 1H, H-6), 3.33 (t, J = 3.6 Hz, 1H, H-2), 3.10 
(dd, J = 3.3 Hz, 1H, H-3), 2.19 (ddd, J = 15.3, 5.9, 3.2 Hz, 1H, H-4ax), 1.94 (d, J = 15.3 Hz, 1H, H-
4eq). 13C NMR (101 MHz, CDCl3) δ 98.0 (C-1), 68.0 (t, J = 23.1 Hz, C-6), 67.2 (C-5), 53.7 (C-2), 46.3 
(C-3), 30.0 (C-4). ESI-HRMS: m/z calcd for C6H7DO3Na [M + Na]+ 152.0434, found 152.0438. 
1,6-Anhydro-2-azido-2,4-dideoxy-D-xylopyranose (70ax). Compound 69 (75.0 mg, 






mL) were added to a microwave vial and irradiated while stirring in a Biotage® Initiator set to 110 
oC for 75 minutes. The reaction mixture was then diluted with DCM and washed with aqueous 
saturated NaHCO3 solution and brine. The organic layer was dried with Na2SO4 and filtered 
followed by concentration. The residue was subjected to silica gel preparative HPLC eluting with 
a gradient from 20 % to 60 % EtOAc in hexanes to give 70(ax) (4.7 mg, 0.027 mmol) in 5 % isolated 
yield. [α]D23 = 19.57 (c = 0.2, CHCl3), 1H NMR (600 MHz, CDCl3) δ 5.53 (t, J = 2.0 Hz, 1H, H-1), 4.59 
(d, J = 4.4 Hz, 1H, H-5), 4.19 (s, 1H, H-6), 4.00 – 3.96 (m, 1H, H-3), 3.30 (d, J = 2.2 Hz, 1H, H-2), 2.55 
(d, J = 7.7 Hz, 1H, -OH), 2.31 (dt, J = 15.2, 4.9 Hz, 1H, H-4ax), 1.84 (ddt, J = 15.3, 2.9, 1.6 Hz, 1H, H-
4eq). 13C NMR (151 MHz, CDCl3) δ 100.8 (C-1), 72.0 (C-5), 67.6 (t, J = 23.3 Hz, C-6), 66.9 (C-3), 61.7 
(C-2), 33.6 (C-4). 
Methyl 2-amino-2,4-dideoxy-6-(S)-deuterio-D-xylopyranose acetate salt (54) TFA (0.05 
mL) was added to a stirred solution of compound 70(ax) (4.6 mg, 0.27 mmol) in Ac2O (0.5 mL) at 
0 oC and the reaction mixture was stirred for 3 hours monitoring by TLC. The reaction mixture 
was then diluted with Et2O and washed with aqueous saturated NaHCO3 solution and brine, dried 
with Na2SO4, and concentrated to give an inseparable mixture of anomers (8.3 mg, 0.026 mmol, 
97 %) which were used in the next step without purification. ESI-HRMS: m/z calcd for 
C12H16DN3O7Na [M + Na]+ 339.1014, found 339.1027. The mixture of anomers from the previous 
step (8.3 mg, 0.026 mmol) were stirred in 10 % HCl methanol solution (0.6 mL) under reflux for 3 
hours. After the reaction was complete by TLC and LCMS the reaction mixture was concentrated 
under vacuum and the resulting inseparable mixture of anomers of methyl glycosides was used 






found 227.0864.  10 wt% Pd/C (5.0 mg) was added to a solution of methyl glycosides (6.1 mg, 
0.30 mmol) in 1:1 dioxane/10% aqueous acetic acid (0.4 mL) and the reaction mixture was stirred 
under 50 psi H2 for 6 hours. The reaction mixture was then filtered through Celite® and 
concentrated under vacuum to give a mixture of anomers 54 (5.4 mg, 0.023 mmol, 76%) in a ratio 
of 2:1 α/β as the acetate salts. 54α: 1H NMR (600 MHz, D2O) δ 4.87 (d, J = 3.6 Hz, 1H, H-1), 3.92 
(td, J = 11.0, 5.0 Hz, 1H, H-3), 3.80 (ddd, J = 12.1, 6.3, 2.2 Hz, 1H, H-5), 3.42 (d, J = 6.0 Hz, 1H, H-
6), 3.26 (s, 3H, -OCH3), 3.03 (dd, J = 10.4, 3.7 Hz, 1H, H-2), 1.87 (ddd, J = 12.1, 5.0, 2.1 Hz, 1H, H-
4eq), 1.78 (s, 3H, AcOH), 1.34 (q, J = 12.1 Hz, 1H, H-4ax). 13C NMR (151 MHz, D2O) δ 180.2 (AcOH), 
96.6 (C-1), 68.7 (C-5), 64.3 (C-3), 63.2 – 62.8 (m, C-6), 55.2 (C-2), 55.0 (-OCH3), 34.2 (C-4), 22.5 
(AcOH). 54β: 1H NMR (600 MHz, D2O) δ 4.37 (d, J = 8.4 Hz, 1H, H-1), 3.76 (dt, J = 10.9, 5.4 Hz, 1H, 
H-3), 3.57 (ddd, J = 11.8, 6.7, 2.1 Hz, 1H, H-5), 3.45 (d, J = 6.6 Hz, 1H, H-6), 3.41 (s, 3H, -OCH3), 
2.69 (dd, J = 10.3, 8.4 Hz, 1H, H-2), 1.91 (ddd, J = 12.9, 5.2, 2.0 Hz, 1H, H-4eq), 1.78 (s, 3H, AcOH), 
1.31 (dt, J = 12.9, 11.5 Hz, 1H, H-4ax). 13C NMR (151 MHz, D2O) δ 180.2 (AcOH), 100.1 (C-1), 72.7 
(C-5), 66.8 (C-3), 63.1 – 62.6 (m, C-6), 57.4 (C-2), 57.2 (-OCH3), 34.4 (C-4), 22.5 (AcOH). ESI-HRMS: 
m/z calcd for C7H14DNO4Na [M + Na]+ 201.1962, found 201.1956. 
4-C-Allyl-1,6-Anhydro-6-(S)-deuterio-2,4-dideoxy-2-O-p-toluenesulfonyl-β-D-
glucopyranose (71). Freshly prepared 0.5 M allylMgCl THF solution (16 mL) was added to an ice-
cold stirred solution of epoxide 67 (0.590 g 1.97 mmol) and CuI (0.38 g, 0.20 mmol) in THF (20 
mL). The reaction mixture was stirred for 11 hours followed by addition of more allylMgCl 
solution (8 mL). After another 17 hours the reaction mixture was concentrated under vacuum 






layer was dried with Na2SO4 and concentrated. The crude residue was then purified using silica 
gel flash column chromatography in 35 to 40 % EtOAc in hexanes to give 71 (0.24 g, 36 %). NMR 
spectra of 71 matched that of the non-deuterated isotopomer. [α]D23 = -51.3 (c = 1.0, DCM), 1H 
NMR (600 MHz, CDCl3) δ 7.83 – 7.78 (m, 2H, Ar-H), 7.37 – 7.33 (m, 2H, Ar-H), 5.74 (ddt, J = 16.3, 
10.5, 7.1 Hz, 1H, CH2CHCH2-), 5.27 (d, J = 1.5 Hz, 1H, H-1), 5.13 (dq, J = 6.1, 1.2 Hz, 1H, CH2CHCH2-
), 5.10 (t, J = 1.3 Hz, 1H, CH2CHCH2-), 4.39 (s, 1H, H-5), 4.18 (dt, J = 2.5, 1.2 Hz, 1H, H-2), 3.99 (s, 
1H, H-6), 3.69 (tt, J = 2.7, 1.2 Hz, 1H, H-3), 2.45 (s, 3H, ArCH3), 2.37 – 2.33 (m, 2H, CH2CHCH2-), 
1.68 (t, J = 7.7 Hz, 1H, H-4). 13C NMR (151 MHz, CDCl3) δ 135.3 (CH2CHCH2-), 130.0 (Ar), 127.9 (Ar), 
118.0 (CH2CHCH2-), 99.7 (C-1), 78.9 (C-2), 74.2 (C-5), 70.0 (C-3), 68.0 (t, J = 23.4 Hz, C-6), 43.0 (C-
4), 35.4 (CH2CHCH2-), 21.7 (ArCH3). ESI-HRMS: m/z calcd for C16H19DO6Na [M + Na]+ 364.0941, 
found 364.0936. 
4-C-Allyl-1,6;2,3-bisanhydro-6-(S)-deuterio-4-deoxy-β-D-mannopyranose (72). NaOMe 
(0.088 g, 1.63 mmol) was added to an ice-cold stirred solution of compound 71 (0.240 g, 0.704 
mmol) in 1:1 mixture of methanol and chloroform (3.5 mL) and the solution was allowed to warm 
to room temperature. After 2 hours the reaction mixture was diluted with Et2O and washed with 
aqueous saturated NH4Cl solution and brine. The organic layer was dried with Na2SO4 and 
concentrated to give 72 (0.118 g, 99 %) as a white waxy solid which was used without further 
purification. [α]D23 = -15.2 (c = 1.0, DCM), 1H NMR (600 MHz, CDCl3) δ 5.82 (ddt, J = 17.2, 10.2, 7.0 
Hz, 1H, CH2CHCH2-), 5.65 (d, J = 3.2, 1H, H-1), 5.16 – 5.10 (m, 2H, CH2CHCH2-), 4.23 (s, 1H, H-5), 
3.70 (d, J = 1.6 Hz, 1H, H-6), 3.34 (ddd, J = 3.8, 3.1, 0.7 Hz, 1H, H-2), 2.93 (dd, J = 4.0, 1.3 Hz, 1H, 






CDCl3) δ 135.2 (CH2CHCH2-), 117.8 (CH2CHCH2-), 98.0 (C-1), 70.9 (C-5), 68.2 (t, J = 23.0 Hz, C-6), 
53.8 (C-2), 50.4 (C-3), 39.0 (C-4), 35.1 (CH2CHCH2-). ESI-HRMS: m/z calcd for C9H11DO3Na [M + 
Na]+ 192.0747, found 192.0746. 
4-C-allyl-1,6-anhydro-6-(S)-deuterio-2-N-benzyl-2,4-dideoxy-β-D-glucopyranose (73). A 
stirred solution of epoxide 72 (0.118 g, 0.427 mmol) in benzylamine (5.0 mL) was heated to 155oC 
for 1.5 days before concentration under vacuum. The crude residue was then purified using silica 
gel column chromatography in 40 % EtOAc in hexanes with 1% triethylamine added to give amine 
73 (0.166 g, 86 %). [α]D23 = -32.9 (c = 1.0, DCM), 1H NMR (400 MHz, CDCl3) δ 7.36 – 7.30 (m, 4H, 
Ar-H), 7.29 – 7.23 (m, 1H, Ar-H), 5.88 – 5.76 (m, 1H, CH2CHCH2-), 5.46 (s, 1H, H-1), 5.16 – 5.10 (m, 
2H, CH2CHCH2-), 4.38 (s, 1H, H-5), 4.03 (s, 1H, H-6), 3.90 (d, J = 13.2 Hz, 1H, PhCH2N-), 3.86 (d, J = 
13.2 Hz, 1H, PhCH2N-), 3.64 (dq, J = 3.0, 1.4 Hz, 1H, H-3), 2.64 (p, J = 1.2 Hz, 1H, H-2), 2.50 – 2.30 
(m, 2H, CH2CHCH2-), 1.76 (t, J = 7.7 Hz, 1H, H-4). 13C NMR (101 MHz, CDCl3) δ 139.9 (Ar), 136.1 
(CH2CHCH2-), 128.5 (Ar), 128.1 (Ar), 127.2 (Ar), 117.5 (CH2CHCH2-), 102.6 (C-1), 74.6 (C-5), 70.3 
(C-3), 68.2 (t, J = 23.4 Hz, C-6), 62.2 (C-2), 51.7 (PhCH2N-), 44.6 (C-4), 36.5 (CH2CHCH2-). ESI-HRMS: 
m/z calcd for C16H21DNO3 [M + H]+ 277.1657, found 277.1664. 
2-amino-1,6-anhydro-6-(S)-deuterio-2,4-dideoxy-4-C-propyl-β-D-glucopyranose 
acetate salt (74). Pd/C (10 % w/w, 27 mg) was added to a solution of 73 (0.137, 0.496 mmol) in 
a 1:1 mixture of 10 % aqueous acetic acid and 1,4-dioxane followed by pressurization to 40 psi of 
H2. The reaction mixture was stirred vigorously for 9 hours before filtration through celite® and 
concentration under vacuum to give amine 74 (0.122 g, 99%) as the acetate salt which was used 






H-1), 4.45 (s, 1H, H-5), 3.87 (s, 1H, H-6), 3.47 (t, J = 4.6 Hz, 1H, H-3), 3.01 (dd, J = 4.4, 1.0 Hz, 1H, 
H-2), 1.75 (s, 3H, AcOH), 1.53 (tdd, J = 6.8, 4.6, 1.5 Hz, 1H, H-4), 1.43 – 1.37 (m, 2H, CH3CH2CH2-), 
1.32 (dp, J = 13.3, 7.2 Hz, 1H, CH3CH2CH2-), 1.21 (tdd, J = 15.1, 13.4, 7.1 Hz, 1H, CH3CH2CH2-), 0.76 
(t, J = 7.3 Hz, 3H, CH3CH2CH2-). 13C NMR (151 MHz, D2O) δ 98.5 (C-1), 75.3 (C-5), 68.7 (t, J = 23.5 
Hz, C-6), 68.3 (C-3), 55.6 (C-2), 43.6 (C-4), 33.0 (CH3CH2CH2-), 23.0 (AcOH), 19.3 (CH3CH2CH2-), 
13.0 (CH3CH2CH2-). ESI-HRMS: m/z calcd for C9H17DNO3 [M + H]+ 189.1349, found 189.1357. 
1,6-anhydro-2-azido-6-(S)-deuterio-2,4-dideoxy-4-C-propyl-β-D-glucopyranose (75). 
Stick’s reagent (0.209 g, 0.997 mmol) was added to an ice cold stirred solution of CuSO4 (11 mg, 
0.07 mmol), triethylamine (0.28 mL, 2.0 mmol), and compound 74 (0.123 g, 0.495 mmol) in 4:1 
MeCN/water (6.6 mL). The reaction mixture was stirred for 9 hours before MeCN was removed 
under vacuum and the residue was diluted with EtOAc, washed with 1N HCl, saturated NaHCO3 
solution, and brine. The organic layer was dried with Na2SO4 and concentrated to give 75 as a 
colorless gum (0.1014 g, 96%). [α]D23 = -40.5 (c = 1.0, DCM), 1H NMR (600 MHz, CDCl3) δ 5.41 (s, 
1H, H-1), 4.38 (s, 1H, H-5), 4.04 (s, 1H, H-6), 3.60 (s, 1H, H-3), 3.42 (s, 1H, H-2), 2.71 (br s, 1H, -
OH), 1.66 – 1.51 (m, 3H, H-4, CH3CH2CH2-), 1.50 – 1.41 (m, 1H, CH3CH2CH2-), 1.40 – 1.30 (m, 1H, 
CH3CH2CH2-), 0.93 (t, J = 7.3 Hz, 3H, CH3CH2CH2-). 13C NMR (151 MHz, CDCl3) δ 100.5 (C-1), 74.9 
(C-5), 71.1 (C-3), 68.2 (t, J = 23.2 Hz, C-6), 63.7 (C-2), 44.2 (C-4), 33.3 (CH3CH2CH2-), 20.5 
(CH3CH2CH2-), 14.0 (CH3CH2CH2-). Product was not visible on ESIMS 
Methyl 2-azido-6-(S)-deuterio-2,4-dideoxy-4-C-propyl-D-glucopyranoside (76α and 
76β). Compound 75 (0.091 g, 0.4248 mmol) was dissolved in 4.0 mL Ac2O followed by addition 






Et2O and washed with saturated NaHCO3 solution and brine, dried with Na2SO4, filtered, and 
concentrated. The crude residue was then dissolved in 10 % HCl MeOH solution (3.4 mL) and 
heated to reflux for 10 hours followed by concentration under vacuum. The resulting residue was 
subjected flash column chromatography over silica gel in 45 % to 50 % ethyl acetate in hexanes 
which afforded 11.7 mg 76α (11 %), 9.5 mg 76β (9 %), and 11.8 mg (11 %) of a mixture of anomers. 
76α: [α]D23 = 98.75 (c = 1.0, MeOH), 1H NMR (600 MHz, CD3OD) δ 4.76 (d, J = 3.5 Hz, 1H, H-1), 
3.78 (t, J = 10.2 Hz, 1H, H-3), 3.58 (dd, J = 10.6, 5.4 Hz, 1H, H-5), 3.55 (d, J = 5.5 Hz, 1H, H-6), 3.37 
(s, 3H, -OMe), 3.09 (dd, J = 10.1, 3.5 Hz, 1H, H-2), 1.61 – 1.49 (m, 2H, -CH2CH2-, H-4), 1.49 – 1.27 
(m, 3H, -CH2CH2-), 0.91 (t, J = 7.2 Hz, 3H, -CH3). 13C NMR (151 MHz, CD3OD) δ 99.2 (C-1), 71.8 (C-
5), 68.5 (C-3), 65.2 (C-2), 61.5 (t, J = 21.3 Hz, C-6), 53.9 (-OMe), 43.1 (C-4), 28.8 (-CH2CH2-), 18.7 (-
CH2CH2-), 13.6 (-CH3). ESI-HRMS: m/z calcd for C10H18DN3O4Na [M + Na]+ 269.1336, found 
269.1334. 76β: [α]D23 = -35.37 (c = 0.003, MeOH), 1H NMR (600 MHz, CD3OD) δ 4.13 (d, J = 8.1 Hz, 
1H, H-1), 3.57 (d, J = 5.5 Hz, 1H, H-6), 3.52 (s, 3H, -OMe), 3.30 – 3.24 (m, 2H, H-3, H-5), 3.02 (dd, 
J = 9.5, 8.1 Hz, 1H, H-2), 1.58 – 1.24 (m, 5H, H4, -CH2CH2-), 0.90 (t, J = 7.1 Hz, 3H, -CH3). 13C NMR 
(151 MHz, CD3OD) δ 102.7 (C-1), 76.1 (C-5), 72.6 (C-3), 68.6 (C-2), 61.5 (t, J = 21.9 Hz, C-6), 55.6 (-
OMe), 42.6 (C-4), 28.6 (-CH2CH2-), 18.6 (-CH2CH2-), 13.6 (-CH3). ESI-HRMS: m/z calcd for 
C10H18DN3O4Na [M + Na]+ 269.1336, found 269.1326. 
Methyl 2-amino-6-(S)-deuterio-2,4-dideoxy-4-C-propyl-α-D-glucopyranoside (56). 
Compound 76α (9.0 mg, 0.0365 mmol) was dissolved in 0.6 mL of a 1:1 mixture of 1,4-Dioxane 
and 10 % aqueous AcOH followed by addition of Pd/C (1.8 mg). The reaction mixture was stirred 






off white solid (10.2 mg, 99 %). [α]D23 = 56.40 (c = 0.5, water), 1H NMR (600 MHz, D2O) δ 4.84 (d, 
J = 3.6 Hz, 1H, H1), 3.71 (t, J = 10.5 Hz, 1H, H3), 3.62 (dd, J = 10.9, 5.4 Hz, 1H, H5), 3.53 (d, J = 5.5 
Hz, 1H, H6), 3.25 (s, 3H, OMe), 3.08 (dd, J = 10.4, 3.6 Hz, 1H, H2), 1.80 (s, 3H, AcOH), 1.49 (tt, J = 
10.8, 4.0 Hz, 1H, H4), 1.40 – 1.33 (m, 1H, -CH2CH2-), 1.32 – 1.24 (m, 1H, -CH2CH2-), 1.24 – 1.06 (m, 
2H, -CH2CH2-), 0.72 (t, J = 7.2 Hz, 3H, -CH3). 13C NMR (151 MHz, D2O) δ 179.9 (AcOH), 96.3 (C1), 
71.6 (C5), 67.0 (C3), 60.99 (t, J = 21.0 Hz, C6), 55.3 (C2), 54.9 (OMe), 42.0 (C4), 27.7 (-CH2CH2-), 
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 The ever-increasing threat posed by multidrug-resistant infectious bacteria necessitates 
the development of novel antibiotics. Aminoglycoside antibiotics are growing in interest due to 
their broad spectrum of activity, lack of known drug related allergies, low manufacturing cost, 
and their well-studied mechanism of action. The simplification of rational drug design due to the 
well-studied mechanism of action is the key to overcoming the issues presented by these drugs, 
namely ototoxicity and nephrotoxicity. 
 A study of the effect of the conformation of the aminoglycoside ring I side chain is 
described wherein it was discovered that an increase in a particular conformation augments the 
antibacterioribosomal and antibacterial activity of paromomycin, as well as decreasing the 
toxicity to human ribosomes. 
 Chapter one introduces the aminoglycoside antibiotics and describes advantages and 






modification, altered transport, and aminoglycoside modifying enzymes are discussed as is the 
mechanism of bacterial inhibition and how this is related to toxicity in human cells. 
 Chapter two describes the synthesis of paromomycin and neomycin derivatives alkylated 
at C-6’ with both the (R) and (S) configurations as well as NMR spectroscopic studies of the side 
chain conformation of these derivatives. These derivatives were subjected to cell free ribosomal 
translation assays using M. smegmatis ribosomes with decoding A-sites of the wild type, human 
mitochondrial, mutant human mitochondrial, and human cytosolic ribosomes, as well as to 
bacterial MIC assays using E. coli and ESKAPE pathogens. The (R) configuration results in a higher 
solution state population of the bound conformation resulting in higher activity than the 
equivalent modification with the (S) configuration, which reduces the population of the bound 
conformation in solution. 
 Chapter three describes the synthesis of paromomycin derivatives where ring I was fused 
to an additional ring by bridging O-4’ and C-6’, such that the conformation of the C5-C6 bond is 
locked. Conformational analysis by NMR spectroscopy shows a progression from the preferred 
solution state conformation of the ring I side chain to the ideal bound conformation as a function 
of the size of the fused ring. These derivatives were subjected to the cell free ribosomal assays 
and bacterial MIC assays. It was found that as the conformation of the locked side chain 
approached the ideal gauche, trans conformation the activity increased, leading to the conclusion 
that the gt conformation is the bound conformation. 
 Chapter four discusses the effect of the 4’-substituent on the population of ring I side 
chain conformers in an attempt to rationalize the differences in activity between paromomycin, 






published synthetic aminoglycoside demonstrating equal activity to paromomycin and reduced 
toxicity in an animal model. Models of ring I of 4’-deoxy paromomycin and propylamycin were 
synthesized with and without selective deuteration at the side chain carbon. NMR spectroscopic 
studies of the relative populations of conformers of the ring I side chain for these models were 
conducted leading to the conclusion that the substituent at the 4’-position has minimal effect on 
the relative populations of the side chain conformers of ring I: any differences in activity between 
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